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Abstract    The increasing understanding of neurodegenerative diseases at the cellular and molecular 
level has directed part of the research toward the investigation of the role of glial cells in 
the pathogenesis. Specific impairment of this long-time neglected cell type has revealed 
that it was much more than just glue and is now considered a major player in either 
triggering defects or in the progression of nervous system disorders. My thesis proposes to 
investigate the role of glial cells in disease condition but also in “healthy” brain in order to 
uncover new mechanisms important in the complex interactions between glia and neurons. 
Using glial expression of the polyglutamine Atrophin as a disease model, I first 
characterized the importance and the participation of each glial subtype in the reduction of 
the Drosophila lifespan. The use of different specific glial drivers to express the mutated 
protein showed that the astrocyte-like glia might be the most important cell type, but not the 
only one, involved in the decrease of the lifespan. Then, using an unbiased RNAi-based 
screening method, I modulated neuronal gene expression in a newly established Drosophila 
model with impaired glial functions via the expression of a newly engineered 
polyglutamine Atrophin. Lifespan was used as a read out for the impairment of the nervous 
system homeostasis, leading to the discovery of genes able to modulate the reduction of the 
lifespan due to glial toxicity. The diversity of the candidate gene functions highlights the 
complexity of glia-neuron interactions involved in the disease and demonstrates that more 
investigation need to be done in order to fully understand the multifactorial causes of 
neuronal dysfunctions or death in neurodegenerative diseases. Beside the impairment of 
Drosophila glial cells in a disease condition, I also investigated the role of glial cells in 
adult CNS homeostasis. Via the downregulation of a transcription factor common and 
specific to all adult glial cells, called repo, I uncovered new glial functions involved in 
general brain homeostasis. Finally, I emphasize the importance of non-autonomous effect 
of glial transcription in neuronal function and morphology, using the visual system as a 
model. The results suggest that repo-dependent glial function is constantly needed during 
adult life in order to maintain a functional nervous system. 
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1.1 Glial cells 
 
1.1.1 In mammals 
 
There are five main types of glial cells in the mammalian central nervous system (CNS): 
the astrocytes, oligodendrocytes, microglia, ependymal cells and radial glia. The glial cells 
in the peripheral nervous system (PNS) is composed of mostly the Schwann cells, the 
satellite cells and the enteric cells (Rasband 2015). They are subdivided according to their 
morphology, function, origin and molecular compositions. The major difference from 
vertebrates to invertebrates is the presence of microglia, from mesodermal origin, which are 
the immune cells of the brain. 
 
During development, gliogenesis follows temporally neurogenesis in mammalian CNS. The 
development of glial cells has been mostly characterized for astrocytes and 
oligodendrocytes, both of them originally coming from neuroepithelial cells. These cells 
will give rise to radial glial cells, which can generate either neurons or glial progenitors 
(Malatesta et al. 2000). These progenitors will then produce astrocytes or oligodendrocytes 
depending on a complex epigenetic/signalling regulation. Radial cells also generate 
ependymal cells. Also, there are temporal distinct waves of gliogenesis, producing 
oligodendrocytes in different regions of the brain while production and migration of 
astrocytes remains unclear because of the lack of tools differentiating radial glial cells, 
precursors of astrocytes and mature astrocytes (Figure 1.1) (Rowitch et al. 2010). The 
higher complexity in mammalian gliogenesis relates to a higher diversity of glial 
specialized functions and morphologies depending on their interactions with a greater 
diversity of neurons. For instance, astrocytes have been divided into two main categories, 
the fibrous astrocytes and protoplasmic astrocytes, residing in the white matter and grey 


















Astrocytes have various physiological functions, one of them being an active member of 
the Blood-Brain-Barrier (BBB). Tight junctions are formed by the endothelial cells of the 
blood vessels and then, postnatally, astrocytes project endfeet surrounding the blood vessels 
and help maintain the function of the BBB. This system is called the neurovascular unit 
(Figure 1.2). Thanks to these direct interactions, astrocytes are proposed to regulate blood 
flow and also to take up glucose, convert it to lactate and release it to the neurons for local 












The astrocytes are the most numerous glial cells in the CNS. They are highly ramified but 
do not overlap in territory (Bushong et al. 2002) (Figure 1.3). Besides contacting blood 
vessels, astrocytes are also extensively studied for their interactions with neurons at the 
synaptic level where in addition to clearing the synaptic cleft from neurotransmitters to 
avoid excitotoxicity, they also regulate their activity. A study suggests that one astrocyte 
could associate with 4 neurons, 105 synapses (300-600 dendrites) and 1-2 capillaries 
(Halassa et al. 2007). They regulate many components of the synapse: they buffer the K+ 
concentration (Butt et al. 2006), the volume by water homeostasis (Nagelhus et al. 2004) 
and can compete with post-synaptic neurons for neurotransmitter modulating their activity 
(Pannasch et al. 2014). More than regulating the extracellular components of the synapses, 
astrocytes are also known to regulate the formation and the plasticity of synapses via the 
secretion of molecules such as thrombospondins (Risher et al. 2012). Interestingly, a very 
recent discovery has highlighted a potential bi-directional communication between neurons 
and astrocytes in the cerebellum, with the neurons also being able to control astrocyte 







Oligodendrocytes (CNS) and Schwann cells (PNS) are wrapping axons via myelin sheath. 
Contrary to the oligodendrocytes capable of wrapping many axons, Schwann cells wrap 
only one in the PNS, with one axon being wrapped by many Schwann cells in line with 
each other (Feltri et al. 2015). Both cell types actively recruit ion channels in a very 
controlled spaced manner along the axons, forming nodes of Ranvier. Together with the 
isolating properties of the myelin sheath, this clustering of ion channels increases the 
conduction velocity of axonal action potentials. These modifications of electric properties 
allow a reduced size of axons and use of energy to maintain ionic gradients (Howe et al. 
1990). In mammals, axons can range from millimetre to meter (one meter for the sciatic 
nerve in human) and are isolated from the extracellular space except at the node of Ranvier. 
Thus, it was suggested that myelinating glia provide direct metabolic support to axons. It 
has been recently proposed that both cell types provide some metabolites such as 
cholesterol, lactate or glycogen (Hirrlinger et al. 2014). 
 
The other most prominent glial cell type, even though from mesodermal origin, is 
microglia. This cell type is the immune cell of the brain, having highly ramified processes 
thought to cover a defined territory. Following an injury, microglia change shape, migrate 
to sites of injury and change their protein expression (Atallah et al. 2014). Once on the site 
of injury, they release cytokines which can have a dual role of either triggering cell death or 
survival and are also responsible for the removal of cell debris by phagocytosis (Cherry et 
al. 2014, Fernandes et al. 2014). However, beside this role of “immune cell”, it has recently 
been shown that a deficit in microglia could trigger behavioural deficits and impaired 
learning-dependent synaptic plasticity (Parkhurst et al. 2013), extending the role of 
microglia in the CNS. Evidence increasingly points toward not only a role in defence 








1.1.2 In Drosophila 
 
In Drosophila, glial cells have not been studied as extensively as neurons. However, glial 
cells possess a wide range of functions that are being more and more investigated at the 
cellular and molecular levels. The development of glial cells has been very well 
characterized in Drosophila, from birth to mature positioning, especially in the embryonic 
Ventral Nerve Cord (VNC). Glial cells would account for roughly 10% of the cells in the 
Drosophila central nervous system (Edwards et al. 2010), which is much lower than the 
ratio in mammals of 1:1 (Azevedo et al. 2009, Herculano-Houzel 2014). There are two 
types of glial cells based on their origin. The midline glia derive from the mesectoderm and 
thus are distinct by their origins to the lateral glia, deriving from the neuroectoderm (Parker 
et al. 2006). At the molecular level, the difference in this origin is marked by the absence of 
the initial glial fate determinant glial-cell-missing (gcm) and the terminal glial fate 
determinant reversed polarity (repo) expressions, which are present in all neuroectodermal 
glial cells. The midline glia are present only during development and their known function 
is to regulate the cross of the midline by commissural axon tracts by the expression of 
guidance cues (Mitchell et al. 1996). The other glial cells come from different neural stem 
cells (NSCs), also called generally neuroblasts (NBs). Some NBs will only give rise to 
neurons, some to both neurons and glia (called neuroglioblasts, NGBs), and few only to 
glia, called glioblasts. During embryogenesis, NBs give rise to another NB and a daughter 
cell, called ganglion mother cell (GMC), which will divide once to produce neurons and/or 
glial cells. A second wave of neurogenesis during larval stage, after the remaining 
embryonic NBs will exit quiescence state, will give rise to 90% of the neurons in the adult 
CNS. Based on their positions and their lineage characteristics, mainly two types of NBs 
can be distinguished (in addition to VNC, mushroom body and optic lobe NBs). Type 1 
NBs are similar to embryonic ones by giving rise to a GMC which will divide once more to 
produce two differentiated cells. The type 2 NBs divide asymmetrically and give rise to 
another NB and an transient cell called intermediate neural progenitor (INP), which will 
mature by a series of transcriptional changes and ultimately will produce a GMC and 
another mature INP (Figure 1.1 and 1.4) (Homem et al. 2012). The differentiation into 
glial cells is marked by the expression of gcm, triggered by Prospero which split 
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asymmetrically in the NGB from the former division into the future glial cell, to activate a 











Different lineages of lateral glia have been extensively characterized by their positions and 
migrations in the VNC. Three main groups of glial cells are differentially produced. The 
first one is called surface associated glia and comprises subperineurial glia and channel 
glia. The second one is neuropil-associated glia, comprising longitudinal glia and nerve root 
glia and the third one is cortex-associated glia comprising only cell body glia (Edwards et 
al. 2010). There is also another type of non-neuronal cell present in the CNS, from 
mesodermal origin that can be considered as surface glia by their position, the embryonic 
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perineurial glia (Beckervordersandforth et al. 2008). They do not express gcm or repo in 
early development but do express repo later from larval stage and thus, can be considered 
as glial cells. However, the origin of the latter ones are supposed to be from quiescent 
neuroblast, questioning the similarities between the embryonic and post embryonic 
development of this outermost layer of the surface glia. 
 
The subperineurial glia are considered to be the one forming the “Blood-Brain-Barrier” 
(BBB), isolating the brain from the K+ rich hemolymph through tight septate junctions 
(Figure 1.2) (Limmer et al. 2014). The role of the perineurial glia has not been well 
investigated but a recent study has shown that these cells would be an important player in 
glial glycolysis for neuronal survival via the active import of trehalose from the 
hemolymph to the brain (Volkenhoff et al. 2015). 
 
A second pool of glial cells is then produced during larval stages when the neuroblasts 
come out of their quiescent state (Sousa-Nunes et al. 2011). Then, in the adult stage, we can 
distinguish four types of CNS glial cells: the surface glia, the cortex glia, the neuropil glia 
and the “tracts” glia (not well defined yet) (Awasaki et al. 2008, Edwards et al. 2010). In 
the adult, beside the subperineurial glia, the surface glia comprise also the perineurial glia, 
which is the outermost layer of the BBB covered by an extracellular matrix called the 
neural lamella (Schirmeier et al. 2015). Both these layers actively participate in the 
filtration of molecules from the hemolymph to the CNS, in order to maintain a functional 
concentration of ions around the neurons and to provide them with energy metabolites 
(Limmer et al. 2014). The cortex glia are surrounded by the neuronal cell bodies and are 
able to wrap up around 20 neuronal cell bodies (Awasaki et al. 2008). By their location and 
being also directly in contact with the BBB glia, it has been suggested that they have a role 
in providing energy directly to the neurons (Freeman et al. 2006, Kis et al. 2015), which 
would mimic closely the role of astrocytes in mammalian BBB, highlighting functional 
similarities between vertebrates and invertebrates BBB (Figure 1.2). Furthermore, some of 
the cortex glia are also labelled by the dEAAT1-Gal4 driver, constructed from the promoter 
of the only known Drosophila glutamate transporter (characterized in this thesis). It is thus 
possible that at least some of the cortex glia are able to regulate glutamate transports in the 
 22 
cortex. In the visual system, the cortex glia are called satellite glia. Two different 
populations have already been isolated by the class of neurons they surround. However, it is 
not known yet whether such subdivisions apply elsewhere in the brain, although it is likely 
(Edwards et al. 2010). The neuropil glia have their cell bodies laying around the neuropil. 
They are composed of the ensheathing glia, surrounding the axonal bundles composing the 
neuropils and the astrocyte-like glia, sending projections in close proximity to the synaptic 
regions (Awasaki et al. 2008). The first ones help to isolate nerves and can also support 
neuronal survival by providing them with trophic support (Schirmeier et al. 2015). The 
astrocyte-like glia, named according to the similar star-shaped mammalian astrocytes, 
express neurotransmitter transporters and are thus important for neurotransmitter clearance 
and recycling (Agarwal et al. 2014, Chaturvedi et al. 2014, Stork et al. 2014). Similarly to 
mammalian astrocytes, astrocyte-like glia do not overlap in their projection domains 
(Figure 1.3) (Awasaki et al. 2011, Peco et al. 2016). They are also known to engulf 
neuronal debris during development but this function has not been proven yet in the adult 
(Tasdemir-Yilmaz et al. 2013). It is also possible that Drosophila astrocyte-like glia could 
regulate synaptic activity by controlling neurotransmitter and ion transports at the synaptic 
cleft. Indeed, it has been recently demonstrated that glial transcriptional activity via the 
transcription factor repo is needed for long-term memory (LTM) especially in astrocyte-
like glia, which suggests an important role of Drosophila glial cells in the modulation of 
neuronal activity (Matsuno et al. 2015). Contrary to the mammalian CNS, Drosophila does 
not possess microglia. This role is taken over by different types of glial cells, among which 
the ensheathing glia (Doherty et al. 2009), the astrocyte-like glia (Tasdemir-Yilmaz et al. 
2013, Hakim et al. 2014) and perhaps even the cortex glia, which express the engulfment 
receptor Draper (Doherty et al. 2009). 
 
An increasing body of evidence suggests that Drosophila glial cells are very similar to their 
mammalian counterparts by developmental, morphological, functional and molecular 
criteria. However, contrary to the mammalian glia, the Drosophila ones have been 
extensively characterized, even to a single-cell resolution in the embryonic CNS thanks to 
the availability of a wide range of genetic tools and specific markers. Similarly to the 
mammalian glia, the Drosophila glia subtypes have not been clearly subdivided further 
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even though specific markers are already available. Further investigation of potential new 
subtypes of glia would provide a better insight into the functions of glial cells in a simpler 
organism, which however possesses very similar functional cells to maintain the 
homeostasis of its nervous system. 
 
1.1.3 repo regulation in glial cells during development 
 
repo is a transcription factor expressed specifically in Drosophila glial cells but does not 
have a clear ortholog in mammals, apart from DMBX1, the closest mammalian ortholog 
(with around 26% identity and 38% similarity). It contains a homeodomain that belongs to 
the paired (PRD)-like group. This homeodomain is closely related to the murine Pax-3, C-
elegans unc-4 and Drosophila Aristaless. It has been discovered in a screen looking at 
electroretinogram (ERG) recordings of mutants in Drosophila. Among 7000 lines tested, it 
was the only mutant that had a reversed polarity phenotype of the ERG. This mutant was a 
hypomorph allele of repo, called repo1, which develops to the adult stage with abnormal 
glial localization in the optic lobe. Strong mutant alleles, called repo2, repo3 and repo4 were 
embryonic lethal (Xiong et al. 1994). However, using the hypomorph allele, it was shown 
that the ERG was only reversed during few days post eclosure and then would be reduced 
to almost being absent after 14 days post eclosure. It would be mostly due to the neuronal 
apoptosis triggered by the disorganisation of the glia in the optic lobe, leading to the retina 
degeneration. Interestingly, split rhabdomeres could be observed, sometimes, in non-
degenerating ommatidia (related to Chapter V, section 5.2.5.3) (Xiong et al. 1995). 
Following this discovery, repo was shown to be required for the nervous system 
development and for the differentiation and maintenance of glia functions during 
embryogenesis. However, it is necessary for the initial determination of glial cells (Halter et 
al. 1995). In the same study, it was demonstrated that it is expressed in all glial cells except 
the midline glia, which come from a different origin and do not express the initial glial cell 
fate determinant gcm either. repo being expressed only later during embryogenesis, repo 
mutant embryos display late developmental defects with disrupted axonal fasciculation and 
less glial cells. The migration of glial cells was also affected. 
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The expression of repo starts precisely at the stage 11 of embryogenesis under the direct 
transcriptional activation of gcm, with repo possessing 11 Gcm binding sites in its promoter 
region (Lee et al. 2005, Laneve et al. 2013). Then, it remains expressed in all glial cells 
until adult stage (see Chapter V) and (Soustelle et al. 2007, Matsuno et al. 2015). It has 
been demonstrated that gcm is the earliest glial cell fate determinant, directly switching 
cells to glial fate when expressed during early development, acting as a binary switch for 
glia versus neurons (Hosoya et al. 1995, Jones et al. 1995, Vincent et al. 1996). This 
activation of glial cell fate by gcm arises from the asymmetric localization of Prospero 
proteins during neuroglioblast division, which will trigger gcm expression to induce glia 
development (Freeman et al. 2001). After a complex regulation of Repo and Gcm protein 
levels via interlocked loops, the Repo protein will take over the regulation of its own 
expression and triggers gcm degradation and repression at the same time via competition 
with the dCBP acetylase at stage 14 (Figure 1.5)  (Lee et al. 2005, Laneve et al. 2013, Flici 
et al. 2014). Lee et al. have further characterized repo transcriptional regulation by isolating 
a 4.2kb sequence upstream the repo start sites sufficient to trigger wild-type expression 
(related to Chapter V, section 5.2.2.2). However, different elements present in the 
regulatory sequence of repo would be responsible for its specific activity in subsets of glia. 
Moreover, according to the same study, other elements than gcm could be responsible of 
the repo activation in glia. Indeed, the presence of gcm in hemocytes during embryogenesis 
does not trigger the expression of repo in this cell lineage, from mesodermal origin (related 
















repo controls the terminal differentiation of glial cells. gcm directly activates several other 
transcription factors, which will cooperate to trigger different glial programs and fully 
differentiate subsets of glial cells. At the same time, this cooperation will also repress 
neuronal development, by synergic effect between repo and tramtrack69 (ttk69) (Yuasa 
2003). Indeed, even though repo is expressed in all glial cells, other transcription factors, 
such as ttk69 or Pointed P1 (pntp1), are expressed in specific subsets of glia. As an 
example, loco, a gene required for glial differentiation, morphogenesis and BBB formation 
(Granderath et al. 1999), is first triggered by gcm (Granderath et al. 2000) but its later 
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expression will become dependent on the cooperation between repo and pntp1 (Yuasa 
2003). It has also been shown that other specific glial genes are regulated by repo. In repo 
mutant embryos, terminal glial differentiation involving the expressions of the glutamate 
and taurine/aspartate transporters dEAAT1/2 are abolished in glial cells (Soustelle et al. 
2002). More recently, using chromatin immunoprecipitation (ChIP) in S2 cells (embryonic 
Drosophila cells), several potential repo direct target genes have been discovered. Different 
groups of genes have been highlighted, amongst which are specific glial genes, such as the 
only glutamine synthetase present in Drosophila (Gs2). This gene has been confirmed to be 
regulated by repo in repo null mutant embryo. However, even though it possesses repo 
binding sites in its promoter, a direct regulation has not been confirmed yet. Several other 
genes non-specific to glia have been found. Among them, several are involved in wg/wnt 
signalling (Kerr et al. 2014). In the same study, it has been confirmed that repo regulates 
the expression of wg in glial cells, and that glia-secreted wg at the larval neuromuscular 
junction (NMJ) regulates glutamate receptor clustering and synaptic physiology. 
 
The function and regulation of repo during embryogenesis has already been well 
documented, however, its expression remains through all Drosophila stages and as a 
transcription factor, is expected to control other gene expressions. It is the case at the larval 
stage where its expression is necessary for the correct function of the NMJ. Moreover, it 
has recently been found that the expression of repo in adult glia is required for LTM 
(Matsuno et al. 2015). An adhesion molecule called Klingon (Klg) is expressed in both 
neurons and glia and its protein level increases upon LTM induction, which triggers an 
increase in repo expression as well. It is proposed that repo controls the activation of genes 
in glial cells that are necessary for neuronal activation involved in LTM via Klg-mediated 
communication between neurons and glia (Matsuno et al. 2015). However, this study is the 
only one investigating the role of repo in adult glial cells.  
 
Even though repo does not have clear ortholog genes in mammals having a similar 
function, it seems that the logic of the molecular mechanisms regulating gliogenesis, at 
least in mice, are relatively similar, though to a higher level of complexity. In both cases, 
some transcription factors are used at the very early stages to trigger glial fate but later to 
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differentiate astrocytes from oligodendrocytes (ensheathing glia in Drosophila) as it is the 
case for NFIA (in mammals) and Prospero (in Drosophila) (Figure 1.1) (Deneen et al. 
2006, Namihira et al. 2009, Kang et al. 2012, Peco et al. 2016). However, mammals are 
more complex, especially at the molecular level. In Drosophila, a unique gcm-repo 
pathway controls general glial fate, with repo binding to different partners such as ttk69 and 
pntp1 to trigger glial subtype specification later on. In mammals, even though Sox9 
cooperates with NFIA to initiate glial differentiation, at least characterized for astrocytes 
and oligodendrocytes so far, at later stages, other transcription factors will take over the fate 
specification for oligodendrocytes. Olig2 blocks NFIA function in oligodendrocyte while 
Sox10 will cooperate with Myrf in the CNS to differentiate oligodendrocytes by activating 
myelinating genes for instance (Hornig et al. 2013) and with Krox20 in the PNS Schwann 
cells. However, the role of Prospero in Drosophila astrogenesis has only been discovered 
very recently and more work would be required to investigate possible equivalent 
mechanisms for other glial lineages, similarly to what happens in mammals. Actually, 
similar complexity can also be observed between invertebrates and vertebrates in the 
redundancy of the use of one cell fate determinant transcription factor in different cell type. 
Similarly to gcm being expressed in both neuroectodermal glia and mesodermal hemocytes, 
triggering immune cell differentiation early in development of the Drosophila embryo, Sox 
10 is also expressed in melanocyte lineage in order to maintain melanocyte stem cell 
progenitors (Harris et al. 2013). 
 
 
Overall, glial cells actively participate to the development and function of the brain at many 
different levels, from the maintenance of the BBB to the regulation of the synaptic activity. 
Being in such dependence to their trophic support and regulation, neurons are easily 
vulnerable when glial cells are impaired. It is now well established that glia have a major 
role in neurodegeneration, which can be either protective or harmful but could be still an 





1.1.4 The role of glial cells in neurodegeneration 
 
During neurodegeneration or after an injury, glial cells can change morphology, 
particularly observed for microglia, or change gene expression profile, such as an increase 
in Gfap expression level in astrocytes. However, it still remains controversial whether they 
are just reacting to neuronal impairment or if they are active players in the impairment. 
 
In the case of astrocytes, this activation is called astrogliosis and is defined by 
morphological and molecular changes and is mostly characterized by an increase in Gfap 
expression (Burda et al. 2014) and extracellular matrix molecules forming a scar around the 
injury site (Yuan et al. 2013). This scar can have both positive and negative sides. The 
positive one is the limitation of the tissue damage due to inflammation by restricting the 
injured site (Sofroniew 2015). The negative side is that the formation of this scar has the 
potential of inhibiting axonal regeneration which is a big challenge to overcome after spinal 
cord injury for instance (Sharma et al. 2012). Beside the formation of the scar, cell-
autonomous impairment of astrocytes due to the expression of mutated proteins such as 
polyglutamine expansion can lead to neurodegeneration by impairing glutamate transport 
for instance by changing the transcription profile of  cells, either directly by the intrinsic 
function of the mutated protein or by sequestering other transcription factors or regulators 
in the aggregates (Custer et al. 2006). On top of that, the dynamic of polyglutamine protein 
expression in time and toxicity has not been assessed in glial cells and could be different 
from the one in neurons, which do not divide in the adult brain (apart from the 
subventricular zone). Indeed, the expression of polyQ-Atro in Drosophila adult glial cells 
for only 3 days does not reduce the lifespan (data not shown). Thus, the involvement of 
astrocytes in neurodegenerative diseases (as well as other glial cell types) has to be well 
defined for each of them in order to understand the role in the progression of the disease. A 
better understanding of their participation to the disease would help to design drugs either 
to promote some of their functions or to inhibit others. 
 
The myelination of axons by oligodendrocytes or Schwann cells is also directly involved in 
some neurodegenerative diseases. De- or dysmyelination can result from different origin; 
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genetic, such as the Charcot-Marie-Tooth peripheral neuropathies or Pelizeaus-Merzbacher 
CNS hypomyelinating disease, or auto-immune, such as PNS demyelinating Guillain-Barre 
syndrome or CNS demyelinating multiple sclerosis. The major cause in these diseases is 
the loss of axonal support leading to axonal degeneration and permanent loss of function 
(Trapp et al. 1998, Lee et al. 2012). 
 
Microglia, as immune cells, have a primary role in brain injury or disease via the secretion 
of cytokines responsible of inflammation, reactive oxygen and nitrogen species and 
proteolytic enzymes triggering cell death (Baburamani et al. 2014). However, similarly to 
astrocytes, they can also have a neuroprotective role, downregulating inflammation and 
promoting tissue repair. It is also suggested that microglia change in morphology and 
function with aging, resulting in a decline in their ability to repair and protect the CNS 
(Benarroch 2013). To add another layer of complexity of glial participation to 
neurodegenerative diseases, it has been suggested that inflammation plays an important role 
in neurodegeneration in multiple sclerosis (Derfuss et al. 2009). Moreover, a wrong 
expression of pro-inflammatory cytokines by microglia can trigger mitochondrial 
dysfunction in both glia and neurons (Lisak et al. 2009, Campbell et al. 2011). All these 
observations have attracted interest toward the use of drugs to modulate microglial 
activation for therapeutic purposes. However, the variety of their functions, either 
neuroprotective or neurodegenerative make the development of future drugs challenging by 
targeting specific functional states by suppressing deleterious effects and promoting 
protective ones (Correale 2014). 
 
The importance of glial cells in the process of neurodegeneration is now taken into account 
in more and more studies and it has been already demonstrated that removing 
polyglutamine proteins specifically in glial cells can reduce the symptoms (Furrer et al. 
2011) but also that expressing mutated proteins exclusively in glial cells is enough to 





1.2 Drosophila as a model for neurodegenerative diseases 
 
Drosophila has been one of the first animal models to study genetics and has helped to 
describe a lot of conserved cellular mechanisms throughout its extensive use in 
laboratories. Numerous fly models for human diseases and especially neurodegenerative 
diseases have been backed up by a relatively recent study where it was estimated that 75% 
of genes related to a disease in human have orthologs in Drosophila (Bier 2005). Other 
“small” animal models have been developed in the attempt of deciphering molecular 
pathways involved in human diseases. Understanding the molecular mechanism behind 
cellular defects that lead to a certain phenotype (e.g. specific death of Purkinje cells in 
some spinocerebellar ataxias (SCAs) for instance) will increase the chances to find 
therapeutic treatments by isolating specific therapeutic targets or signalling pathways. The 
use of Drosophila has come as a good compromise between gene homology, fast life-cycle, 
reduced maintenance and costs and genetic tools available for molecular investigations. 
 
1.2.1 Using Drosophila models for high-throughput screening 
 
The use of Drosophila as a genetic model for human diseases has to be well characterized 
and its limitations have to be understood. Indeed, while most of the age-related 
neurodegenerative diseases appear in the mid-life in humans, developmental phenotypes 
are observed in flies. Many screens have been done in flies using the GMR-Gal4 driver to 
find enhancer or suppressor of the famous “roughness of the eye” phenotype, associated 
with neurodegeneration (Figure 1.6) (Kazemi-Esfarjani et al. 2000). However, even though 
it is often ignored, this phenotype is the result of developmental defects of the eye, which 
does not form correctly and is mainly due to the dysfunction of the supportive non-neuronal 
cells. This questions the characterization of this phenotype as being “neurodegeneration”. 
However, several screens carried out using this dogma have been partly successful, or at 
least have given indications toward potential molecular mechanisms underlying cellular 
defects. A fly model for the SpinoCerebellar Ataxia 1 (SCA1), an ataxic disease 
characterized by cerebellum degeneration and specific motor defects, has been used to 
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screen modifiers of this eye roughness (Fernandez-Funez et al. 2000). Even though in the 
same study Fernandez-Funez and his colleagues also characterize an age-related phenotype 
using a ventral-nerve-cord Gal4 driver specific to the adult, the GMR-Gal4 driver was the 
one used for the screen and do not confirm their modifier effects using this other adult-
specific driver. However, out of the genes discovered in the screen, two groups of them 
were known to be involved in the nuclear pore complex and RNA-processing, which are 
now thought to be two of the major pathways involved in the disease (Orr 2012) and this 
has been confirmed in mammalian cell culture (Irwin et al. 2005). Using the same paradigm 
of the eye roughness  neurodegeneration, but this time on pre-validated compounds that 
went through a yeast assay of polyglutamine huntingtin (htt) aggregation, mammalian cell 
culture and then R6/2 mouse slices in culture, the use of Drosophila has confirmed the 
validity of some candidate drugs, as a first step of whole-animal model evaluation of FDA 
approved drugs (Zhang et al. 2005, Desai et al. 2006). However, those drugs were already 
known to be toxic in a long term use in humans, which is obviously a problem is this kind 
of diseases, showing the limitation of Drosophila for clinical evaluation of drug toxicity 
translatable to human. More success has been obtained using more developmental disease 
models such as for the study of the fragile X syndrome. Using mutant embryonic lethality 
of the Fmr1 gene in Drosophila (ortholog of the FXR1 in human responsible for the 
disease), a screen of 2000 FDA approved compounds has highlighted the importance of 
GABA signalling in the disease (Chang et al. 2008). Indeed, it has been shown in a mouse 
model of the disease that a GABA receptor antagonist rescues some of the symptoms 
















More recently, adult-specific screens have started to emerge in order to model more reliably 
age-related phenotypes and thus, investigate more accurately adult specific molecular 
defects effective with ageing. Using the strategy of drug-inducible system to allow specific 
expression in a time-controlled manner, a screen using a Drosophila SpinoCerebellar 
Ataxia 7 (SCA7) model has been done in the adult fly neurons and has identified a drug, 
sodium butyrate, a histone deacetylase inhibitor, as a potential candidate drug that improves 
survival in adult fly (Latouche et al. 2007), which seems appropriate given that the SCA7 
gene, ataxin-7, encodes for a protein known to be involved in histone acetylation. In the 
same study, the results were confirmed using rat cortex cell culture. Sodium butyrate has 
also been shown to have a positive effect on the DentatoRubro-PallidoLuysian Atrophy 
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(DRPLA), a polyglutamine disease caused by the expansion of the glutamine stretch in the 
Atrophin-1 gene, being a transcription co-repressor (see 1.4.2 section). Indeed, common 
mechanisms have been found between polyglutamine (polyQ) diseases (see 1.3 section). It 
is actually using Drosophila that for the first time it was shown in vivo that the expression 
of polyQ alone was intrinsically toxic and caused neurodegeneration (Marsh et al. 2000). 
 
1.2.2 The genetic power of Drosophila for molecular dissection of disease 
mechanisms 
 
Drosophila models are not only used for screening genes or pharmacological compounds 
on big scales. The genetic tools available to target the expression of transgenes in a cell-
specific and time controlled manner allow a deeper investigation of molecular mechanisms 
involved for each disease modelled in Drosophila. The case of the mitochondrial defects 
involving parkin and Pink1 in the familial cases of Parkinson’s disease (PD) is the perfect 
example as it has been first discovered in Drosophila models phenocopying human 
symptoms when Drosophila parkin and Pink1 were mutated (Park et al. 2009, Muñoz-
Soriano et al. 2011). The similarities in the molecular pathways between mammals and 
invertebrates involved in this disease allow a better understanding of the pathways 
potentially affected in the disease by studying Drosophila ortholog genes. Another 
conserved pathway between species is the autophagy pathway, increasingly found to be 
defective in many neurodegenerative disorders. It is the case for the DRPLA where a fly 
model has been used to investigate the molecular mechanisms involved in the defects, also 
observed in a DRPLA mouse model (reviewed in the 1.4 section) or for the Vici syndrome 
where epg5 has also been shown to be involved in autophagy, observed in a fly model and 
human brain tissue of patients with this disease (Cullup et al. 2013, Byrne et al. 2016). 
 
The use of the fly as a model is not even limited to genes having orthologs between 
mammals and invertebrates. The example of the investigation of the ALS-related gene 
C9orf72 is interesting since this gene does not have an equivalent in Drosophila. However, 
the use of several different models of the disease by overexpression of G4C2 repeats in 
different transgene environments has allowed the discovery of a major pathway potentially 
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directly involved in the disease. Indeed, several independent studies have discovered 
through specific screenings that the nuclear-cytoplasmic shuttle was affected by this repeat 
and confirmed the data in iPSCs from patients and post-mortem human brain tissue, beside 
the publication of a similar independent screen carried out in yeast demonstrating similar 
results (Freibaum et al. 2015, Jovičić et al. 2015, Zhang et al. 2015). These major 
discoveries confirmed in human patient samples were made using fly models expressing an 
exogenous gene not even present in Drosophila, highlighting the power of this model for 
understanding conserved cellular and molecular pathways involved in various diseases, 
especially neurological disorders reviewed in this section. 
 
1.2.3 Improving the understanding in the glia-neuron communications 
impaired in neurodegenerative diseases 
 
In most cases, the models are designed to study the effects of mutant genes on neurons and 
very few studies have come out about the importance of glial cells in neurodegenerative 
mechanisms. Two recent studies exemplified the importance of glial cells in CNS 
homeostasis in Drosophila via neuronal mitochondrial dysfunction or energy-dependent 
functions. Indeed, one study has demonstrated that neuronal mitochondrial dysfunction 
accompanied by generation of reactive oxygen species (ROS) often encountered in 
neurodegenerative disease triggers accumulation of lipid droplets (LD) in glial cells. 
Reducing LD accumulation in glial cells was able to lower ROS significantly and delays 
the onset of neurodegeneration, also observed in an Ndufs4 mutant mouse having similar 
defects showing a conserved phenomenon in the interaction between glia and neurons (Liu 
et al. 2015). Another interesting study has shown that a single mutated gene, in this case 
Drosophila htt, could have different effects depending on its localized expression. It was 
shown that the energy-dependent functions of glial cells challenged by the expression of 
polyQ htt could be rescued by the modulation of the expression levels of the mitochondrial 
uncoupling proteins (UCPs) by increasing the glial glucose uptake, but failed to do so in 
neurons. On the other hand, the expression of the superoxide dismutase (SOD) and catalase 
to reduce the oxidative stress in neurons improved the neuronal toxicity triggered by polyQ 
htt but failed to do so in glial cells, demonstrating differences in mechanisms affected 
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between glia and neurons (Besson et al. 2010). These studies suggest that glial cells can be 
directly involved in neurodegeneration, independently of the neuronal expression of the 
mutated protein and highlight the differences in the mechanisms that can lead to the cellular 
defects in these two cell types. The emergence of glial cells as an important component of 
neurodegeneration has started to be also investigated in mice models with the example of 
the expression of ataxin-7 (SCA7) in Bergman glia leading to Purkinje cells degeneration 
via the impairment of glutamate transport (Custer et al. 2006, Furrer et al. 2011). 
 
 
Overall, the use of Drosophila as a model for studying human diseases has proven to be a 
rapid and effective way to decipher molecular pathways involved specifically in each 
disease, with either common defects, such as autophagy, or different ones, such as energetic 
functions for glia and oxidative stress in neurons for HD. Thus, it allows the dissections of 
conserved molecular mechanisms that would not be possible in mammalian models. 
Furthermore, it is also extensively used for high throughput screening of genes or 
pharmacological compounds to narrow down the number of potential positive candidates to 
evaluate in mice, which has a much higher cost. 
 
 
1.3 Polyglutamine (PolyQ) diseases 
 
At the beginning of the 90’s, a new class of neurodegenerative diseases started to be 
characterized. Spinal and bulbar muscular atrophy (SBMA) was the first shown as being 
the result of an expansion of unstable trinucleotide repeats, CAG, present inside the 
androgen receptor gene (La Spada et al. 1991). The CAG triplet codes for the amino acid 
glutamine. Several neurodegenerative diseases have been characterized with this CAG 
repeat abnormal expansion: Huntington’s disease (HD), SBMA, DentatoRubro-
PallidoLuysian Atrophy (DRPLA) and 7 SpinoCerebellar Ataxias (SCA1, SCA2, SCA3, 
SCA6, SCA7, SCA12 and SCA17) (Margolis et al. 1993, Rubinsztein et al. 1993, Koide et 
al. 1994, Orr et al. 2007). On average, the size of the CAG repeat ranges from 5 to 35 and 
expands from 40 to 100 in disease condition, leading to the formation of big aggregates at 
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the cellular level. The expansion would occur in the gamete during cell division. The 
transcriptional machinery would abnormally generates extra number of CAG repeats due to 
the misreading of a long repeated unstable DNA sequence. All these neurological disorders 
are dominantly inherited. They are progressive by increasing neuronal dysfunction and 
mostly striking in midlife with an average age of onset of 40 years old. Another common 
feature is the negative correlation between the size of the repeats and the age of onset and 
the severity of the disease (Figure 1.7) (Zoghbi et al. 2000). However, the speed of the 
progression does not seem to correlate with the length of CAG repeats (Hasegawa et al. 
2010). 
 
The specificity of neuronal populations affected in each disease remains to be understood. 
Indeed, each of the proteins involved are widely expressed in the brain but also in other 
tissues. However, even though the SCAs are mostly affecting the cerebellum, each of these 
diseases has special features in terms of brain regions affected or neuron/fibre loss, thus 
leading to different symptoms. The most affected regions/cell populations in this group of 
diseases are the cerebellar Purkinje cells, dentate nucleus, brain stem and basal ganglia that 
can be shared between some, or the striatum, which is more pronounced in the HD for 
instance. Most of them if not all, lead to motor dysfunction, though with different 
characteristics such as chorea, dystonia, myoclonus, rigidity, parkinsonism and generally 
ataxia, tremor and dysarthria for the SCAs and DRPLA. However, other symptoms can 
















Several of these diseases have different models, from cells to mice, but also Drosophila. 
Some therapeutical strategies attempt at using CAG specific antisense oligonucleotides to 
knock-down or splice the CAG expanded exon but the fact that the non-affected allele also 
carries CAG repeats, albeit shorter, makes this strategy difficult to apply (Glorioso et al. 
2011, Arechavala-Gomeza et al. 2014). Thus, animal models can help to understand the 
specific biology behind each of these disorders in order to find either specific or common 
pathways affected by the polyglutamine proteins. Understanding why only specific 
neuronal populations are affected and what the impaired cellular mechanisms behind it are, 
would help finding new therapeutic interventions for these neurodegenerative diseases, 






1.4.1 Characterization of the disease in patients 
 
Following the discoveries of triplet repeat expansions in 1991 being responsible for the 
SBMA, several attempts to identify new genes containing triplet repeats responsible of 
uncharacterized diseases were done. One study led to the discovery of 14 novel human 
genes of which 8 were sequenced and analysed for their repeats (Li et al. 1993). In this 
study, they found one clone called CTG-37, which appeared later on to be the gene coding 
for Atrophin-1, responsible for the DRPLA (Koide et al. 1994, Nagafuchi et al. 1994). 
These two studies confirmed that the repeat length negatively correlates with the age of 
onset and the severity of the symptoms in DRPLA, comparable to other polyglutamine 
disorders. Also, Nagafuchi et al. found that there was an intermediate repeat length in the 
Japanese population studied, which could predispose certain populations to further 
expansion over generation leading to DRPLA. These intermediate lengths have already 
been reported for other diseases such as myotonic dystrophy (DM), fragile X syndrome and 
HD. The first cases in Europe were reported in United Kingdom and Malta (Warner et al. 
1994). Though, it has to be mentioned that having very similar symptoms to HD, 
misdiagnoses were common. In the same study, more detailed later on (Komure et al. 
1995), it was also reported that the increase in repeat length over generation was more 
prominent when coming from the father than from the mother, probably due to the 
instability of the repeat during spermatogenesis rather than in oogenesis. However, a single-
cell analysis has demonstrated that the expansion can be very heterogeneous within tissues. 
For instance, the DRPLA allele in the cerebellum shows smaller expansion than in the 
molecular layer and white matter. Also, repeat expansions are more prominent in the 
Purkinje cells than in the granule layer but still less than in the glial cells, especially in the 
late onset patients (Hashida et al. 2001). These findings demonstrate that there are 
differences in length within neuronal subgroups and that number of cell division cycles is 
not only the determinant for this mosaicism. 
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The brain regions affected in DRPLA are rather specific and different from the other 
polyglutamine diseases. Indeed, while most of the SCAs affect the Cerebellum and the 
brain stem and for HD the striatum, in DRPLA, it is mostly the dentate nucleus, the red 
nucleus and the globus pallidus. As a result, it is characterized by various clinical features 
including ataxia, chorea, epilepsy, myoclonus, cognitive impairment and psychiatric 
symptoms. Epilepsy and myoclonus are frequently observed in early-onset patients whereas 
the other symptoms appear at later onset. The age of onset varies from 0 to 72 years old and 
the age of death from 18 to 80, with an average of 49 y/o (Hasegawa et al. 2010). The 
analysis of the brains regions affected by neurodegeneration was helped by the case of a 
father and his son who went through magnetic resonance (MR) examination prior to death 
and in whom post-mortem examination of the brains were obtained (Sunami et al. 2010). 
MR imaging showed atrophy of the cerebellum and the brain stem, lesions of the cerebral 
white matter and brain stem, progressive cerebral atrophy, which were more marked in the 
patient with the juvenile-onset DRPLA. The lesions observed in the white matter and brain 
stem reflect loss of myelinated fibers. Also, cerebral atrophy mainly corresponds to atrophy 
of the neuropil. Neuronal loss was observed along with astrocytosis in the dentate nuclei, 
subthalamus and external segment of the globus pallidus. Neurons in the pontine nuclei and 
in the cortical layers were shrunken, with phosphorylated neurofilaments. 
 
The Atrophin-1 gene codes for a protein identified as 190kDa in normal human (with 25-30 
glutamine repeats on average) but shift up on Western blot in DRPLA patients (with 60-70 
glutamine repeats on average) (Yazawa et al. 1995). Accumulation of aggregates in 
neuronal cytoplasm of DRPLA patient brains was reported (Yazawa et al. 1995) though it 
is now known that aggregates are formed in both cytoplasm and nucleus, interestingly with 
different dynamics (Hinz et al. 2011). 
 
It has been demonstrated, by isolating DRPLA protein complex, that the cytoplasmic 
inclusions and the nuclear membrane were aberrantly phosphorylated in neurons, 
suggesting that the nuclear membrane could be another pathological feature of degenerating 
neurons in DRPLA (Yazawa 2000). However, in order to study the molecular mechanisms 
that lead to these defects in humans, different animal models have been generated. 
 40 
1.4.2 DRPLA mouse models 
 
Three mouse models have been generated so far, mostly with different CAG repeat number, 
going from 65 glutamine repeats to 129 (in the range of human disease length, compare to 
around 10-20 for non-disease length), cloned in the human Atrophin-1 (Sato et al. 1999, 
Schilling et al. 1999, Ying et al. 2005, Sakai 2006). All these models have different 
characteristics from age of onset to type of symptoms. For instance, the mouse model 
generated with 65 repeats has a lifespan of about 12 months but starts to develop severe 
tremors and impaired gait by 2-4 months (Schilling et al. 2001). This model also displays 
nuclear aggregation of a 120kDa fragment, present in human tissues as well. The symptoms 
resemble closely the phenotype of human DRPLA patients having ataxia, tremors, 
abnormal movements and seizures. Interestingly, this model develops aggressive behaviour, 
similarly observed in patients, which is often associated with abnormalities in the 
serotonergic system. However, the levels of serotonin and dopamine (related to motor 
activity) were normal, suggesting that the defects in these pathways could come from the 
receptors of these neurotransmitters or additional unrelated pathways involved in 
aggression. 
 
Another mouse model, this time generated by cloning human Atrophin-1 gene in embryonic 
stem cells, possesses 76 to 78 repeats. This model has been extensively used to study 
intergenerational CAG repeats instabilities. Indeed, similarly to humans, this mouse model 
displays an increase in the CAG expansions specifically via male transmission (Sato et al. 
1999). This model, unlike the others, could be used to investigate the molecular 
mechanisms of instabilities of CAG repeats and highlights the complexity of the genomic 
sequence surrounding the gene enabling such instability. One such expansion, containing 
129 CAG repeats, shows a strong neurological phenotype similar to the juvenile form of 
DRPLA (cerebellar ataxia, myoclonus and epilepsy, and die by 16 weeks of age). 
Interestingly, no obvious neuronal loss could be observed in any brain regions (Sakai 
2006). This model has been used to analyse more in details the morphology of neurons and 
found changes in dendritic spine morphology and number and shrinkage of Purkinje cells 
dendrites (Sato et al. 2008). Using different sizes of expansion, 76, 96, 113 and 129Q, the 
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same group has characterized the evolution of the changes of behaviour and gene 
expression over time in a length dependent manner (Suzuki et al. 2012). 
 
The generation of these models has allowed the investigation of molecular mechanisms 
underlying cellular defects due to the polyQ expansion. Indeed, one of the first discoveries 
of such abnormalities at the molecular level was the fact that polyglutamine proteins are 
able to interact more strongly to other proteins containing short polyglutamine tracts, as it is 
the case for the transcriptional co-activator CREB binding protein, CBP (Nucifora Jr 2001). 
It was found in both HD and DRPLA mice models that CBP was depleted from its normal 
nuclear location, interfering with CBP-activated gene transcription. This finding was 
further strengthened by another study where they found similar genes with abnormal 
expression levels, common to HD, DRPLA but also to SBMA and SCA7 mice models 
(Luthi-Carter et al. 2002). These results show that even if the proteins affected are different 
between all the polyglutamine disorders, they still share some common molecular defects 
independent of protein context. Also, the large alterations of gene expression in the brain 
due to retaining of transcription factors will certainly lead to the disruption of many 
different downstream molecular pathways, increasing the complexity of defects at the 
cellular level. Actually, using a DRPLA mouse model with 118 glutamine repeats, it has 
been shown that the use of sodium butyrate, a histone deacetylase inhibitor, ameliorates 
neurodegenerative phenotypes by modifying the histone acetylation profile (Ying et al. 
2005). These mice also had strong reduction of their lifespan and dramatic impairment of 
their motor capacity. These results further confirmed that transcriptional changes play an 
important role in the pathogenesis of DRPLA and suggest that the reversion of the 
transcription repression could be an approach for therapeutic intervention. 
 
Overall, using different models, it is quite clear that the polyQ stretch expansion in the 
Atrophin-1 gene leads to changes in the transcription profile of the neurons and could be an 
important feature of this pathophysiology. The symptoms were triggered at different time 
points with different lifespans according to the model used but no obvious neuronal loss 
could be observed in any case. 
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However, most groups have disregarded the participation of glial cells in DRPLA. One 
group has investigated the potential implication of oligodendrocytes since it was reported in 
human DRPLA brain tissue that there was a reduced number of glial cells in the lesions and 
an involvement of oligodendrocytes in the nuclear inclusion formation. They suggested that 
glial cells could actually be involved in the pathogenesis (Yamada et al. 2002). Indeed, 
following the discovery of white matter damage and that polyQ Atrophin-1 immobilizes 
GAPDH, glycolysis and related pathways were investigated. It was concluded that along 
with astrocytosis present in the white matter damaged regions, CAG triplet expansion 
caused mismetabolism of polysaccharides contributing to the formation of the lesions in 
DRPLA (Shiozawa et al. 2003). In our lab, using the 65Q mouse model, it has been 
established that both transient astrocyte activation in the corpus callosum, and chronic 
astrocytosis in the internal capsule are displayed with the progression of the disease 
(unpublished). All these studies suggest that beside the clear direct implication of neurons 
in the disease, glial cells could at least participate in the progression of DRPLA. 
 1.4.3 Using Drosophila models to study DRPLA 
 
The in vivo function of Atrophin-1 in mammals was unknown when it was discovered that 
there were transcriptional changes in DRPLA. The use of Drosophila as a model for the 
genetic dissection of its function helped in the understanding of its role in the pathogenesis 
DRPLA. The Drosophila homolog, called Grunge (Gug) but later renamed Atro (used in 
this thesis), was discovered and characterized in 2002 (Schematic below and Figure 4.1A) 
(Zhang et al. 2002). It was shown to be a transcriptional corepressor in multiple 
developmental processes and the authors proposed that a deregulation of transcription could 
contribute to the pathogenesis of neurodegeneration. These results support the data from the 
mouse models and point toward a more direct implication of Atrophin proteins in the 
transcriptional deregulation rather than just sequestrating other transcription factors in 
inclusion bodies. 
 
Schematic from Figure 4.1 comparing 
mammalian Atrophins to Drosophila Atro 
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Furthermore, Drosophila Atro has been demonstrated to physically interact with fat to 
control planar cell polarity during development (Fanto 2003). This functional analysis 
during development led to the later discovery that in a DRPLA Drosophila model, 
polyglutamine expansion in the Drosophila Atro protein triggers neurodegeneration by 
downregulating fat in adult flies (Napoletano et al. 2011). Furthermore, it was shown that 
the defects were not due to the developmental function of the fat/Hippo signalling on 
regulating growth, a known pathway well characterized for tumour growth but were rather 
due to autophagic deregulation, affecting cell homeostasis. The characterization of the 
autophagic defects was done using the same model and demonstrated that the expansion of 
the polyglutamine stretch in Atrophin proteins blocks the autophagic digestion at the 
lysosomal level and that contrary to other autophagic defects, neurodegeneration was not 
rescued by inducing more autophagy (Nisoli et al. 2010). This model has given a better 
insight into the potential cellular mechanisms affected by deregulation of transcription 
triggered by polyglutamine Atrophin. The discovery that polyQ Atro downregulates fat and 
triggers autophagic defects in neurons has now been confirmed in a mouse model, similar 
to the 65Q one develop by Schilling et al. (Baron et al. submitted). The similarities between 
the invertebrate and vertebrate models in the cellular pathways involved DRPLA allow a 

















To provide insights into the role of “diseased” glia during neurodegeneration, the aim is 
first to characterize the importance of each glial cell population using the expression of a 
toxic protein responsible for a rare neurodegenerative disease called DRPLA. Then, in 
order to investigate the interactions occurring during the progression of the disease, a new 
fly model is generated in which glial cells are specifically impaired and neuronal gene 
expression is modulated. The screening of neuronal genes involved in the modulation of the 
phenotypes given by the impaired glia will shed lights on potential new communications 
between neurons and glia involved in the progression of the disease. Such genes can open 
up avenues to finding new therapeutic targets that could delay neuronal death and maintain 
a functional nervous system longer, which would improve patient disease conditions. On 
the other hand, the general understanding of glial functions in healthy condition can 
improve our knowledge on potential new mechanisms regulated by glia, thus, 
understanding better their interactions with neurons but also with themselves. The second 
part of this thesis aims at unrevealing glial functions and regulatory pathways in the adult 





































2.1.1 Drosophila stocks and husbandry 
 Flies were maintained at either 18°C or room temperature on standard cornmeal agar 
medium (0.8% w/v agar, 2% w/v cornmeal, 8% w/v glucose, 5% w/v Brewer’s yeast, 1.5% 
v/v ethanol, 0.22% v/v methyl- 4-hydroxybenzoate, 0.38% v/v propionic acid). The w1118 
(w-) was used as control (unless mentioned otherwise) and for RNAi TRiP lines, an 
mCherry-RNAi in the same background was used. Genetic manipulations, including 
balancers and phenotypic markers are described in Lindsley & Zimm (1992) and Flybase 
(www.flybase.org). The RNAi lines used for the screen or throughout the study are from 
either the VDRC (Vienna Drosophila RNAi Centre) collection (KK and GD lines) or from 
the Bloomington Stock Centre (TRiP lines). 
 
Drosophila stocks used: All the following lines were obtained from the Bloomington 
collection: w1118, Repo-Gal4, dEAAT1-Gal4 (II and III chromosomes), NP2222-Gal4, 
Gliotactin-Gal4, MZ0709-Gal4, Moody-Gal4, UAS-CD8-GFP, UAS-nls-GFP, LOT-
mCherry, GMR-Gal4, Elav-Gal4, Ubi-Gal80ts (II and III chromosomes), mfas-RNAi (TRiP 
59205), caps-RNAi (28020), trn-RNAi (28525 and 50520) and UAS-dEAAT1 (8202). The 
mfas-RNAi (103621 KK and 37888 GD), caps-RNAi (3046 GD and 27097 GD) were 
obtained from the VDRC collection in addition to all the RNAi lines used for the screen. 
 
Alrm-Gal4 (II and III chromosome) and UAS-Gat were kindly given by M. Freeman. Elav-
Gal80 and Tsh-Gal80 were kindly provided by R. Sousa-Nunez. Repo-Gal80, UAS-Repo#9 
(myc-repo), UAS-Repo#14 (myc-repoΔAD302), UAS-Repo, UAS-Repo RNAi 1 and 2 (GD 
10424 and TRiP 28339 respectively), Repo-nGFP and Repo-LexA were given by A. 
Giangrande. UAS-miR-1 and miR-1 KO were given by E. Lai. UAS-Atro75QN was 
generated in a previous study (Nisoli et al. 2010). UAS-Gs2 was given by R.W. Ordway, 
UAS-loco was given by U. Gaul. 
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The dEAAT1-LexA::GADs, dEAAT1-LexA::VP16, LOT-wt-Atro and LOT-polyQ-Atro were 
generated in this study. 
 
2.1.2 Transgenic flies 
 
Purified plasmids containing the transgenes of interest and the mini-white “w+” marker 
gene were sent to inject to Fly-Facility company for LOT-sAtro wild-type or polyQ and for 
dEAAT-LexA. All transgenic flies that developed to adult were crossed to w1118 (w-) flies. 
The eye color (w+) of the progeny was used to identify the transgenic flies that had inserted 
the plasmid containing the mini-white gene and thus, the transgene of interest. Males with 
eye-color were then crossed to w- balancer stocks on the second (If/CyO) and on the third 
chromosomes (TM3/TM6) to identify the location of the transgene insertion. 
 
 




Crosses were maintained at 18°C during the developmental stages of the progeny. Newly 
eclosed adult flies were collected within 5 days at 18°C. 60 flies were selected per 
genotype, 30 females and 30 males, equally distributed within 3 vials. Lifespan is done in a 
controlled environment at 29°C and 60% humidity. Using CO2 to asleep the alive flies, 
dead and alive flies are counted and transferred into new fresh vials three times per week. 
Data are analysed using GraphPad Prism software. Statistical analysis was done using the 
log rank test of the Kaplan and Meier method. The Chi square (χi2) value was used as a 
measure of strength to compare the phenotypes as it is directly proportional to the 
difference between two curves and proportional to the P-value. χi2 also takes into account 
the number of flies assessed. Thus, this value can be compared between different lifespan 
only when similar number of flies was used. The median survival of each curve will also be 
used to compare the curves, being independent of the number of flies used. The error bars 
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represent the standard error. It reports the uncertainty of the fractional survival and is 
calculated by the method of Greenwood. For the lifespans done with only 3 days at 29°C 
and then the vials transferred at 18°C, the flies were still counted three times per week but 
were transferred into a fresh vial only once a week. 
 
2.2.2 Paraquat assay 
 
4 to 5 days old adult flies raised at 18°C were transferred to 29°C for 3 days in standard 
food then put back to 18°C, into tubes containing filter paper soaked in 20mM paraquat 
diluted with sucrose, or just in water as a control. The flies were kept in a humid chamber 
and were counted every two to three hours during the day. Data analysis was done as 
previously described in Lifespan section. 
 
2.2.3 Climbing assay 
 
Flies were collected from the same cross used for the lifespan experiment in order to assess 
their negative geotaxis reaction. This assay is generally used to evaluate the motor capacity 
of the flies, even though the negative geotaxis reaction can be impaired by a loss of balance 
or geotaxis orientation loss. The flies were put into a graduated tube with four lines drawn 
every centimetre. The flies climbing above 4 cm were scored 4. The tubes containing each 
genotype were assessed at the same time using a home-made tool to bang down the tubes 
all together to avoid any differences in the strength of the banging movement. Each session 
were recorded to evaluate the scores. 5 females were assessed three times for each 
genotype. An average of the scores from the 5 females was made for each repeat. The 
average of the three repeats was then calculated. Statistical analysis was made by one way 
ANOVA using Dunnett’s multiple comparison post hoc test. The experiment was repeated 





2.3 Tissue culture 
 
2.3.1 S2 cell maintenance 
 
Drosophila Schneider 2 (S2) cells were maintained in Schneider’s medium supplemented 
with 1/100 dilution of antibiotics (5000 units/mL of penicillin and 5000 µg/mL of 
streptomycin solution, GIBCO) and 10% Fetal Calf Serum (FCS). The cells were cultured 
in either T25 or T75 flasks and split 1:10 when full confluence was reached. Cells were 




Cells were split 1:20 from a full confluent T75 flask into a 6-well plate with 2mL of 
medium. Plasmids transfections were carried out using Effectene (Qiagen) following 
manufacturer’s instructions. pMT-Gal4-GFP, pUAST-Luciferase-Luciferase 3’UTR, 
pUAST-Luciferase-Repo 3’UTR, pUAST-Luciferase-RepoΔ 3’UTR and pTK-Renilla were 
all used at 20ng/mL. pTub-miR-1 was used at 50ng/mL. The plasmid pBluescript was used 
at the same concentration as pTub-miR-1 to adjust equal total DNA transfected. The cells 
were cultured 2 days prior induction, which was done adding 500µM of copper sulphate to 
the medium. 
 
2.3.3 Luciferase assay 
 
The Luciferase assay was done 24h after induction. The cells were removed from the wells 
and transferred into Eppendorf tubes. 600µL were used for the Luciferase assay. The cells 
were spinned down, the medium removed and 75µL of PBS were added to each tube. The 
assay was then done using the Dual-Glo® Luciferase assay kit (Promega) according to 
manufacturer’s instructions. The Luciferase and Renilla activities were measured in an 
opaque 96-well plate using a standard plate reader (Mithras LB 940, Berthod technologies). 
The Luciferase signal is normalized to the Renilla one. Then, the ratio between miR-1 and 
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no miR-1 conditions is calculated. Three independent transfections were averaged. Error 
bars represent standard error. Statistical significance was calculated with GraphPad Prism 




2.4 Dissections and Immunostaining 
 
2.4.1 Imaginal discs staining 
 
L3 larvae were anesthetized in cold PBS (see 2.7 Table of solutions). The head part of the 
larvae was dissected in cold PBS followed by the separation of the imaginal discs from the 
brain. They were transferred immediately into chilled PLP (see 2.7 Table of solutions) for 
45 min at room temperature (RT). The discs were then washed in Wash Buffer (see 2.7 
Table of solutions) for 15 min. They were blocked in wash buffer with 10% Fetal Bovine 
Serum (FBS) for an hour at RT in a 72-microwell plate. Primary antibodies were diluted in 
the blocking buffer and the discs were incubated overnight at 4°C in a humid chamber. The 
discs were washed three times 15 min in wash buffer and then incubated 2 hours at RT in 
secondary antibodies diluted 1/200 in blocking solution.  After three washes of 15 min, 
they were washed in phosphate buffer without detergent and dehydrated overnight at 4°C in 
a PBS (20%)-Glycerol (80%) solution. They were finally mounted on slides in 
Vectashield®. 
 
2.4.2 Adult brain and larval brain staining 
 
Adult flies or L3 larvae were anesthetized on ice. Brains were dissected and put straight 
into 4% paraformaldehyde (PFA) for 45 min fixation. They were then washed in wash 
buffer for 30 min before blocking for an hour at RT in a 96-well plate. Primary and 
secondary antibody steps were similar to imaginal disc section with secondary antibodies 
being incubated overnight at 4°C. After three wash of 15 min, brains were put in 
Vectashield® in a 72-microwell plate overnight at 4°C. The brains were then mounted in 
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Vectashield® on a slide, surrounded by two coverslips on each side, before being covered 
by another coverslip on top. This mounting prevents the brains from being squashed by the 
top coverslip. 
 
2.4.3 Embryos staining 
 
Adult flies were laying eggs on apple juice plates with yeast paste. After aging the embryos 
to the desired stage at 25°C, they were collected and dechorionated with 50% bleach for 5 
min and rinsed well with ddH2O. The embryos were placed into a 1.5mL eppendorf tube 
containing heptane::PBS-formaldehyde (4%) in a 1:1 ratio (vol.:vol.). They were incubated 
30 min rotating. The aqueous layer (PBS-FA) was removed and replaced by an equal 
volume of MeOH. The tube was vortexed for a minute for the embryos to pop out of their 
vitelline membranes and fall down to the bottom of the MeOH phase. The devitellinized 
embryos were then washed three times in MeOH to remove residual heptane. MeOH was 
replaced by PBS-T and rinsed three times in wash buffer. They were then blocked an hour 
at RT and then stained with primary antibodies overnight at 4°C followed by three wash 
and by secondary antibodies incubation overnight at 4°C as well. The embryos were 
washed three times in PBS-T and once in PBS before being mounted in Vectashield® the 
same way as for adult brains. 
 
2.4.4 TUNEL assay 
 
Fly brains were dissected in cold PBS and fixed for 45 min in PFA 4% at RT. After three 
wash of 10 min in PBS, the brains were incubated 10 min in 50 µL of Proteinase K 
(20µg/mL in PBS). The brains were washed twice 10 min in PBS to stop the 
permeabilization. For the positive control, a 10 min incubation in DNAse I buffer was 
followed by a 10 min incubation in DNAse I (7 U/mL in DNAse I buffer) and then washed 
three times in ddH2O. The brains for all the conditions were then equilibrated 30 min in 
equilibration buffer and incubated 1h at 37°C with a mix solution (44 µL of equilibration 
buffer, 5 µL of marked nucleotide mix, 1 µL of TdT enzyme, Promega). The reaction was 
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stopped for 15 min in 2X SSC solution (diluted in ddH2O) and washed three times in PBS. 
The brains were then mounted in Vectashield. 
 
2.4.5 Dye injection 
 
~0.5 µL of Fluorescein Dextran (50mg/mL, 10 kDa, Invitrogen, D1821) was microinjected 
into the soft tissue at the basis of the first pair of leg in anesthetized adult flies after 6 days 
spent at 29°C when the Repo-RNAi 1 flies start to have motor defects, or a specified time 
point for the Repo-RNAi 2 flies. After 18h, the heads are fixed 30 min in PFA 4%. Then, 
the proboscis were removed and the heads were fixed for another 30 min before brain 
dissection. The brains were then washed three times 20 min in PBS. Then, they were 
mounted straight after on a coverslip in Vectashield. Before taking the pictures, the settings 
were adjusted using a control sample in order to get reference parameters such as laser 
intensity, gain, offset and pinhole. All the pictures were then taken using these settings. 
 
Confocal pictures were taken with an Olympus FV500, analysed with ImageJ Fiji software 
and processed with Adobe Photoshop 7.0.1. 
 
Antibodies used: anti-GFP (1/500, rabbit polyclonal, Molecular Probes), anti-GFP 
(1/100, mouse monoclonal, Roche), anti-GFP (1/500, chicken, kindly provided by 
M.Meyer), anti-Repo (1/100, DSHB 8D12), anti-Srp (1/1000, rabbit polyclonal, kindly 
provided by A.Giangrande), anti-Elav (1/500, rat, DSHB 758A10 or 1/2000 mouse, DSHB, 
9F8A9), anti-Atro (1/200, mouse monoclonal, Abmart), anti-ß-Gal (1/500, rabbit 
polyclonal, Molecular Probes, A11132). 
 
2.4.6 Semi-thin retinal sections 
 
Fly heads were cut after anaesthesia with CO2. Female right eyes were kept for the 
experiments. Eyes were incubated in a fixative solution (2% glutaraldehyde in phosphate 
buffer 0,1M). Same volume of post-fixation solution was added (50% osmium, 50% 
phosphate buffer 0,2M). Samples were kept on ice for 30 minutes. The mix solution was 
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then replaced by a 100% post-fixation solution for 5 hours. A progressive dehydration by 
ethanol was proceeded prior to 2 propylene oxide washes of 10 minutes each at room 
temperature. Eyes were then incubated in a polymerisation solution (50% propylene oxide, 
50% epoxy resin) overnight. Cut eyes were incubated in a 100% epoxy resin between 4 and 
6 hours the following day. Eyes were then embedded in a mould filled with polymerization 
solution. They were then placed in the oven at 65-80°C overnight. After trimming, 1μm 
sections were performed by using a microtome (Leica Ultracut UTC). Sections were 
stained with 1% toluidine-blue in borax. Images were taken with light microscopy. 
 
 
2.5 Molecular Biology 
 
2.5.1 RNA extraction 
 
50 heads were cut and placed into a 1.5mL eppendorf tube followed by a snap freeze in 
liquid nitrogen. The heads were then homogenized in 100µL of TriZol (Invitrogen) and 
200µL of TriZol were topped up. The mix was incubated 10 min at RT before adding 60µL 
of Chloroform. The tubes were vigorously mixed during 20sec and then incubated 2 min at 
RT prior to 15min centrifugation at 4°C, 12000rpm. 200µL of the aqueous phase 
containing the RNA was taken out and transferred into another 1.5mL eppendorf tube and 
150µL of isopropanol was added. A pellet of RNA will appear after 10 min centrifugation 
at 4°C and 12000rpm. The pellet was then washed three times with 75% EtOH and let dry 
before adding 40µL RNase free water with 1µL of RNasin® (Promega). The quality of the 
RNA extraction was assessed on a 1.5% agarose gel and the concentration and the 280/260 
and 260/230 ratios were measured with a Nanodrop®. 
 
2.5.2 DNA/RNA gels 
 
DNA/RNA gel electrophoresis was done in TAE buffer (see 2.7 Table of solutions) using 
1.5% agarose gel with 0.1µg/µL of Ethidium Bromide. DNA and RNA samples were 
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supplemented with DNA Loading buffer and run alongside 1kb or 100bp DNA ladder 
(New England Biolabs (NEB) or Promega) at 100V. DNA and RNA bands were visualized 
under UV light (Biospectrum® imaging system). 
 
2.5.3 Cloning steps and DNA preparation 
 
DNA digestions were done using restriction enzymes from NEB according to 
manufacturer’s instructions. Linearized plasmid was dephosphorylated 3h at 37°C with 
phosphatase alkaline (New England Biolabs). DNA bands for future ligations were cut 
from the agarose gel on a UV-light platform and DNA was purified using QIAquick gel 
extraction kit (QIAGEN) according to manufacturer’s instructions. The concentration of the 
DNA extracted was measured by NanoDrop®. Ligation was done using T4 DNA Ligase 
(NEB) according to manufacturer’s instructions. The product of the ligation was 
transformed into competent bacteria (Invitrogen) according to standard transformation 
procedure. Bacteria were grown overnight at 37°C onto LB agar plate (see 2.7 Table of 
solutions) supplemented with antibiotics according to the resistant gene present in the 
plasmid. Several minipreps were made from single colonies cultured in 2mL LB (see 2.7 
Table of solutions) supplemented with the appropriate selective antibiotics. The presence of 
the plasmid was assessed by a quick DNA extraction and purification using QIAGEN® 
plasmid mini kit reagents according to manufacturer’s instructions. Appropriated restriction 
enzymes were used before running a DNA gel to evaluate the size of the bands from the 
plasmid extracted. A midiprep is then cultured from a good colony overnight at 37°C. The 
DNA is then extracted and purified using QIAGEN® plasmid midi kit protocol (QIAGEN) 
according to manufacturer’s instructions. Its concentration and quality is assessed by 
NanoDrop®. 
 
2.5.4 Genomic DNA extraction 
 
Genomic DNA isolation was made out of one adult fly or one egg. They were placed into a 
0.5mL eppendorf tube and homogenized with 50µL of proteinase K buffer (see 2.7 Table of 
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solution). The tube was incubated at 37°C for 30min. The proteinase K is then inactivated 
95°C for 2min. 1µL is used for a PCR reaction. The tube is then stored at -20°C. 
 
2.5.5 PCR reaction 
 
PCR was done to identify the presence of endogenous or exogenous genes, using exons for 
primer design for endogenous genes. For the PCR of mfas, two sets of primers were 
designed. The first one, targeting the first exon, amplifies a product of 106bp and the 
second set, targeting the 4th exon, amplifies a product of 160bp. (See Table below). A 
master mix of PCR reagents was made when necessary. Otherwise, for each reaction, the 
following protocol was used: 5µL of Flexibuffer 5X (Promega), 0.5µL of dNTPS (10mM, 
Promega), 0.5µL of primers (10 pmol/µL, Eurofins Genomics), 1.5µL of MgCl2 (25mM, 
Promega), 0.2µL of GoTaq polymerase (Promega) and 15.8µL of DNase/RNase free water. 
1µL of the genomic DNA was added to the mixture. The PCR reaction program used was 
as following: 10min denaturation at 95°C, start a loop for 34 cycles, 30sec denaturation at 
95°C, 30sec annealing at 56°C, 1min elongation at 72°C, end of the loop, 5min final 
elongation at 72°C and store at 8°C. 10µL of the PCR reaction is then loaded on a 1.5% 
agarose gel beside 6µL of 100bp DNA ladder. 
 
Table 1: Primers used for PCR amplification of mfas 
 
Name Primer sequence 
mfas 1st exon Forward CCAACCGAGGCTCCAGATTA 
mfas 1st exon Reverse GCCGTAGAATGGAACCGC 
mfas 4th exon Forward CTGACTTCACAACGCCCTG 








1.5µg of each RNA sample was sent to the King’s college London Genomic Centre Facility 
for processing. The qPCR was made using UPL probes and primers designed by the 
Universal Probe Library software (Roche) for quantification (see Table below). Three 
independent biological replicates were measured for each genotype of each time point. 
Gapdh and eIF4A were used as house keeping genes for controls. 9 genes were quantified, 
depending on the genotype and the time point. 
 
 
Table 2: Oligos and UPLs used for qPCR 
 




Left Oligo 5’-3’ Right Oligo 5’-3’ 
repo CG31240 65 GCATCAAGAAGAAGAAGACGAGA GTTCAAAGGCACGCTCCA 
loco CG5248 116 CTGGTTTATCAACGCCTATGAA GAGTGCGGAAGGAAGACTGT 
Glio-
tactin CG3903 69 CGAATCGTCCAATTACAGAGC GAAAAATTCCAGGAGAAACTGG 
Gs2 CG1743 127 GCACCCTCGACTTCATTCC GCACGAGCTTCCATCGTAGT 
Pointed CG17077 63 CTTTCTGTCCAGCCTAGTTGAGT TGCACAGATCCTTGCATCC 
dEAAT1 CG3747 30 GAATAAATTTGCTTGACATCCTTTT AAAGCACGATTGGCAGTCA 
wg CG4889 81 GGCAAAATCGTTGATCGAG GCAGGACTCTATCGTTCCTTCA 
Gapdh CG12055 18 AAAAAGCTCCGGGAAAAGG AATTCCGATCTTCGACATGG 
Gal4  139 CCCGACCATGATTACGGATA TTGAAGTAAACGGGATGTTGTG 
eIF4A CG9075 104 CGTGAAGCAGGAGAACTGG CATCTCCTGGGTCAGTTGGT 







2.6.1 Fly head homogenisation 
 
10 male and 10 female flies per genotype were decapitated with a scalpel, snap-freezed and 
homogenized using a pestel in 75µL of 1X Sample Buffer (SB) (see 2.7 Table of solutions) 
with 5% ß-mercaptoethanol freshly added. The tube was centrifuged at 12000 rpm at 4°C 
for 5min. 70µL of the supernatant was taken out and transferred into a new tube. The 




Protein samples were boiled 3min and spinned down prior loading. They were then loaded 
on 10% w/v polyacrylamide gels using BioRad gel electrophoresis apparatus. The samples 
were run at 60V while in the stacking part of the gel and then at 90V in the resolving part, 
constant voltage, in running buffer (see 2.7 Table of solutions) 
 
2.6.3 Western Blot 
 
After separation in the gel, proteins were transferred onto a nitrocellulose blotting 
membrane (Amersham™, Protran™, 0.2µm, GE Healthcare, Life sciences) for 1 hour at 
60V, kept in cold, in transfer buffer (see 2.7 Table of solutions). The membrane was then 
blocked for an hour in 5% BSA or 5% milk in TBS-T (see 2.7 Table of solutions) at RT 
before incubation in primary antibody diluted in blocking buffer overnight at 4°C. The 
membrane was washed three times 15min in TBS-T at RT and then incubated 1 hour at RT 
in secondary antibody. After three wash in TBS-T, the membrane was washed again in TBS 
without Tween20. ECL reagent was mixed according to manufacturer’s instructions 
(SuperSignal WestPico or ECL Western blotting substrate, Pierce) and put onto the 
membrane to fully cover it. After 3min of incubation, the ECL liquid was removed and the 
membrane placed between two transparent plastic sheets and transferred into a cassette. 
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Once into the dark room, a film was disposed into the cassette for a certain amount of time, 
depending on the strength of the signal, and then transferred to a developer. The film was 
then scanned and processed using Adobe Photoshop 7.0.1 and the bands were quantified 




Anti-Repo (mouse monoclonal, 1/200 in blocking solution, DSHB 8D12), anti-GAT (rabbit 
polyclonal, 1/10000 in 5% milk-TBS-T, gift from Marc Freeman), anti-ß-actin (rabbit 
polyclonal, 1/3000 in blocking solution, SAB 21338), anti-myc (mouse monoclonal, 1/1000 






















2.7 Appendix   Table 3: Solutions used in this study  
Solutions Compositions 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.2 
TBS 50 mM Tris-HCl, 150 mM NaCl pH 7.6 
TAE 40 mM Tris-HCl, 20 mM acetic acid, and 1mM EDTA 
TBS-T TBS with 0.1% v/v Tween20 (Calbiochem) 
Wash buffer PBS + 0.2% Tx-100 
PLP 1/4 8% paraformaldehyde and ¾ lysine (0.12 mol/L) with Na2HPO4 
Blocking solution TBS-T with 5% BSA Running Buffer 25 mM Tris, 0.193M Glycine and 0.1% SDS Transfer buffer 25 mM Tris, 0.193M Glycine, 10% v/v MeOH 4X Sample buffer 200 mM Tris-HCl (pH 6.8), 6.4% v/v SDS, 16% v/v glycerol, 0.25% w/v bromophenol blue Proteinase K buffer 10 mM trisCl pH 8.2, 1mM EDTA, 25 mM NaCl and 200 µg/mL of Proteinase K (Invitrogen) freshly added 
LB medium 1 % w/v bacto-tryptone, 0.5% w/v bacto-yeast extract, 1% w/v NaCl      (pH 7) 
LB agar LB medium containing 1.5% w/v agar 
 
         
 60 
                  Chapter III:  
Effect of polyQ Atro expression in glial cells 




Drosophila melanogaster has been proven to be an excellent model to study 
neurodegenerative diseases. A lot of different models have been established to study 
specific genetic diseases such as ALS/FTD, Parkinson’s disease, Alzheimer’s disease or 
Huntington’s disease (Muqit et al. 2002, Hirth 2010, McGurk et al. 2015, Zhang et al. 
2015). The powerful genetic tools available for Drosophila offer the possibility to express 
mutated genes or any other transgene in specific subtypes of cells in a tightly controlled 
manner. The use of different systems such as UAS/Gal4, LexAop/LexA combined with a 
temperature sensitive Gal80 (Gal80ts) allows the expression of different genes in different 
cell types and thus deciphering cell-cell interactions. Moreover, Drosophila models have 
also been established to study recessive diseases. It is the case for Parkinson’s disease for 
instance, with the study of parkin and pink mutants. Using loss of function (LOF) or 
knockdown by RNAi of recessive genes could provide useful models as it is the case for 
recessive familial Parkinson’s disease (Muñoz-Soriano et al. 2011). 
 
However, most of the research in the field so far has focused on the neuronal contribution 
to the phenotypes they observe for a particular disease. Indeed, a common pattern between 
all neurodegenerative diseases is the actual loss of neurons in specific part of the brain. This 
specificity will give rise to distinct symptoms coming from the function of the brain region 
affected. Another pattern commonly observed in many neurodegenerative diseases is 
exacerbated gliosis in specific regions of the brain (Pekny et al. 2005, Sargin et al. 2009, 
Schwab et al. 2010). However, whether it is protective or harmful for the neurons in those 
regions is still open to debate (Jha et al. 2012). DRPLA is not an exception in that sense, as 
mentioned earlier in Chapter I. 
 
A recent DRPLA fly model established in our group has been used to understand the 
interaction between polyQ Atro (and human polyQ Atrophin-1) and the autophagy pathway. 
Beside the discovery of a link between polyQ Atro expression and the blockage of the 
autophagic flux, this study has revealed for the first time a potential contribution of glial 
cells to the pathology. The expression of polyQ Atro has been shown to be toxic in neurons 
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and glial cells, even when the expression is limited to the adult stage of Drosophila. Indeed, 
polyQ Atro expression from developmental stage compared to adult specific expression 
showed a similar phenotype (Nisoli et al. 2010). The drivers used for this study were Elav-
Gal4, a pan-neuronal driver and dEAAT1-Gal4, a driver commonly used to target astrocyte-
like glia using the promoter of the only glial glutamate transporter present in Drosophila, 
known to be expressed in the neuropil (Seal et al. 1998, Besson et al. 1999, Kawano et al. 
1999). This study also shows that expressing the human mutated Atrophin-1 in glia or in 
neurons has a similar phenotype to what is observed with Drosophila polyQ Atro. 
However, using the same drivers for glial or neuronal expression, the expression of polyQ 
huntingtin, the mutated protein responsible for Huntington’s disease, showed an inversion 
of the drivers’ strength. The neuronal one has a stronger phenotype than the glial one, 
contrary to the opposite effect observed with polyQ Atro. Taking together, these results 
show that in comparison to another polyQ protein, the balance of toxicity is more towards 
the glial cells for polyQ Atro. 
 
Not all the brain regions are affected in the same way for each neurodegenerative disease. It 
remains unclear why some neurons are more sensitive than others to the expression of 
mutated proteins. Depending on their functions, their gene expression profile or their 
connections to other regions of the brain, neurons can be affected and then die due to this 
particular mutation, or just survive and function normally. It is now well established that 
glial cells contribute to neuronal functions, regulating their excitation rate by acting at the 
synaptic level, or providing the neurons with energy, using the well characterized lactate 
shuttle for instance (Bélanger et al. 2011, Pannasch et al. 2014, Tang et al. 2014). It is then 
easy to understand that if glial cells are also affected by these mutations, it can trigger some 
dysfunctions that can affect directly or indirectly neurons (Volkenhoff et al. 2015). In the 
case of DRPLA, as mentioned above, the mutated glial cells seem to be sensitive to the 
toxicity of the autonomous glia specific polyQ Atro expression. However, the questions are: 
are all the glial cells equal to the sensitivity to these mutated proteins? Or, are some, 
similarly to neurons, more affected than others, and thus having a more important role on 
the disease progression? 
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The aim of this chapter is to understand whether all or some glial subpopulations are 
affected by the expression of polyQ Atro. And from the ones that are affected, which ones 
seem to be more important. Using different glial cell drivers, specific to the different 
subtypes of glia present in the Drosophila adult brain, polyQ Atro was expressed 
specifically in subsets of glial cells. Lifespan was used as readout in order to assess the 





























3.2.1 Glial subtypes display different sensitivity to polyQ Atro toxicity 
 
In order to characterize polyQ Atro toxicity on glial subtypes, I first wanted to see its effect 
when the mutated protein was expressed in all adult glial cells. Lifespan assay was used to 
monitor the toxic effect on the glial cells and the impact on the organism. To this end, the 
pan-glia driver Repo-Gal4 was used, which uses the promoter of the repo gene, expressed 
in all glial cells from development to adulthood, apart from midline glia, which are present 
only during embryogenesis. For these sets of experiments, Gal80ts (“temperature sensitive”, 
inhibiting Gal4 at 18°C but unfolded at 29°C) was not used as it has been shown that the 
expression of polyQ Atro in glial cells during development did not influence the adult 
lifespan of the Drosophila using either dEAAT1-Gal4 (Nisoli et al. 2010) or Repo-Gal4 at 
least (in this study). The crosses between the driver and the UAS-Atro75QN (polyQ Atro 
line) or w1118 (control) were kept at 18°C in order to keep the Gal4 activity as low as 
possible during development even though the adult does not seem to be affected. Once the 
progeny hatched from the pupae, they were collected and transferred to 29°C (see Chapter 
II for Materials and Methods). 
 
The lifespans were analysed using the software Prism GraphPad and the Kaplan-Meyer 
method (using the log-rank test). In addition to the P-value, this method also provides a Chi 
square value (χi2), used to calculate the P-value, both being dependent from the number of 
flies used in the assay. Thus these values can be directly compared only when the same 
number of flies is used. While the P-value is used to determine the statistical significance of 
an experiment, the χi2 value will be used in this thesis to rank the strength of the phenotype, 
being directly proportional to the difference between the curves. Indeed, it is more intuitive 
than the P-value, inversely proportional to the difference between the curves. However, this 
value provides only an indication of the strength and will be used in addition to the median 
survival of each curves, which is independent of the number of flies used. From the 
experience acquired in the lab on lifespan experiments, the use of two sets of 60 flies 
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genetically identical can give a P-value statistically significant. It demonstrates the 
variability of the assay and the limit of the use of the P-value to assess the biological 
significance. Thus, for the rest of the thesis, I will use the χi2 value and the median survival 
to compare different phenotypes but it will only provide an indication for the strength of a 
phenotype but not the statistical or biological significance of it. 
 
The lifespan of the flies expressing polyQ Atro in all the glial cells is dramatically reduced 
compared to the control lifespan (Figure 3.1A). Indeed, the median survival of the polyQ 
Atro expressing flies is 14 days compared to 34 days for the control. The corresponding χi2 
value is 111. This reduction by 60% of the lifespan highlights the importance of glial cells 
to maintain a functional organism. However, in this set up, polyQ Atro protein is expressed 
from development. Thus, it is also possible that some developmental defects can take part 
of this phenotype. Furthermore, the comparison of the median survival obtained using 
Repo-Gal4 to the one published by Nisoli et al. using dEAAT1-Gal4 in the same conditions 
shows a similar strength of phenotypes. Its median survival is 16 days compared to the 
control one of 30 days. This difference of only 2 days between dEAAT1-Gal4 and Repo-
Gal4 drivers shows the high importance of the dEAAT1 positive cells in the toxic effect due 
to polyQ Atro expression. However, Repo-Gal4 driver being pan-glial, it will be used as a 
reference phenotype for further glial subtypes comparison. 
 
Another line of dEAAT-Gal4 was then assessed and compared to the one used in the past. 
The evaluation of a similar driver but inserted in another locus in the genome allows a more 
accurate evaluation of the driver’s effect. Indeed, depending on its insertion, different levels 
of Gal4 expression can be obtained using the same promoter. This variation can result in 
different strength of phenotype. In the case of dEAAT1-Gal4, two different lines located on 
two different chromosomes, one on the second and one on the third chromosome, were 
assessed. Using the same UAS-Atro75QN and w1118 lines, the strength of both insertions can 
be directly evaluated. The dEAAT1-Gal4 inserted on the third chromosome has a median 
survival of 15 days when crossed to UAS-Atro75QN compared to 36 days when crossed to 
w1118 as control (Figure 3.2B). However, the one inserted on the second chromosome has a 
median survival of 20 days for UAS-Atro75QN with a control median survival of 30 days. 
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The Chi square obtained for those two lines are respectively 109 and 42 for dEAAT1-Gal4 
on the II and on the III chromosome. More than the tail of the curve of dEAAT1-Gal4 III, 
the difference is also due to the fact the lifespans of the control and the UAS-Atro75QN are 
crossing each other from 6 to 16 days, decreasing the Chi square value, which is 
proportional to the area between two curves. In conclusion, when comparing the strength of 
the phenotypes using the Chi square values, the dEAAT1 driver on the II chromosome is 
stronger than the one on the III. 
 
Another way to characterize a cell population is to use different drivers meant to target the 
same population. A driver known to be specific to the astrocyte-like glia also targeted by 
dEAAT1-Gal4 is Alrm-Gal4. Alrm codes for Astrocytic leucine-rich repeat molecule. Its 
function is not known, however its expression profile matches exactly the astrocyte-like 
glial cell population (Doherty et al. 2009). Similarly to dEAAT1-Gal4 driver, two different 
lines of Alrm-Gal4 are available, one on the second chromosome and one on the third. As 
seen in Figure 3.1C, both lines have the same phenotype when expressing UAS-Atro75QN, 
with a median survival of 26-27 days. However, when crossed to w1118 as control, they are 
slightly different. The insertion on the II chromosome has a median survival of 36 days 
while the one on the III has a median survival of 34 days. The respective Chi square values 
of Alrm-Gal4 II and Alrm-Gal4 III are respectively 49 and 33 between polyQ-Atro and 
w1118 curves, which is half of what was obtained using dEAAT1-Gal4 II driver, which is 
supposedly targeting the same glial cell population. In the attempt to avoid any problems 
due to the strength of each promoter, which could explain this difference, a Drosophila line 
having both Alrm-Gal4 was generated. This line was crossed to a recombined double UAS-
Atro75QN line to avoid any limiting effect from the UAS. However, the lifespan of this 
double Alrm-Gal4 does not increase the phenotype compared to one Alrm-Gal4 only even 
though the Chi square values are different. The polyQ Atro lifespan is compared to either 
the drivers crossed to w1118 or the double UAS crossed to w1118. The respective Chi square 
values are 80 and 53 (Figure 3.1C). It shows the variability of the Chi square value and the 
need to evaluate the median survival as well. The Chi square value is good for screening 
phenotypes but the median survival provides a better accuracy of the phenotype strength. 
This difference could be the result from a potential leakage of the UAS-Atro75QN 
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transgenes. The fact that the dEAAT1 drivers and the Alrm ones have different strength 
could reflect different cell populations targeted by dEAAT1-Gal4 drivers, which are not 
targeted by Alrm-Gal4 ones, inside or even outside the CNS. 
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To verify this hypothesis, a staining of the brains from the Gal4 drivers crossed with the 
reporter UAS-CD8-GFP was done. The GFP signal from dEAAT1-Gal4 shows GFP 
positive cells that can be seen located all around the brain, and not only surrounding the 
neuropil (Figure 3.2A). Alrm-Gal4 driver expressing the GFP reporter clearly shows cells 
surrounding the neuropil and sending projections in its direction (Figure 3.2B). These 
pictures confirmed the previous observations done by the MARCM (Mosaic Analysis with 
a Repressible Cell Marker) technique using Alrm-Gal4 driver to identify and characterize 
the astrocyte-like population (Doherty et al. 2009). However, cells with star shape, having 
processes like Alrm-Gal4 positive cells, are observed but these are not the only ones present 
when the dEAAT1-Gal4 driver is used. In some specific areas, GFP signal surrounding 
potentially neuronal cell bodies or axonal bundles in the optic lobes is also present, 
suggesting other populations of glial cells expressing dEAAT1-Gal4. These populations can 
be identified with the ensheathing glia and cortex glia. This difference in the cell 
populations targeted could explain, at least partially, the different phenotype strength 
between the drivers. 
 
These other potential glial subtypes, surrounding neuronal cell bodies and/or axonal 
bundles, look like the so-called cortex glia and neuropil ensheathing glia, characterized by 
MARCM technique using the drivers NP2222-Gal4 (Gal4 insertion into the Akap200 gene) 
and MZ0709-Gal4 respectively (Doherty et al. 2009, Awasaki et al. 2011). I confirmed the 
specificity of these drivers using again the UAS-CD8-GFP reporter. The so called “cortex” 
glia is present only in the “cortex” part of the brain, surrounding neuronal cell bodies and 
their membranes are absent from the neuropil, providing an opposite picture to the Alrm-
Gal4 positive glia (Figure 3.2C). The neuropil ensheathing glia send projections to 
surround the glomeruli within the neuropils, being the limit between the astrocyte-like glia 
and cortex glia membrane domains (Figure 3.2D). Furthermore, at the level of the optic 
lobe, the ensheathing glia membranes form a specific pattern of axonal bundles reminding 
the shape of the cortex glia surrounding the cell bodies. However, by costaining with DAPI, 
this pattern does not contain nucleus and might represent aligned tubular structures formed 





Using MARCM to label only one cell, it has been demonstrated that one “cortex” glia could 
ensheath a high number of neuronal cell bodies. Thus, NP2222-Gal4 driver has then been 
used to characterize the effect of polyQ Atro on this glial subtype, which shows similar cell 
shape to some observed in the dEAAT1-Gal4 staining. When crossed to the UAS-
Atro75QN, the median survival is 29 days, compared to 45 days for the control (Figure 
3.1D). Using the Kaplan-Meyer method, it gives a Chi square of 56. The phenotype of 
NP2222-Gal4 driving polyQ Atro is also weaker than the dEAAT1-Gal4 one. However, it is 
close to that of Alrm-Gal4, even though the control for NP2222-Gal4 lives much longer. A 
possible difference in genetic background could be responsible for this effect. The targeted 
cell populations are completely separated, having different functions in the CNS. However, 
they seem to have an equal sensitivity to the expression of polyQ Atro and a similar effect 
on the Drosophila lifespan. However, only one Gal4 line is available for the NP2222-Gal4 
driver, limiting the interpretation of the results. In order to complete the study of the glial 
cells being present around the neuropils, I also evaluated the sensitivity of the ensheathing 
glia to the toxicity of polyQ Atro. Unlike astrocyte-like glia, ensheathing glia surround the 
neuropil glomeruli but do not closely associate with synapses unlike astrocyte-like glia 
(Figure 3.2D). Those cells remain poorly studied in the adult Drosophila CNS, however it 
has been demonstrated that they function as phagocytes in larvae to clear degenerating 
axons in injured brain through the Draper/dCed-6 signalling pathway (Doherty et al. 2009). 
One driver has been characterized to be specific to ensheathing glial cells, called MZ0709-
Gal4. When crossed to UAS-Atro75QN line or w1118, its median survival is 33 days for the 
Atro polyQ and 39 days for the control (Figure 3.1E). This difference between the lifespan 
gives a Chi square value of 44. This value is in the range of Alrm-Gal4 even though the 
phenotype seems weaker comparing their respective median survival. Moreover, similarly 
to NP2222-Gal4, only one driver line has been assessed for this cell population, which 
limits the interpretation of the results. Thus, its weak phenotype could be due to a weak 
Gal4 expression caused by a positional effect of the transgene or a weak expression level 
from the promoter itself. 
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In addition to the shortening of the lifespan of glial polyQ Atro expression, climbing defects 
have also been previously reported (Nisoli et al. 2010). This alteration of the motility could 
come from different CNS dysfunctions but also developmental defects or impairment of 
sensory organs. Astrocyte-like glia regulate the synaptic activity, thus impairment at this 
level could trigger this phenotype. However, it has also been reported that a defective 
insulation of the nervous system results in a similar behaviour (Kim et al. 2010). The 
Drosophila BBB is composed of two layers. The outer one, in direct contact with the 
hemolymph, is made by perineurial glia while the inner one, directly protecting the neurons 
and the cortex glia, is composed of subperineurial glia. The first layer does not form tight 
junctions and has a role of pre-filtering big molecules. However, the subperineurial glia 
forms tight septate junctions that prevent non-required molecules to get inside the brain 
(Schirmeier et al. 2015). Gliotactin-Gal4 was used first to drive the expression of UAS-
Atro75QN in the subperineurial glia of both CNS and PNS. Gliotactin codes for a 
transmembrane protein required for the septate junction development and especially for the 
formation of the blood-nerve barrier (Auld et al. 1995). The Gal4 driver using its promoter 
is used to target peripheral glia. However, a recent study using UAS-CD8-GFP as a reporter 
has shown that it is also expressed in the subperineurial glia of the CNS (Zwarts et al. 
2014). When crossed with UAS-Atro75QN, Gliotactin-Gal4 lifespan has a median survival 
of 29 days. Its control lifespan has a median survival of 43 days (Figure 3.1F). When it is 
around 33 to 37 days for the previous drivers used, Gliotactin-Gal4 and NP2222-Gal4 have 
a control median survival of respectively 43 and 45 days. The Chi square of this 
subperineurial glia driver is 65, compared to 56 for NP2222-Gal4. Another “BBB” driver 
specific to subperineurial glia called Moody-Gal4 was also assessed. moody encodes for 
two G-protein coupled receptor proteins (GPCRs) that are required continuously to 
maintain the BBB integrity (Bainton et al. 2005). As previously done with the other drivers, 
the driver was crossed to either UAS-Atro75QN or w1118 flies. The difference between the 
two lifespans is milder than the other drivers assessed so far (Figure 3.1G). The median 
survival of the UAS-Atro75QN is 29 days compared to its control of 34 days. The Chi 
square value obtained for Moody-Gal4 is only 4, the weakest value of all drivers used for 
this study. However, as mentioned before, its p-value is statistically significant (p=0.023). 
It is possible that the level of Gal4 expression by moody promoter is a lot weaker than 
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Gliotactin promoter. Thus, it is possible that the sensitivity of subperineurial glia to polyQ 
Atro expression participates to the observations made with Repo-Gal4 on motor defects and 
overall lethality. 
 
According to the drivers used and the ranking of their Chi square values, the ensheathing 
glia, via the MZ0709-Gal4 driver, seem to be the less convincing cell type to follow up as 
being important in the reduction of the lifespan observed by a pan-glial expression of polyQ 
Atro (summary Table 4). Indeed, there is only 6 days difference in the median survival 
between the polyQ and control flies. However, only one line was assessed for this subtype, 
which limits the confidence in the phenotype observed. Also, for subperineurial glia, both 
drivers assessed have very different phenotypes, which could lead to different 
interpretations on the role of this glial subtype in the polyQ Atro toxicity. So far, the most 
convincing phenotypes come from Gal4 drivers being expressed in astrocyte-like glia, 
dEAAT1 driver on the II chromosome being the strongest after the pan-glia Repo-Gal4. To 
this end, I decided to further analyse the population targeted by dEAAT1 drivers by 
generating new dEAAT1 tools to allow this study. 
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 3.2.2 dEAAT1 positive cells are not only astrocyte-like glia  
Expressing polyQ Atro in dEAAT1 positive cells has the strongest phenotype after Repo-
Gal4 expression. dEAAT1 is a glutamate transporter and is thought to be astrocyte-like 
specific in the CNS. However, the mCD8-GFP staining shows a different pattern between 
Alrm-Gal4 and dEAAT1-Gal4. dEAAT1-Gal4 phenotype is relatively similar to Repo-Gal4 
having a Chi square of about 100 each. However, while Repo-Gal4 targets all adult glial 
cells, dEAAT1-Gal4 is supposed to be expressed only in glia invading the neuropil and a 
subset of neurons present in the lamina of the optic lobe (Rival et al. 2004). It raises the 
following question: what are the subsets of cells expressing dEAAT1-Gal4 that are 
responsible for the toxic effect? The characterization of this population could help us 
understand the role of each glial subtype in the polyQ toxic effect on the organism. The use 
of this driver instead of Repo-Gal4 could allow us to address more specific questions on 
physiological problems that occur due to polyQ Atro expression, which ultimately result in 
the fly death. 
 
3.2.2.1 Generation of new dEAAT1 driver lines 
 
To address this question, I decided to generate two different drivers using the dEAAT1 
promoter from the dEAAT1-Gal4 plasmid. The first one is dEAAT1-LexA-GAD (Gal4-
Activating-Domain). LexA-GAD binds to a sequence called LOT (also called LexAop), in 
the same way UAS/Gal4 system does. The LexA DNA binding domain is specific to its 
upstream activating sequence (from genes known to be activated by LexA), which in this 
case comes from E.coli instead of yeast for UAS/Gal4. The LexA sequence used in this 
study comes from an improved form of its former toxic sequence, which also had weak 
expression levels. The addition of the Gal4-hinge domain (hinge domain referred later as H, 
a short stretch enriched in acidic amino acids, from aa 148 to 196 of Gal4, known to serve 
as auxiliary activation domain in yeast) and the modifications of the activating domains 
(shorter GAD or VP16 in place of the formerly developed version) have increased the 
efficiency and decreased leakage and toxic effect. The GAD sequence used to add 
downstream LexA is a short version of the Gal4 GAD (amino acid 768 to 881 of Gal4), 
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which is the minimal sequence required to activate the transcription (Yagi et al. 2010). The 
use of GAD as transactivator allows the inhibition of the LexA activity by the use of Gal80. 
It provides a tight control of its activation in time, using Gal80ts, but also a more specific 
expression in subset of cells, by potentially using Gal80 lines that would partially overlap 
with dEAAT1-Gal4 expression. The second one is dEAAT1-LexA-VP16. The VP16 protein 
comes from the herpes virus and its activating domain has been restrained to a small 
sequence in order to be incorporated downstream the DNA-binding domain (minimal 
activation domains from VP16 from positions 436 to 447, put twice in a row according to 
(Baron et al. 1997)). The construction of such driver allows a transgene expression 
independently from Gal80 activity. 
 
The constructions of the plasmids were made using dEAAT1-Gal4 sequence incorporated 
into a pCASPER4 plasmid (see map Figure 3.3A), LHV2 insert (LexA:H:(VP16mAD)2) 
and LHG insert (LexA:H:GAD). First, I wanted to confirm the location of XbaI restriction 
sites that would be later used to remove Gal4. XbaI and SpeI restriction sites were cut to 
confirm their presence and their good locations in the plasmid (Figure 3.3A). The XbaI 
restriction enzyme digestion of the plasmid gives rise to 3 bands. The top one is the 
linearized plasmid pCASPER4 with a size of around 14kb. The middle band is the 5kb 3’ 
end of the dEAAT1 promoter (which is 8.5kb overall) and the lower band just above the 3kb 
ladder correspond to the Gal4 sequence with the hsp70 3’UTR region. The digestion using 
SpeI gives unexpectedly 3 bands instead of two. The top one is the pCASPER plasmid 
linearized and the middle one at a size of 3.5kb should be the Gal4 sequence. However, a 
band of 2kb is also present. The plasmid was then digested using both restriction enzymes 
at the same time to be able to confirm the unknown Spe site that seems to be within the 
dEAAT1 sequence. As expected, the product of the digestion was 4 bands. The 5kb band 
from the dEAAT1 sequence is cut into 2.8kb and 2kb sequences, surrounded by XbaI sites. 
A band at 200bp is actually also expected but is visible only with a high UV exposure 
(Figure 3.3A). 
 
To remove the Gal4 sequence, the restriction enzyme XbaI was used. However, as 
previously mentioned, this enzyme will cut the 5kb of the dEAAT1 promoter. Thus the cut 
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was performed in two different tubes, one being dephosphorylated to avoid the vector to re-
ligate itself (Figure 3.3B). The middle band phosphorylated and the top band 
dephosphorylated, corresponding respectively to the 5kb lacking of dEAAT1 and 
pCASPER4 were extracted from the gel and ligated to form pCASPER4-dEAAT1 plasmid. 
The selected transformed bacteria were then checked using SpeI and NotI restriction 
enzymes in order to confirm that the 5kb dEAAT1 fragment has been correctly inserted 
back (Figure 3.3C). 
 
The following step was to insert the LHV2 sequence into the dEAAT1 vector using NotI 
restriction sites. dEAAT1 vector has been dephosphorylated, and both dEAAT1 and LHV2 
plasmids were cut using NotI. The dEAAT1 vector and LHV2 fragment were then extracted 
from the gel and ligated. After bacteria amplification, the ligation was controlled using 
either KpnI or NotI for the presence of the LHV2 insert in the good direction (Figure 3.3D). 
The plasmid was then amplified and purified to be sent to inject. Its concentration after the 
purification step was 944 ng/µL. 
 
The replacement of LHV2 by LHG was done using NotI restriction sites. LHV2 was first 
excised. LHG and dEAAT1 were cut with NotI and in a similar manner than previously, 
were ligated, amplified from the good bacterial colonies (Figure 3.3D) and purified. The 
final concentration of the dEAAT1-LHG plasmid ready for the injection was 1345 ng/µL. 
 
Both plasmids were sent to inject into fly embryos. The larvae that have survived the 
injection and became adult were crossed to w1118 flies. Using standard procedures with eye 
colour phenotype for the insertion of the plasmid (the plasmid contains the mini-white “w” 
gene) and double balancers to identify the chromosome in which it is inserted, I isolated 5 
different lines of dEAAT1-LexA::GAD and 4 dEAAT1-LexA::VP16. Out of the 5 
LexA::GAD, one is on the II chromosome, 3 on the III and one on the X. Two on the III are 
homozygous lethal. For the LexA::VP16, two lines are on the second and two on the third. 






3.2.2.2 dEAAT1 positive cells are not only different types of glial cells but also neurons 
 
First, I verified that the dEAAT1-LexA was indeed activating transgenes downstream LOT 
sequence in a similar pattern than dEAAT1-Gal4. To this end, UAS-nls-GFP and LOT-
mCherry were used as reporters and respectively combined to dEAAT1-Gal4 and dEAAT1-
LexA::GAD1 drivers. An identical pattern was confirmed by colocalization of GFP and 
mCherry signals in adult brain (Figure 3.4A). The lifespan phenotype of all the LexA lines 
was then assessed. They were crossed with either LOT-polyQ-Atro or LOT-wt-Atro. The 
construct LOT-wt-Atro was used as a control because it was built beside the LOT-polyQ-
Atro and is a better control for the toxicity of polyQ. All the phenotypes observed using 
LexA::GAD were weaker than the ones using dEAAT1-Gal4. This is not due to the 
difference between UAS-polyQ-Atro and LOT-polyQ-Atro since using respectively Repo-
Gal4 or Repo-LexA, it gives the same strength of phenotype (compare Figure 3.1A and 
4.1C in Chapter IV). The lines with the strongest phenotypes were dEAAT1-LexA::GAD 1 
and 3 which have respectively a Chi square of 70 and 35, and a median survival of 27 days 
and 22 days (Figure 3.5A). The Chi square of the GAD 1 line is double the one of GAD 3 
because of the extended lifespan of its control with wt Atro, which has a median survival of  
38 days, compared to 30 days for the GAD 3 line. The lifespan of the dEAAT1-LexA::VP16 
could not be assessed since no adult progeny were obtained when crossed to LOT-polyQ-
Atro. This might be due to VP16 toxicity during development, even though it was 
developed to be reduced. Indeed, no developmental problem was ever observed using both 
Gal4 and LexA::GAD when expressed with polyQ-Atro. It is also possible that LexA::VP16 
expresses a much higher level of polyQ-Atro, which becomes toxic during development. 
And the fact that it is Gal80 insensitive, it is then impossible to bypass the development of 
the fly. The dEAAT1-LexA::GADs expression levels may be weaker than dEAAT1-Gal4. To 
try and solve this issue I recombined both the GAD1 and GAD3 lines to increase the level 
of polyQ-Atro expression. However, the combination of the two did not increase the 
strength of the phenotype (Figure 3.5B). Actually, both control and polyQ-Atro flies have 
an identical lifespan. This is mostly due to the reduced controlled lifespan, caused possibly 
by a toxic effect of having two LexA::GADs expressed in the same cells. 
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dEAAT1-LexA::GAD1  was then used to identify which cell populations were targeted by 
the driver. Both NP2222-Gal4 and Alrm-Gal4 were combined with UAS-nls-GFP. Using 
the previously recombined dEAAT1-LexA; LOT-mCherry line, I looked at the 
colocalization profile for each of them. Most of the GFP dots from NP2222-Gal4 and Alrm-
Gal4 colocalize with the mCherry from dEAAT1. However, some cells from each of Gal4 
drivers are not dEAAT1 positive (Figure 3.4B). This result is surprising because the 
dEAAT1 driver has been generally used to target astrocyte-like glia since it is from the glial 
glutamate transporter promoter and not cortex glia. However, from the CD8-GFP staining, 
some dEAAT1 positive cells that had the same pattern as NP2222 positive cells could 
already be observed (Figure 3.2A and 3.2C) as well as some ensheathing glia-like pattern 
in the optic lobe, surrounding axonal tracts. Altogether, these results mean that there is at 
least another glial population of astrocyte-like glia that does not express dEAAT1. 
Nevertheless, dEAAT1 positive cells recapitulate a big part of Alrm and NP2222 positive 
cells. Hence, I asked whether combining Alrm-Gal4 and NP2222-Gal4 drivers could 
phenocopy the polyQ-Atro lifespan phenotype of dEAAT1-Gal4. Surprisingly, expressing 
polyQ-Atro in both cell populations at the same time does not increase the phenotype 
obtained with Alrm-Gal4 alone. Indeed, it has the same median survival for polyQ-Atro and 
a slightly reduced lifespan for the control, may be due to a toxic effect from the 
combination of both drivers (Figure 3.4C). Its Chi square is 50, which is in the range of 
both Alrm-Gal4 and NP2222-Gal4 Chi square values. It is possible that the effect of the 
impairment of both cell types together has reached a threshold of toxicity for the organism 









It has been shown that dEAAT1 could be expressed in some repo negative cells in the 
lamina of the adult optic lobe (Rival et al. 2004). To confirm this observation, Repo-Gal80 
was co-expressed beside dEAAT1-Gal4>UAS-eGFP to inhibit Gal4 in all glial cells. As 
expected, some cells remained labelled. The labelling of a group of neurons in the optic 
lobe expressing dEAAT1 was confirmed as previously described; however, some cells and 
their processes were also seen around the central complex and the oesophagus (Figure 
3.6A). However, the majority of the dEAAT1 cells being glial cells, I wondered if it was 
possible to rescue the polyQ-Atro phenotype by the use of the pan-glial Repo-Gal80. The 
lifespan of dEAAT1>polyQ-Atro in the presence of Repo-Gal80 is not fully rescued 
(Figure 3.6B) but the Chi square value decreases from 69 without Repo-Gal80 to 16 with 
it, which is close to the variability level observed in these assays, between genetically 
identical controls, though statistically significant (both p<0.0001) (see next chapters). It is 
also possible that Gal80 expression is not high enough to compensate the Gal4 expression 
by dEAAT1 driver. I decided to try and rescue the polyQ-Atro phenotype of Repo-Gal4 
driver, which has a strong level of expression in all glial cells. As expected, Repo-Gal80 
expression was able to fully rescue the lifespan phenotype of Repo-Gal4>polyQ-Atro 
(Figure 3.6C). Indeed, the Chi square in this case goes from 106 without Repo-Gal80 to 
0.01 with it, which is not statistically significant. Thus, Repo-Gal80 is capable of blocking 
the activity of Gal4 expression to at least Repo-Gal4 level. It is noteworthy that Repo-Gal4 
is a knock-in insertion of Gal4 into the endogenous locus of the repo gene. However, Repo-
Gal80 is a construct made of a part of the repo promoter, and then inserted randomly into 
the genome, thus, potentially having a different level of expression. I then wondered if the 
fact that Repo-Gal80 was not rescuing fully dEAAT1 expression of polyQ-Atro was due to 
its expression in repo-negative cells and especially in the subset of dEAAT1 positive 
neurons. This question was addressed by the use of Elav-Gal80, which similarly to Repo-
Gal80 is not temperature sensitive. The inhibition of any potential activity of Gal4 in 
neurons by Elav-Gal80 did not rescue the lifespan phenotype (Figure 3.6D). Furthermore, 
compared to the respective lifespans without Elav-Gal80, it seems that this transgene is 
toxic and decreases mildly the Drosophila lifespan by itself. The Chi square is 96 with 
Elav-Gal80, and 67 without. However, from the same experiment done previously without 
Elav-Gal80, the Chi square of dEAAT1-Gal4 II was in the range of 100. Overall, it suggests 
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that the neuronal cells positive for dEAAT1 do not seem to have a major role in the 
reduction of the lifespan due to polyQ-Atro even though it is possible that the Gal80 level 
from the Elav promoter might not be sufficient to counteract the Gal4 level from the 
dEAAT1 promoter. It is also possible that the driver’s expression outside the CNS can 
impact the lifespan. 
 
Taken together, these data show that dEAAT1 positive glial cells are a mix of some 
astrocyte-like glia Alrm positive, some cortex glia NP2222 positive and potentially some 
ensheathing glia in the optic lobe. However, the strong reduction of the lifespan by dEAAT1 
drivers was not recapitulated by combining Alrm-Gal4 and NP2222-Gal4 drivers. 
Furthermore, it seems that a subset of Alrm and NP2222 positive cells do not express 
dEAAT1-Gal4. I also confirmed that the glutamate transporter driver is expressed in some 
neurons present in the adult optic lobe, but is also expressed in few neurons in the central 
brain. However, it is unlikely that its neuronal expression is responsible for the partial 
rescue observed with Repo-Gal80. It is possible that an expression in other tissue outside 







 3.3 Discussion 
 
3.3.1 Astrocytes and cortex glia are sensitive to polyQ Atro 
 
Is there a certain variation of polyQ Atro toxicity among the different glial subtypes? Five 
types of glial cells present in Drosophila nervous system have been assessed. The outer 
layer of the BBB (the perineurial glia) has not been studied, as their role in the Drosophila 
CNS remains unclear. There is another kind of glial subtype recently discovered. These 
cells have been characterized as Glutamine synthetase 2 (Gs2) and dEAAT1 positive and 
are in very close proximity to the neuromuscular junctions (McCabe et al. 2015). Gs2 is 
also present in wrapping glial cells, which form the BBB around the nerves in the 
peripheral nervous system. Using Moody-Gal4 or Nrv2-Gal4 drivers to downregulate Gs2 
in BBB/wrapping glia, Gs2 was indeed knocked-down from those cells. However, some 
cells remained Gs2 positive, having their cell bodies and processes closer to fine motor 
axon branches forming neuromuscular synapses. These cells seem to be peripheral 
astrocyte-like glia, but might be targeted by dEAAT1-Gal4 driver. This discovery being just 
made, no specific Gal4 drivers are yet available for this subtype. 
 
The differences in the lifespan phenotypes from the different drivers assessed can come 
from different origins. First, the level of expression of each Gal4 driver has not been 
assessed since it is relatively difficult to compare the levels between different cell types and 
the immunofluorescence is not accurate to do so. Coming from different promoters, it is 
highly likely that the Gal4 expression levels are different and in a build-up process such as 
for polyQ aggregation it can change the onset of the phenotype. It is also possible that the 
temporal expression of the different lines is different, especially during development. 
Again, for the same reasons, if the expressions are not constant, it can affect the build-up 
process. Indeed, the expression of polyQ-Atro only during three days in adult does not 
affect the lifespan (data not shown). Also, it is possible that there is a developmental 
component in the lifespan phenotypes, which can differ from each driver by their 
developmental expression levels or the sensitivity of each cell type to the polyQ toxicity 
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during the different developmental stages. However, the use of Gal80 temperature sensitive 
later on in this thesis has shown that developmental defects do not account for polyQ-Atro 
toxicity using Repo-Gal4 driver at least. This driver, having a strong expression level and 
covering most of the glial cell types during all Drosophila stages (apart from midline glia, 
not assessed here), it is likely that the other drivers specific to glial cells would not have a 
developmental component in their lifespan phenotypes. 
 
In the case of dEAAT1-Gal4 drivers, two different lines have been assessed, with similar 
strength of their phenotypes. The fact that they are on different chromosomes, and that they 
have a similar phenotype, means that problems of insertion toxicity or modulation of Gal4 
activity are less likely. The same applies for Alrm-Gal4, more specific to astrocyte-like glia, 
according to the mCD8-GFP stainings. The combination of both drivers from the II and III 
chromosomes did not increase the strength of the phenotype. dEAAT1-Gal4 is also 
expressed in glial cells other than astrocyte-like glia. The labelling with mCD8-GFP 
revealed some cells surrounding neuronal cell bodies and/or axonal bundles, which seem to 
be cortex glia and/or ensheathing glia. The subperineurial glia would require more 
investigation to understand their role in the reduction of the lifespan. Both Moody-Gal4 and 
Gliotactin-Gal4 overlap in expression pattern, being expressed in these “BBB” glial cells in 
the CNS and PNS. However, one is having a relatively strong effect, similar to NP2222-
Gal4 while the other one is having none. It is possible that the Gliotactin promoter used to 
trigger Gal4 expression is stronger than the moody promoter. Some co-staining would be 
needed to evaluate the overlap between both drivers. However, a LexA line would need to 
be established in order to carry out this investigation in the most rigorous way. Thus, it 
remains unclear whether subperineurial glia, or at least part of them, are sensitive to the 
toxic effect of polyQ Atro and participate to the phenotypes observed with Repo-Gal4. For 
the neuropil ensheathing glia, MZ0709-Gal4, unfortunately only one driver was available. 
In this case, the weak phenotype can be due to the weakness of the Gal4 expression due to 
the insertion of the transgene. For the same reason, the phenotype observed for NP2222-
Gal4 (cortex glia) could be different using drivers inserted into other genomic locus. Also, 
the control lifespan for this driver is abnormally extended, similarly to Gliotactin-Gal4. 
Even though all Gal4 drivers have been generated on a w1118 genetic background, over 
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time, mutations might have accumulated, which can result in phenotypic differences, 
especially relevant for the lifespan. To solve this problem, an isogenisation of all the lines 
used could be done on the same genetic background, with the experiment repeated straight 
after to avoid any accumulation of different mutations in each line. Another way would be 
to generate new drivers that are also specific to similar glial cell populations, or at least 
different insertions similarly to what was available for Alrm-Gal4 or dEAAT1-Gal4. 
 
However, the strongest phenotypes for specific glial subtypes are observed using drivers 
that target astrocyte-like glia and cortex glia (neuronal cell body ensheathing glia). 
Gliotactin-Gal4 is also comparable to NP2222-Gal4, both of them having higher Chi 
square than Alrm-Gal4 drivers but it is the only one having a phenotype for this subtype 
compared to the use of two for dEAAT1-Gal4 or Alrm-Gal4. Taken together, these data 
strongly suggest that astrocyte-like glia are sensitive to polyQ Atro, and their dysfunction 
triggers a clear reduction of Drosophila viability. However, dEAAT1-Gal4 does not seem to 
be very specific and I have been unable to pin down which other population of glial cells is 
responsible for the strong effect of dEAAT1-Gal4. Further investigation would be required 
to establish clearly the role of each glial subtype in the toxic effect of polyQ Atro on the 
Drosophila organism. The use of Alrm-Gal80 combined with dEAAT1-Gal4 for instance, 
would help to specifically isolate the role of the astrocyte-like glia population positive for 
dEAAT1-Gal4 and understand their participation to the phenotype. Our results may suggest 
also that some glial cells would be more affected than others or that the dysfunction of 
some glial cells might have a higher impact on Drosophila viability than others. It is for 
instance still controversial whether BBB defects affect the lifespan of adult flies or not 
(Kim et al. 2010). 
 
3.3.2 dEAAT1-Gal4 expression is not restricted to a specific subset of glial 
cells 
 
dEAAT1 is one of the two glutamate transporters expressed in the Drosophila nervous 
system, the other being dEAAT2. They are differentially expressed throughout 
development. In the adult, dEAAT1 seems to be mostly glia specific, even though few 
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neurons in the optic lobe express it as well. However, dEAAT2 is also neuronal and has 
actually a higher affinity for taurine and aspartate rather than glutamate (Besson et al. 2004, 
Besson et al. 2011). Being a glutamate transporter and expressed mostly in the neuropil 
(Rival et al. 2004), it was thought that dEAAT1 would be an astrocyte-like marker. 
Different cell patterns could be observed by labelling these cells using the membrane-
bound mCD8-GFP. Some star shape cells are supposedly astrocyte-like glia as expected, 
but neuronal cells bodies surrounded by GFP could also be seen, similarly to NP2222-Gal4 
(cortex glia) pattern. However, the use of Gal4 drivers using the promoter region of a gene 
do not necessary represent the gene endogenous expression and it is possible that dEAAT1-
Gal4 targets cell types that do not express the dEAAT1 gene or vice-versa. Indeed, flybase 
website reports dEAAT1 RNA expression in fat bodies, muscles and to a low level in the 
gut, all of them being able to affect the lifespan. I have demonstrated that using a newly 
established dEAAT1 driver combined with LexA, the dEAAT1 promoter does not only 
recapitulate astrocyte-like glia pattern in the CNS. It has a stronger phenotype than Alrm-
Gal4 with the expression of UAS-polyQ-Atro. However, expressing polyQ-Atro in both 
astrocyte-like glia and cortex glia at the same time does not match the strength of the 
dEAAT1 lifespan phenotype. Furthermore, the expression of dEAAT1-Gal4 in a subset of 
neurons does not seem to be responsible for the difference observed with the other drivers. 
It is also possible that the expression of Gal4 in the dEAAT1 cells is stronger than Gal80 
from repo or elav promoters. A leakage of polyQ-Atro expression due to a reduced but not 
fully inhibited Gal4 activity could result in the partial rescue of the lifespan. It is also 
surprising that some Alrm positive cells do not express dEAAT1-Gal4. So far, nothing has 
been described on the potential heterogeneity of astrocyte-like glia in Drosophila but it is 
likely that there are different subtypes of astrocytes having specialized functions. The 
heterogeneity of astrocytes in mammals has been studied only recently and we are still far 
from understanding the real complexity of the functions achieved by the different types of 
astrocytes (Bayraktar et al. 2015, Bribián et al. 2015, Johnson et al. 2015, Schitine et al. 
2015). It is likely that, there is also a certain diversity of astrocyte-like glia in Drosophila. 
Drosophila astrocytes are also known to express a GABA transporter called Gat, recently 
identified as astrocyte marker in the CNS (Muthukumar et al. 2014, Stork et al. 2014). The 
pattern of expression overlaps with the Alrm-Gal4 one, being expressed exclusively in the 
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neuropil via the astrocyte processes. It is possible that some astrocytes have specialized in 
GABA clearance and do not express glutamate transporters. 
 
The fact that dEAAT1-LexA::GADs are weaker than dEAAT1-Gal4 drivers, and that 
dEAAT1 promoter targets a rather complex population of cells, it makes its further use for 
the study of glial cell functions in the CNS not specific enough and thus not dissimilar from 
Repo-LexA, which is however stronger (see next chapter). Also, the expression of polyQ-
Atro with dEAAT1-LexA::VP16 drivers seem to be very toxic for the flies. This result is 
surprising as all the lifespan done so far, including Repo-Gal4 and dEAAT1-Gal4 with 
polyQ-Atro, had no developmental defects. Moreover, when dEAAT1-LexA::VP16 is 
crossed with w1118, adult flies are viable. Hence, the expression of LexA::VP16 in dEAAT1 
positive cells is not toxic by itself. It is possible that the level of expression triggered by 
VP16 is much higher than Gal4 or LexA::GAD and thus, becomes toxic during 
developmental stages. In any case, the use of dEAAT1-LexA drivers generated by us do not 
appear to be of direct use for the study of polyQ Atro effects on adult glial cells. 
                        
 91 
         Chapter IV:  
Using a DRPLA fly model to screen for 
neuron-glia interactions 




As described in the previous chapter, polyQ Atro expression in glial cells display a dramatic 
phenotype, reducing lifespan and motility. Compared to the effects of polyQ Atro 
expression in neurons, glial cells seem to be more sensitive to its toxicity, pointing toward 
an important participation of glial cells in the pathology due to polyQ toxicity (Nisoli et al. 
2010). Indeed, its glia specific expression triggers motor defects, which are attributable to 
neuronal dysfunctions. Also, it has been shown that there were no signs of cell death prior 
to organism death using the dEAAT1-Gal4 or Elav-Gal4 drivers (glial and neuronal drivers 
used in that study), suggesting that it is possible that the fly dies from general deregulation 
of CNS homeostasis before losing any cells. Altogether these results demonstrate that glia 
polyQ Atro expression triggers alterations in glia function, which may result in neuronal 
dysfunction through alterations in neuron-glia communication. 
 
Beside the autonomous effect of polyQ Atro toxicity in different cellular pathways, it is also 
of interest to better understand how glial cells defects can impact neuronal functions. These 
two cell types interact at different levels, depending on their functions. As described in the 
previous chapter, different glia subtypes have an effect on viability when specifically 
expressing polyQ Atro. It suggests that neurons can be affected in many different ways, 
depending on whether the astrocyte-like glia are affected or cortex glia, which have 
different functions leading to different interactions with the neighbouring neurons. For 
instance, astrocyte-like glia dysfunctions can modify neuronal activity through changes in 
neurotransmitter uptake or synapse formation and stability for example (Kerr et al. 2014, 
Muthukumar et al. 2014). However, cortex glia, which surround neuronal cell bodies, are 
thought to provide trophic and metabolic supports for neurons. It is yet to be shown that the 
so-called lactate shuttle is also present in Drosophila but it has been recently demonstrated 
that glial glycolysis is essential for neuronal survival (Volkenhoff et al. 2015). Also, this 
cell type expresses the engulfment receptor Draper, which suggests that they could 
participate in the clearance of neuronal cell debris when needed (Doherty et al. 2009). 
Modifications in each of the glial functions interacting with neuronal pathways important 
for CNS homeostasis will affect organism viability. It is highly likely that the expression of 
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polyQ Atro will trigger large transcriptional alterations, leading to different functional 
changes in glial cells. The dysregulation of autophagy, which was reported also in glial cell 
(Nisoli et al. 2010), is also likely to affect the trafficking machinery and possibly also the 
secretory, phagocytic and endocytotic pathways, leading to the impairment in processes 
critical for several glial functions. However, relatively little is known about glia-neuron 
interactions, especially in a disease context. In most of the cases, models express the 
mutated protein in the entire CNS using prion protein promoters (PrP) for instance (Garden 
et al. 2002, Loftus et al. 2002, Shin et al. 2005), which prevent the specific understanding 
of the participation of only one cell type to the pathology. Or, when the study is restricted 
to one cell type, the mutated protein is most of the time expressed in neurons (Latouche et 
al. 2007, Thomas et al. 2010, Zhang et al. 2015), which is for historical reasons the most 
obvious target to tackle the impaired mechanisms of neuropathological disorders (Wong et 
al. 2002). However, increasing number of studies try to change the approach by specifically 
expressing mutated proteins in glia subtypes. Several have already demonstrated that it is 
sufficient to trigger neurodegeneration but so far much of the effort has been to characterize 
defects in neurotransmitter transport (Liévens et al. 2001, Custer et al. 2006) or in 
autophagy (Di Malta et al. 2012) for instance. Most of these studies have been done using 
mouse models, which limit the use of genetic modifications in order to modify pathways 
independently of the mutated protein expression. Thus, it is difficult to study neuron-glia 
interactions in a cell-type specific manner, which would help to decipher molecular 
pathways mediating the toxic effects from one cell to another. 
 
Drosophila has been historically a model used to screen for genes (Dietzl et al. 2007) or 
compounds (Levine et al. 2016) that would modify a defined phenotype. Its costs, fast life-
cycle and available genetic tools make it an ideal model to screen for a high number of 
selected genes in a reasonable time, which would not be possible in mice. A perfect 
example of this process is the recently published work using C9orf72 screens on 
Drosophila that identified defects in nuclear-cytoplasmic transport, which has been then 
confirmed in iPSCs from patient and post mortem staining on ALS patient’s brains 
(Freibaum et al. 2015, Tran et al. 2015, Zhang et al. 2015), highlighting the relevance of 
such screens for the discovery of disease mechanisms conserved across species. In order to 
 94 
uncover new interactions between neurons and glia that could be involved in mediating 
glial polyQ toxicity, several screens have been designed in our lab. Using the broad range 
of genetic tools available in Drosophila, it is possible to express independently two 
transgenes in two different cell types. 
 
In this study, the focus is on the role of impaired glial cells in neuronal dysfunction. It has 
been established that expressing polyQ Atro in glial cells reduces Drosophila lifespan. 
Using this paradigm, the aim of this chapter is to discover genes expressed in neurons that 
would be involved in the mediation of the glial polyQ toxicity on the lifespan. Using this 
strategy, it would be possible to uncover neuronal genes that are required to detect 
phenotype of glial impairment. Indeed, the effect of polyQ expression in glial cells is 























4.2.1 Establishment of a new DRPLA fly model to study glia-neuron 
interactions 
 
In the previous chapter, the characterization of the impact of each glia subtype was done 
using a full length transgenic polyQ Atro and was expressed throughout development that 
has no or very little impact on viability or on lifespan. In order to identify genes expressed 
in neurons that modify the adult lifespan, an RNAi-based strategy was chosen to knock-
down specific genes. For the Drosophila melanogaster, more than 80% of the genes have 
their corresponding RNAi lines. Also, 3 to 4 different RNAi collections exists from 
different stock centers (VDRC “stockcenter.vdrc.at” (Austria) and Bloomington 
“flystocks.bio.indiana.edu” (USA) being the main ones), each of them having generated 
sometimes several UAS-IR (inverted repeats) RNAi lines per gene, which allow the 
confirmation of a phenotype by independent lines binding other sequences of the mRNAs. 
However, the downregulation of genes in neurons through development is often lethal or 
could trigger developmental defects independently of their adult function (Koizumi et al. 
2007, Paradis et al. 2007, Valakh et al. 2012). To by-pass this problem, a ubiquitously 
expressed Gal80 temperature sensitive transgene will be used (Ubi-Gal80ts). This 
temperature dependent Gal4 inhibitor allows the control of the transgene activation, by 
transferring the flies from 18°C (Gal80 active) to 29°C (Gal80 inactive). Thus, it will be 
possible to specifically activate transgene expressions only at the adult stage. The impact of 
the gene knock-down on the lifespan will then come from adult function and not 
developmental modifications, which could have later impact on the lifespan of the fly. 
 
Being a non-cell autonomous screen, the transgenes have to be expressed in different cell 
types. Two different expression systems are used to independently express polyQ Atro in 
glial cells and the RNAi in neurons. The RNAi collections available are all UAS- based 
lines, meaning that they are activated by Gal4. Thus the Elav-Gal4 driver will be used in 
order to express the different RNAi lines in all post-mitotic neurons. There are other 
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expression systems available in Drosophila, like the Q-system, which is drug dependent. 
However, most of the tools available beside the Gal4-UAS system have been developed for 
the LexA-LexAop (LOT) system, where a Repo-LexA line is actually already available. 
Moreover, even though LexA binds specifically to LOT promoter sequence and do not 
cross react with UAS, it is still Gal80 sensitive. Indeed, the LexA drivers have been 
developed mostly with the activating domain of Gal4 and the DNA binding domain of 
LexA. The combination of both systems will allow the activation of both transgenes at the 
same time, at the adult stage in this case. 
 
The aim of this screen is to identify pathways that are impaired by the expression of a 
disease protein. However, the Drosophila homolog of Atrophin-1, called Atro, is slightly 
different from the mammalian version, as described in the first chapter. The Drosophila 
Atro possesses some domains shared with the human ortholog Atrophin-2, which is not 
responsible for the disease DRPLA (Figure 4.1A). However, Atro is known to give rise to 
two different isoforms, recapitulating both Atrophin-2 and Atrophin-1 expression in 
mammals (Fanto, unpublished). The overexpression of the full length Atro would 
correspond to the overexpression of both Atrophin genes expressing a polyQ mutation in 
human. It is possible that the overexpression of a protein containing such domains, present 
in both Atrophin-2 and Atro but not Atrophin-1, could have undesired molecular changes 
irrelevant to what is happening in DRPLA. To avoid such potential issues, and build a more 
faithful model for DRPLA, a shorter version of Atro lacking the N-terminal domains has 
been designed, downstream of a LOT- sequence, called sAtro. This short version of Atro 
has been constructed with either a wild type stretch of 11 CAG repeats or a disease length 
stretch similar to the UAS- used in the chapter III, containing 75 CAG repeats (Figure 
4.1A). The polyQ construct (LOT-polyQ-sAtro) will allow the overexpression of only the 
Atro isoform lacking the N-terminal domains thus not interfering directly with the 
functions of these domains and resembling more closely the functions of Atrophin-1 in 
humans. This new construct will help modelling more closely DRPLA glial cells. A non-
polyQ construct (LOT-wt-sAtro) has been designed in order to control the effect of the 
overexpression of Atro independently of its polyQ stretch. It will allow us to determine 
whether the phenotype is polyQ dependent or due to the overexpression of Atro itself. 
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The plasmids containing the different versions of LOT-sAtro (pQ or wt) were sent to be 
injected at Fly-Facility in Clermont-Ferrand. Around a hundred and fifty embryos have 
been injected for each plasmid. The Atro expression for each of the positive insertion was 
confirmed first by immunostaining using this time Repo-LexA to visualize the presence of 
overexpressed Atro in glial cells in the L3 larval eye imaginal discs. Two LOT-polyQ-sAtro 
lines were positive, named A and B (Figure 4.1B). The same method was applied to 
generate two LOT-wt-sAtro lines, one on the second chromosome and one on the third. 
Both A and B lines being inserted on the second chromosome, a LOT-wt-sAtro line on the 
second chromosome was selected as well for later use, in order to simplify crossing 
schemes. 
 
The first step was then to generate a line in which there would be both drivers (Elav-Gal4 
and Repo-LexA), glial polyQ Atro (LOT-sAtro-polyQ) and a ubiquitous Gal80 temperature 
sensitive (Ubi-Gal80ts) transgenes and then characterize the lifespan of this line regarding a 
potential toxicity due to the presence of all these transgenes together in the same organism. 
The LOT-sAtro-polyQ lines have been recombined with Ubi-Gal80ts and then combined 
with the two drivers present on the X chromosome. The final genotype of the line later used 
for the screen becomes: Elav-Gal4, Repo-LexA (X chr); LOT-sAtro-polyQ, Ubi-Gal80ts (II 
chr). All these transgenes are homozygous viable. The toxicity of both polyQ lines was then 
evaluated by lifespan in order to see if the combination of Repo-LexA with this new polyQ 
sAtro line would give a similar phenotype to Repo-Gal4 > UAS-Atro-polyQ.  Both lines 
were crossed to w1118 flies. The toxicity of the drivers alone or the transgenic recombined 
lines without driver was assessed. The lifespan of both final lines (with the drivers) have 
identical median survival of 17 days, very similar to what was obtained in the chapter III 
with Repo-Gal4 and without Gal80ts, which was 15 days. This difference of 2 days can 
come from the strength of Repo-LexA driver compared to Repo-Gal4 or the efficiency of 
the LOT compared to UAS as well, or an intrinsic difference between Atro and sAtro 
toxicity. However, when the lines without the drivers are crossed with w1118 flies to assess a 
potential toxic effect of the insertion itself, there is a difference between the two transgenic 
lines. While A lifespan is similar to the drivers alone, with a median survival of 33 days, the 
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B line has a median survival of 26 days (Figure 4.1C). This difference suggests that the 
transgenic insertion of the B line is somewhat toxic for the organism, differently from the A 
one. The respective Chi square for each line compared to their own control are 86 and 75. 
Those numbers, compared to the 111 obtained in the chapter III confirms that the 
phenotype is slightly weaker but still in the range of a pan-glial effect of polyQ Atro 
toxicity on the Drosophila organism. 
 






















4.2.2 Identification of glia-neuron interacting genes using an RNAi-based 
screen 
 
4.2.2.1 Selection criteria for the screening 
 
The first criterion to define was the size of the screen. How many genes to be screened? A 
reasonable number of genes decided to be screened by RNAi was around a thousand, which 
corresponds to less than 10% of the Drosophila genome (between 14000 and 18000 genes 
located to the genome). Each gene would be downregulated by only one RNAi line as a 
compromise between number of gene screened and reliability on the efficiency of the 
RNAi. By setting up on average 35 crosses per week, it should be theoretically possible to 
screen this amount within 8 months since it takes around two months from the set up of the 
cross to the end of the lifespan of the progeny. The VDRC collection being the most 
complete one and made on w1118 genetic background (compare to the Bloomington one 
made on y,v background), all the RNAi lines were ordered from them. The most recent 
RNAi designed by the consortium is the so called KK line. Contrary to its former version 
called GD, the KK is site-directed inserted into the second chromosome, to a location 
known to allow high transgene expression. The GD lines are randomly inserted and can be 
present on either the second or the third chromosome. All the RNAi lines ordered were KK 
lines or GD only when the KK were not available. 
 
The second criterion chosen was the enrichment of the gene expression in the head against 
the rest of the body. Using the website Flyatlas.org, it is possible to sort the genes by a 
multiple range of characteristics. The expression profile of most of the genes has been 
characterized allowing the selection of specific expression patterns (Duncan et al. 
manuscript in preparation). The aim of this study is to find new genes involved in the 
communication between glial cells and neurons and thus, it is more likely that genes 
involved in the interaction between those two nervous system specific cell-types are more 
enriched in the brain compared to the rest of the body. It is obviously possible that very 
common molecular mechanisms, such as autophagy, cell death or cell cycle genes will be 
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disregarded using this method but it will allow us to focus on genes more specific to the 
nervous system and thus more likely to be involved in CNS specific functions. A third 
criterion for the selection was the availability of overexpression lines. Then, from this list, 
the first thousand genes matching these criteria were chosen. 
 
4.2.2.2 Screening method and results 
 
From the experience the lab has acquired in doing lifespan, a number of 60 flies (3 tubes of 
20 flies) per condition was chosen. This number of flies is a compromise between the time 
spent to count dead or alive flies three times per week and having a sample size big enough 
to detect differences in lifespans. As mentioned in the previous chapter, the Chi square 
value given by the software used for the statistical analysis (Prism GraphPad) is the number 
used to compare different strength of phenotypes. This number, related to the P-value, is 
more intuitive in its use than the P-value itself since it is directly proportional to the 
strength of the phenotype. However, likewise, it is also linked to the number of specimen 
assessed in each condition meaning that it can only be used for the comparison of sets of 
experiments using the same number of flies. It has already been established in the lab that 
in the condition of 60 flies assessed per lifespan, a Chi square smaller than 10 is not reliable 
and often not reproducible even though it is transformed in significant P-value. Indeed, two 
genetically identical control lifespans with this amount of flies can have a Chi square of 10, 
giving a statistically significant P-value, which represent the variability of the assay in these 
conditions. Another reason for choosing to use the Chi square rather than the P-value, is 
that we use this parameter only for quantification and ranking of phenotypes and we do not 
wish to assume any statistical or biological threshold of significance in our analysis because 
of the intrinsic variability of the lifespan assay. Moreover, above a Chi square value of 20, 
the software does not give the exact value of the P-value, just mentioning p<0.0001, 
preventing any possibilities to rank the strength of the phenotypes. The aim with this 
reasoning is to pick up the most reliable candidates, with a statistically significant P-value 
but also with a higher threshold of selection using a Chi square value above 10, which 
represent a P-value of 0.01. 
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Out of the thousand RNAi lines assessed by lifespan, 93 of them have been identified to be 
potential suppressor (increase of lifespan) or enhancer (decrease even further the lifespan). 
The decision to select those candidates was however taken by the evaluation of the female 
lifespan. This modification of our intentions was made necessary because male lifespan 
was barely variable and very few RNAi lines (<5) sensibly modulated their lifespan, 
masking any potential effect. This represented a caveat for the screen, which became 
evident only after 30% of the crosses had been already set up and the first ~100 lifespan 
were analysed. Although this reduced the sample size of each lifespan experiment it was 
decided to carry on with the initial set up not to invalidate comparisons with the part of the 
screen already done and because the lifespan of 30 fertilised females seemed to deliver 
meaningful information at that point. In hindsight, it is possible that the use of drivers on 
the X chromosome, present in only one copy on the males, has impacted on the lifespan. 
The genes present on the X chromosome of the males are known to be more expressed than 
on the female X chromosome, having two alleles. Indeed, the final genotype of the assessed 
flies was: Repo-LexA,Elav-Gal4/(wt X or Y from the UAS-IR line) ; UbiGal80ts,LOT-
sAtro-pQ/UAS-IR. This could lead to a stronger expression of polyQ Atro in males that 
could limit the observation of phenotypes. 
 
The candidate that had the strongest suppressor effect in females is VhaSFD RNAi, with a 
Chi square of 21 compared to a control done at the same time with the same number of 
flies. The one with the strongest enhancer effect is smt3 RNAi, with a Chi square of 25 
(Figure 4.2A). As an example, the lifespan of an RNAi line (Adf1) without phenotype is 
also shown in Figure 4.2A, having a Chi square value of 0.2. These values correspond to 
the analysis of 30 flies (females only). 
 
Then, these 93 lines have been repeated all at once in order to confirm the phenotypes 
observed in the first screen, especially since only 30 flies were analysed. Beside the RNAi 
lines several controls were run. This allowed the generation of three random pairs of 
controls, each pair combining two control lifespans, in order to get the same number of flies 
compared to each repeated line, which will rich 60 females assessed. These three pairs have 
been compared to each other in order to evaluate the variability of the assay in these 
 103 
conditions. The Chi square given by the comparison to each other ranges from 0.4 to 16 
(Figure 4.2B). On average, the difference between control lifespan gives a Chi square of 
7.8, which gives the threshold of confidence for this method of analysis, using 60 females 
and 3 pairs of controls. 
 
Each of the repeated line was then compared to each of the established control as shown in 
Figure 4.2C for VhaSFD RNAi line. Having doubled the number of flies assessed this 
time, with 60 females, the Chi square doubles from the first screen since this value is 
dependent on the number of flies assessed. For a similar effect in term of lifespan, using 
double the amount of flies has roughly doubled the Chi square value as seen with the first 
and third graphs in Figure 4.2C, going from 21 with 30 flies in Figure 4.2A to 45-53 with 
60 in Figure 4.2C. The three Chi square values were then averaged and the repeated genes 
were ranked according to their strength. The table in Figure 4.2D shows the repeated lines 
that have an average Chi square value bigger than 7.8, being the limit of the assay. 17 
RNAi lines have a suppressor effect, rescuing the lifespan from polyQ Atro expression in 
glia and 12 have enhancer effect, decreasing even further the lifespan. The genes having an 
effect have a broad range of functions such as zinc transport for ZnT77C, acidification of 
vacuoles (VhaSFD), axon guidance (caps) or sumoylation (smt3). Some of them do not 
















4.2.2.3 Validation of the specificity of the target genes 
 
The RNAi lines that have an effect on the lifespan could have an effect independently from 
the toxicity of polyQ Atro. In order to distinguish the interaction between the 
downregulated genes with glia impairment from intrinsic effects of the RNAi line polyQ 
independent, the wt-sAtro line previously generated was used instead of the polyQ one. 
Two different controls have been obtained using this line. Their Chi square values when 
compared with each other is 2 (Figure 4.3A). For this validation, only two controls have 
been generated. Thus, the pair-averaging method previously done cannot be used for the 
analysis. However, with 30 flies analysed, any Chi square value below 10 will not be 
considered biologically relevant. More flies would need to be analysed in order to 
determine a higher confidence in a potential interaction. All the interacting gene RNAi lines 
have been compared to the controls. For the suppressors, only the RNAi lines against the 
zinc transporter (ZnT77C) and idgf4 show an increase of the lifespan, with a Chi square 
value of 14 and 10.4 respectively, which is still on the low side of confidence (Figure 
4.3A). VhaSFD RNAi line, which was the strongest suppressor, does not increase further 
the lifespan when wt-Atro is expressed in glial cells, indicating that the previous effect 
observed was specific to polyQ Atro. For the enhancer genes, 3 RNAi lines decrease the 
lifespan when wt-Atro is expressed in glial cells, CG31729, lace and RpLP0 (Figure 4.3A 
and 4.3C). It is possible that the downregulation of these genes interact with wt Atro even 
though this does not trigger any lifespan phenotype by itself. It has actually been shown 
previously in the lab that the UAS-wt-Atro line was expressed to a higher level than UAS-
polyQ-Atro without having any lifespan phenotype, ruling out a potential detrimental effect 
from the overexpression of the Atro protein itself. However, this control has not been done 
with the LOT-wt/polyQ-sAtro lines. To rule out a possible interaction with wt-sAtro, the 
RNAi lines having an effect in this case would need to be assessed without the expression 
of any Atro in glial cells. Most likely, however, the downregulated genes have an important 
function in neurons and are necessary for the CNS homeostasis independently of any Atro 
expression. It is actually rather surprising that such a very low number of RNAi lines 
decreased the lifespan when expressed in neurons in the screen, as this was the category of 
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false positive that was the most expected. The use of glial wt-sAtro indicates that most of 
the effects observed in the screen come from the interactions of the genes with polyQ 
toxicity and not the overexpression of Atro itself or the intrinsic function of the different 
RNAi in neurons. However, it is also possible that some of the effects are due to off-target 
effects and that the interacting genes are not the ones supposedly targeted by the RNAi. 
Even though the websites of the stock centers provide potential off-target and in most cases 
there is none, it cannot be ruled out. 
 
Another possibility would be that the insertion of the RNAi line has an effect in itself, by 
disrupting the expression of neighbouring/affected genes. Thus the phenotype would come 
from the affected genes and not the RNAi. Thus, a line expressing LOT-polyQ-sAtro was 
generated in the same condition as before but without Elav-Gal4 to prevent the expression 
of the RNAi in neurons and thus, assess its potential transgene insertion effect. None of the 
5 RNAi lines assessed had any phenotype, indicating that the insertion of the transgenes 
does not affect the lifespan (Figure 4.3C, lower table). Thus, the phenotypes of these 5 
RNAi lines in wt-Atro condition are likely to come from an intrinsic effect of the 
downregulation of these genes in neurons or reflect a possible interaction with the 
overexpression of wt-Atro and are highlighted in orange in each of the previous tables to 
show their positions in the ranking of the candidate genes. 
 
Given the diversity of the positive candidate gene functions, I decided to focus on 
transmembrane proteins since such molecules are natural candidates for mediating direct 
cell-cell interactions. Indeed, several candidate genes are involved in cell adhesion and 
some of them, like capricious (caps), are already known to be involved in neuron-neuron or 






4.2.3 mfas, caps and trn: potential candidate genes interacting with glial 
polyQ-Atro 
 
4.2.3.1 Effects of mfas downregulation in glial cells and neurons in the glial DRPLA 
model 
 
mfas has been named from its expression pattern during embryogenesis where it is 
expressed in the CNS midline cells and trachea and is a member of the Fasciclin-I related 
family (Hu et al. 1998). However, no further studies have since come out apart from one 
where it is suggested that mfas could increase the haematopoietic tumour formation from a 
hop mutant background (Bina et al. 2010). In the RNAi screen, the downregulation of mfas 
in neurons in combination with the glial polyQ Atro expression rescued the lifespan even 
though the effect was mild, being one of the weakest phenotype among the suppressor 
genes. However, out of the 29 confirmed interacting genes from the RNAi screen, mfas is 
the only one also predicted to have a similar effect from the miRNA screens performed in 
our lab (see also next chapter). Interestingly, the analysis of the miRNA screens indicates 
that its downregulation in glial cells in co-expression with polyQ Atro would decrease even 
further the lifespan, thus, having an opposite effect in glia and in neurons. To confirm this 
prediction, several RNAi lines against mfas were assessed in glia polyQ Atro condition. 
Both RNAi lines, KK and GD, worsen the polyQ Atro phenotype, confirming the miRNA 
prediction (Figure 4.4A). However, another line was assessed, from the Bloomington 
collection, which is in a different background. Thus, as a control, an RNAi against mCherry 
on a TRiP background was used. Surprisingly, mfas knock-down using this line rescued the 
lifespan. mfas is a very complex gene having at least 16 predicted isoforms. It is possible 
that the RNAi lines used target different isoforms and thus could have different effect. 
However, even though they target different exons, the KK and GD lines target the exon 8 
and the TRiP one targets the 6th exon, both exons are present in all isoforms. Thus it is 
unlikely that the different RNAi lines target different isoforms and should downregulate the 
expression of all of them. Thus, it is unclear what the real effect of downregulating mfas is 
in the DRPLA fly model. At the same time, the new RNAi lines (GD and TRiP) were tested 
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in neurons to confirm the phenotype obtained with the KK line in the RNAi screen (Figure 
4.4B, left panel). Both of them extended weakly the lifespan, similarly to the KK line. Their 
Chi square values are 8 for the GD and 20 for the TRiP (Figure 4.4B). Thus, 
downregulation of mfas in neurons extends weakly but reproducibly the lifespan of DRPLA 
flies.  
 
As a next step we decided to isogenise the mfas RNAi lines from the VDRC collection in 
an isogenic w1118. Isogenisation is known to reduce genetic variability and is commonly 
used in lifespan assays as definitive proof of any given effect. Each line has been 
backcrossed 6 times in this w1118 strain. The lifespan have been then repeated using these 
newly established lines. Using 60 to 90 females for the lifespan, the GD line shows a 
significant increase in the lifespan with a Chi square of 46 (Figure 4.4B). Unfortunately, 
because of a technical issue not enough flies were obtained to analyse the lifespan of the 
KK line at this time. Thus, this experiment has to be repeated. However, this result with the 
GD line suggests that for weak phenotypes, the diversion of the genetic background over 
time can have a detrimental effect on the lifespan and hide potential effects. The TRiP line 
is on a different genetic background (y, v), and thus would require a different isogenisation 
protocol, which I have not performed for lack of time.  
 
It is rather surprising that the TRiP line has an opposite effect in glial cells compared to the 
KK and GD lines while it has a similar phenotype when expressed in neurons. Because 
mfas has not been investigated and no antibodies have been generated, it is not possible to 
assess the efficiency of the different RNAi lines. In order to go further in the investigation 
of its potential function, I tried to generate a genomic mutation in mfas using the P-element 
jump-out technique. Indeed, there is a P- element (transposable element randomly inserted 
into the genome to overexpress or mutate genes) inserted into the promoter region of the 
gene. It is possible to remove inserted P-elements by the use of a line that expresses an 
enzyme called transposase that can “jump out” the element and normally allows the 
recombination back of the chromosome in a correct reading frame. However, sometimes, a 
correct recombination fails and a big piece of chromosomal DNA can be removed together 
with the P-element, leaving behind a deletion for the gene in which the P-element is 
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inserted. However, among all the 130 lines jumped out for mfas, none of them removed 
mfas. Indeed, some PCR primers were designed on the first exon, next to the P-element 
insertion, but all homozygous knock-out embryos were positive for the amplified fragment 
by PCR (data not shown). It means that it is very likely that all the lines generated have 
removed correctly the P-element from their genome. In order to understand mfas function 
in adult, which could be different from development, a knock-in/out by the CRISP/Cas9 
method would need to be done. It would allow the possibility to tag the endogenous gene 
and knock it out specifically in the adult. However, this method would require months of 


























4.2.3.2 caps and trn genes interact with glial polyQ-Atro expression 
 
Another candidate I followed up from the RNAi screen is capricious (caps). caps was in 
the 6th position of the suppressor genes, with a final Chi square value of 45.96. caps has 
been extensively studied in development along with the close related gene tartan (trn), 
which has been shown to be complementary and shares 65% of its extracellular domain 
with caps consisting in 14 LRR repeats for caps and 10 for trn. They have been involved in 
dendrite targeting in the olfactory bulb (Hong et al. 2009) and synapse formation and target 
recognition at the NMJ (Shishido 1998, Kurusu et al. 2008, Kohsaka et al. 2009). On the 
basis of these complementarities in their functions, several trn RNAi lines were analysed 
along with 2 new RNAi lines against caps. The RNAi lines were first assessed in adult 
neurons in the same set up than for the siRNA screen where caps was identified. Similarly 
to the line assessed in the RNAi screen (3046/GD), the new GD line against caps, 
numbered 27097/GD, also increases the lifespan though to a lower extent compared to 
control, with a Chi square value of 16.5 and a smaller difference of median survival 
(Figure 4.5A). However, the TRiP line did not give any phenotype compared to the 
mCherry RNAi line used as control for this genetic background. caps possesses several 
isoforms, however, all the RNAi lines target exons that are present in all isoforms, ruling 
out a potential specificity of isoforms differentially downregulated. Isogenisation of the GD 
line 27097 did not change the effect and the difference of median survival remained similar 
to prior isogenisation (data not shown). It is thus possible that the effect of this GD line is 
weaker than the previous one used for the screen regardless of the isogenisation of the 
genetic background. 
 
Then, trn having a complementary role, two RNAi lines have been assessed in the same set 
up. Those two RNAi lines are from the Bloomington collection, numbered 28525 and 
50520. None of them had a phenotype when expressed in neurons beside glial polyQ Atro 
expression, with respective Chi square values of 0.1 and 1.5, again with 130 flies assessed 
for each genotype (Figure 4.5A). These results suggest that trn is unlikely to have a role in 
neurons in the impaired interactions between diseased glia and neurons. 
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trn is known to be expressed in different cells than caps, leading to specific target 
recognition. I then wondered whether trn could be expressed in glial cells and would 
potentially interact with caps in a non-cell autonomous mechanism. Thus, all the RNAi 
lines against trn and caps were expressed in glial cells in combination with polyQ Atro. 
Both GD lines of caps did not have any phenotype, with their Chi square values of 5 and 
0.1 respectively and the lifespan curves almost completely overlapping (Figure 4.5B). The 
isogenisation process of these two lines did not change the lifespan and the curves were still 
overlapping (data not shown). However, the TRiP line increases the lifespan, with a Chi 
square value of 33. For the RNAi lines against trn, both rescue the phenotype, with Chi 
square values of 65 and 110 (Figure 4.5B). All the lifespan were done using 160 flies for 
the RNAi lines but only 80 for the TRiP control. This set of experiments would need to be 
repeated to be confirmed in order to validate the lifespan of the control with a higher 
number of flies. However, in the set up where the RNAi lines are expressed in neurons, the 
RNAi TRiP lifespans were overlapping with the TRiP control. It is thus unlikely that the 
RNAi against mCherry is toxic for the cells. However, it is possible that it has off target 
effects specifically in glial cells even though they are supposed to be designed to avoid 
them. Another control line in the TRiP background would be needed to confirm a 
biological effect of the TRiP RNAi lines when expressed in glial cells. 
 
In the presence of a number of contrasting effects of the different RNAi lines it is difficult 
to conclude whether caps and trn play a role in glia-neuron communication during 
neurodegeneration. Downregulation of trn in glial cells appeared to have a strong and 
reproducible phenotype, however this is based on two TRiP lines and in this paradigm, all 
TRiP lines for caps, trn and mfas displayed the same effect, which raises some doubts 
about the appropriateness of the control lifespan. Further experiments need to be done using 
different RNAi lines, especially against trn. It would be ideal to confirm the rescue in glia 
polyQ condition using lines from the VDRC collection, which were not available at that 





 4.3 Discussion 
 
The use of an unbiased screen for new genetic interactions allows the discovery of many 
different pathways that could be involved in cell-cell communication. In this set up, a toxic 
protein is expressed in one cell type, glial cells, and RNAi are independently expressed in 
another one, neurons. Thus, it is rather challenging to uncover genes that could modulate 
the phenotype in a non-cell autonomous mechanism, in addition to the variability to RNAi 
efficiency. The fact that out of a thousand downregulated genes in neurons only 12 
decreased even further the lifespan, it shows that likely the organism is able to cope 
efficiently with defective pathways, possibly by redundancy mechanisms or a high number 
of ineffective RNAi lines. It has to be mentioned that the expression of glial polyQ Atro has 
a strong phenotype, reducing the lifespan by nearly 50%, which is dramatic. And depending 
on the strength of the RNAi, the turnover of the mRNA and the half-life of the protein, it 
can take days before having a knock-down strong enough and then could take more days to 
see an effect in behaviour. All of these could explain why the modulation of such a strong 
phenotype can be challenging. However, 29 RNAi lines were able to modulate it, with 17 
rescuing the lifespan to up to 25%. The candidate genes obtained following the RNAi 
screen were not enriched in a specific type of function. It suggests that many pathways in 
neurons are affected by the glial toxicity, which is in line with the large transcriptional 
alterations triggered by polyQ Atro expression (Napoletano et al. 2011). Those two cell 
types communicate at different levels, either directly by cell-cell contact via membrane 
proteins, by secretion of vesicles or by proteins that will bind to receptors. Also, it could be 
considered as indirect communication when glial cells are not doing properly some of their 
functions such as neurotransmitter clearance/recycling, which will certainly affect non-
autonomously neuronal functions. The examples of the two strongest suppressors and the 
chosen candidate genes show the range of pathways in neurons possibly affected by 
impaired glia. 
 
The three candidate genes were selected based on their related function in cell 
adhesion/communication, which is of high interest in our understanding of glia-neuron 
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interactions in a disease context. Furthermore, mfas downregulation was predicted from the 
miRNA screens to have opposite effect in glia and in neurons, also confirming the RNAi 
screen result. In the case of caps, the preliminary result on trn downregulation effect in glia 
led us to investigate potential direct interaction between both membrane proteins. The other 
top candidates were involved in complex interactions such as VhaSFD, which is involved in 
vesicular acidification, thus, could be responsible of many different impairment of 
signalling pathways at the same time (Thomas et al. 2006, Kolotuev et al. 2009, Vaccari et 
al. 2010, Dupont et al. 2012). Cell-cell direct interactions through membrane proteins 
seemed to be natural candidates to understand communication between glia and neurons, 
which would be provided by the investigation of genes such as mfas, caps and trn. 
 
Except for the result of the TRiP line, mfas has shown opposite effect on the lifespan 
whether it is downregulated in glia or in neurons with the RNAi lines from the VDRC 
collection. The analysis of the miRNA screens have revealed that several miRNAs have 
this differential phenotypes, being enhancer in one cell and suppressor in another cell, 
which is really interesting. The targets of these specific miRNAs are currently being 
analysed to see if such genes can reproduce this specific effect. According to the 
preliminary data obtained with mfas, a predicted target of miR-8 (being one of those 
miRNAs having cell-specific phenotypes), it is possible that this Fasciclin-I related gene 
could be such a candidate. However, it is also possible that those miRNAs have their 
effects by targeting different genes in both cell types since their gene expression profiles 
are very different. Thus, a target gene would be responsible or at least participate in the 
decrease of the lifespan in glia but another one, not expressed in glia would do the opposite 
in neurons. mfas would need to be further investigated as one RNAi line has an opposite 
effect from the two others in glial cells. The genetic background of this RNAi-TRiP line is 
different, being on (y, v) background, and will have to be analysed more thoroughly. 
However, based on the VDRC RNAi lines lifespans, it is possible that mfas has a different 
functions in glia and neurons that lead to opposite effects. mfas seems necessary in glia and 
could participate to the establishment and maintenance of glial shapes. Indeed, Fasciclin-
related genes have been involved in neuronal arborisation by homophilic adhesion 
(Schuster et al. 1996). It is thus possible that disrupting glial shapes is harmful for the CNS 
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function while increasing it in neurons could lead to better synaptic plasticity that could 
delay neuronal impairment. We know now from the I. Salecker group that mfas is 
expressed at least in the glial cells of the optic lobe in pupal stage and could have a role in 
the arborisation of the epithelial glia. It is thus possible that mfas help to fasciculate the 
axons during metamorphosis but it remains to be proven whether it has a role in the adult, 
possibly by maintaining a correct fasciculation of some tracts. 
 
In lifespan especially, genetic background is an important factor and usually the lines have 
to be backcrossed to an isogenised stock in order to limit its impact on the phenotype. In 
the scale of a screen where a thousand genes are assessed, it is not feasible to isogenise 
such an amount of lines. However, 90% of the lines did not show any phenotype in the first 
screen showing that the big majority of the lines, even without being backcrossed did not 
show excessive variability. However, for mild effect such as mfas or caps, it is necessary to 
isogenise stocks in order to be confident on the biological significance of the phenotype 
observed. In the case of mfas, it has revealed a bigger effect, whereas this did not achieve 
any difference for caps. Moreover, increasing the number of flies to few hundreds on 
isogenic background would help to differentiate genetic variability from biological effects 
of an RNAi, especially when the defects are subtle. A more complex issue is that of the 
different effects of RNAi lines coming from different collections and their relative 
efficiency and potential off targets. A careful analysis of the extent of protein 
downregulation and of the effect of genomic mutations would be needed to better 
understand this intricate network of effects but that would require antibodies against the 
proteins, which are currently unavailable. However, should the phenotypes of caps and trn 
downregulation be confirmed, it would be very interesting to investigate the role of a 
possible interaction between these two membrane proteins in the communication between 
glia and neurons in health and disease. So far, they have been mostly studied in neuron-
muscle interactions at the NMJ or target recognition in the olfactory bulb during 
development. It is still possible that at least trn is also expressed in some glial cells and 
tightly interacts with some neurons. More work would need to be done to further 
characterize these potential glia-neuron interactions that seem to be of importance in a 
disease context. 
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                  Chapter V:  
repo expression in adult glia is necessary for 
CNS homeostasis 




5.1.1 Using miRNAs as a tool to discover interacting genes 
 
siRNAs are supposed to be specific to a single gene and have few off-target effects 
predicted. However, this has the consequence that a thousand lines need to be assessed to 
screen a thousand genes, making big screens a hard and long work that requires months of 
experimental work. Another way to downregulate genes is using microRNAs. microRNAs 
are endogenously expressed in eukaryotic cells and in some viruses and are known to be 
able to downregulate several genes through smaller RNA sequence alignment to the mRNA 
(7 nucleotide) than siRNA. Also, the silencing effect does not necessarily require perfect 
complementation between the miRNA and its target mRNA. Some miRNA are predicted to 
have hundreds of potential targets. Thus, another strategy designed in the lab was the 
overexpression of miRNAs instead of siRNAs. By experimental and bioinformatic 
predictions, it would be then possible to narrow down potential targets of positive miRNA 
hits in order to increase the ratio of genes assessed per positive candidates, which was very 
low in the RNAi screen. Actually, a very recent study that has been published has used the 
same strategy and has discovered genes involved in odorant receptor expression (Bhat et al. 
2016). 
 
The Drosophila genome possesses 256 miRNAs including 34 miRtrons (Kozomara et al. 
2011, Kozomara et al. 2014). However, not all of them have been confirmed to be 
expressed. Several collections have been developed for UAS-miRNA or knock-outs. One of 
them includes around 140 UAS-miRNAs and has been kindly shared with our lab by Eric 
Lai (Fulga et al. 2015). Theoretically, screening 140 miRNA overexpression lines would 
give access to thousands potential downregulated genes. This strategy has been used to 
elaborate different screens in the lab. A similar screen to the RNAi one has been done by 
other lab members, with this time its control without polyQ Atro expression. Moreover, two 
other ones have been done, using a cell-autonomous paradigm. The UAS-miRNA lines are 
co-overexpressed in glia beside polyQ Atro or again as control without polyQ Atro 
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expression. The miRNAs having an effect in both conditions (with or without polyQ Atro) 
would be considered non-specific to polyQ Atro expression. Once the miRNAs were 
classified according to their effect on the lifespan and in which screens they had a 
phenotype, their targets were further analysed (Figure 5.1). 
 
The miRNA screens and their analysis have been carried out by other members of the lab. 
However, as an example, mfas came out of it as being a target of miR-8, which has an 
opposite effect on lifespan whether it is overexpressed in glia or in neurons in our DRPLA 


























5.1.2 miR-1 is expressed in the mesoderm during embryogenesis 
 
Beside the RNAi/miRNA screens carried out in glia and neurons in disease condition, I also 
focused on potential miRNAs that would be interesting and relevant to the general function 
of glial cells in Drosophila. Understanding general glial cell functions will help deciphering 
mechanisms and pathways that can be disrupted in neurological disorders. One of those 
miRNAs is miR-1, obtained from preliminary data by other lab members. When 
overexpressed in adult glial cells, the lifespan was dramatically reduced. This effect was 
obtained using two different UAS-miR-1 lines, reassuring on eventual artefacts due to the 
insertion of the transgene. Using the different miRNA databases available (PicTar, 
microRNA.org, EBI/Microcosm Targets and Target Scan), the list of potential targets of 
miR-1 was analysed critically, with a special focus on genes that may be relevant in the 
glial cells, where miR-1 was overexpressed. One of those target genes was repo, which is 
the only specific pan-glial marker constitutively expressed throughout the entire life of the 
Drosophila and the interaction between miR-1 and repo will be further investigated in this 
chapter. 
 
The expression of miR-1 has been mostly characterized in the Drosophila embryo. From 
stage 5 to 10, it is specifically expressed in the mesoderm. At stage 12 and 13, it is visible 
in all differentiating muscles, including somatic muscles and pharyngeal muscles 
(Aboobaker et al. 2005). It has been shown that miR-1 is directly activated by the 
promesodermal transcription factor twist during early embryogenesis and later maintained 
in myogenic cells by the promyogenic transcription factor Mef2 (Sokol 2005). Furthermore, 
the miR-1 expression in cardiac and skeletal muscle precursor cells is conserved across 
species (Lee et al. 2001), including mammals (Sempere et al. 2004). In a microarray 
analysis, Lim et al. show that some miRNAs, including miR-1, could downregulate a large 
number of target mRNAs especially enriched in genes normally expressed in different 
tissues, non-muscle cell genes in the case of miR-1 (Lim et al. 2005). This analysis shows 
that miRNAs could help in maintaining specific cell type identity during development by 
repressing specific genes that could potentially change the fate or function of a cell. Laneve 
et al. strengthen this hypothesis by showing that miR-1 could also be activated by gcm 
 123 
during early embryogenesis (Laneve et al. 2013). At this developmental stage, gcm is 
important in blood cells development, before being the key glial-fate determinant expressed 
at later stages in the neuroectoderm. These discoveries give some ground to speculating 
about miR-1 function in the regulation of blood-muscle-glial cells differentiation. It would 
allow the hemocytes to remain hemocytes early in development and muscle cells to remain 
muscle cells during late development by inhibiting genes that could change fate or 
deregulate cell function. Indeed, gcm is also known to be the first glial cell-fate determinant 
and directly triggers the transcription of repo, responsible for the terminal differentiation of 
glial cells. 
 
5.1.3 repo expression is tightly regulated during embryogenesis but its 
function is unknown in adult Drosophila 
 
As mentioned in Chapter I, repo has been extensively studied during embryogenesis. Its 
expression level is tightly controlled both at the transcriptional and post-transcriptional 
level by gcm and dCBP until repo takes over the control of its own expression by a 
feedforward-loop (Flici et al. 2014). It has also been shown that repo triggers the 
expression of secreted wg by glial cells at the NMJ in larval stage (Kerr et al. 2014), 
regulating glutamate receptor clustering and synaptic physiology. 
 
However, beside its role during development, very little is known about its function in adult 
Drosophila. The only study investigating a potential role of repo specifically in the adult 
has demonstrated that it is important for long-term memory via glial transcription (Matsuno 
et al. 2015). repo is a terminal differentiation factor, triggering specific glial programs 
during late embryogenesis. It remains expressed, constantly, at high levels in all glial cells 
in the adult Drosophila. The Gal4 line used for pan-glial transgene expression is actually a 
knock-in in the endogenous repo locus. This transgenic line is broadly used for all 





This chapter aims at understanding two main mechanisms. The first one is deciphering the 
predicted relationship between miR-1 and repo during development. The complex 
expression pattern of gcm in different cell types has been extensively analysed. miR-1 could 
potentially be a missing key in the understanding on how gcm is expressed in mesodermal 
cells without triggering ectopic repo expression. This hypothesis is in line with the 
microarray analysis done in the study of Lim et al. (Lim et al. 2005) about miRNAs 
downregulating genes specific to other tissues, such as a glial cell fate determinant being 
wrongly expressed in the mesoderm. On the basis of this potential link between miR-1 and 
repo determined using miR-1 KO -/- embryos and luciferase assay, and the effect of glial 
miR-1 expression on adult lifespan, the second main question that arose is: what is the 
function of repo in adult glial cells given its maintained expression? Does it still have a role 
in cell fate determination or maintenance allowing a certain flexibility of cell identity in the 
adult CNS? And/Or does it still regulate specific genes’ expression, as it is the case during 





















5.2.1 miR-1 downregulates repo and participates in its restricted expression 
pattern during embryogenesis 
 
5.2.1.1 Ectopic expression of miR-1 in glial cells has a dramatic effect on Drosophila at 
larval and adult stages and targets repo both in vitro and in vivo 
 
Preliminary data obtained in the glial miRNA screen showed that the adult specific 
overexpression of miR-1 in glial cells using Repo-Gal4 driver recombined with UbiGal80ts 
was reducing the lifespan. I first confirmed this result increasing the numbers of flies 
assessed for the lifespan, using ~ 250 for both control and miR-1 overexpression instead of 
60 in the screen in order to increase confidence in the results. As seen in Figure 5.2A, the 
adult lifespan is reduced by 50%, from a median survival of 25 days in control to 13 days in 
miR-1 overexpression condition (p<0.0001). 
 
Since adult glial miR-1 expression has a dramatic effect on lifespan, I also assessed the 
effect of its expression in glial cells during development. Using temporal control of 
transgene expression, miR-1 was expressed specifically from first instar larvae (L1) 
onwards. The Tubby marker (oval shape instead of elongated larvae) was used to 
discriminate wild-type from miR-1 larvae. All miR-1 larvae died at third instar larvae (L3), 
when the larvae come out of the food to enter pupation for metamorphosis. miR-1 L3 larvae 
bodies were thinner than non tubby wild type L3 larvae (data not shown). The brains of the 
larvae overexpressing miR-1 in all glia were then dissected prior to death and stained for 
repo, the pan-glial marker. The brains seemed obviously smaller and the VNC thinner and 
more elongated (VNC data not shown). The staining of repo confirmed this observation by 
comparing the size of the brain lobes using confocal imaging (Figure 5.2B, white circles in 
Z-projection panels). Also, the glia forming the presumptive lamina layer (outer and inner 
chiasm glia) failed to form a proper bi-layer pattern as compared to wild-type, interestingly 
very similar to the defects observed in repo mutant larvae (Xiong et al. 1994). (Figure 
 126 
5.2B, arrows in confocal section panels). This phenotype strengthens the idea that miR-1 
affects important glial function both during development and adult stages. 
 
According to several databases, repo was predicted to be a target of miR-1. This prediction 
was consistent with western blot using adult fly heads expressing miR-1 specifically in glial 
cells (Figure 5.2C). repo is indeed significantly downregulated by 85% when miR-1 is 
overexpressed in glia, with a P-value of 0.011. The direct effect of miR-1 on repo mRNA 
3’UTR was assessed in vitro by Luciferase assay. repo mRNA possesses two known miR-1 
binding sites in its 3’UTR. Thus, three different plasmids have been designed by our 
collaborators at IGBMC in Strasbourg.  They all express the coding sequence of the 
Luciferase. However, they differ in their 3’UTR sequence. One possesses the wild-type 
3’UTR of repo to confirm that miR-1 can downregulate the Luciferase activity. One control 
plasmid with the Luciferase 3’UTR in order to assess that miR-1 does not decrease 
independently the Luciferase activity. And a third one with the miR-1 sites of the repo 
3’UTR mutated to see whether miR-1 has its activity through these specific sites and point 
toward a direct inhibition.  The miR-1 expression was controlled by a tubulin promoter and 
thus was expressed post transfection. The expression of the other plasmids was controlled 
by copper sulphate activation of the pMT-Gal4 plasmid. This allows the expression of miR-
1 before the expression of the Luciferase plasmid in order to build up the accumulation of 
miR-1 and increase the efficiency of the knock-down. The Luciferase assay shows that miR-
1 does not downregulate the Luciferase activity in the absence of repo 3’UTR, validating 
the assay. However, the Luciferase activity from the mRNA with the repo 3’UTR is 
significantly reduced whereas with the mutated miR-1 sites it is rescued (Figure 5.2D). 
Compare to the western blot, where the Repo protein level is strongly decreased, the signal 
is only decreased by half. In the luciferase assay, the time frame is a lot shorter and it is 
thus possible that the maximum downregulation has not been reached. In any case, these 
results point strongly toward a direct downregulation of repo by miR-1 through its 




To confirm this result in vivo a UAS-Repo line with the 3’UTR from SV40 was used in 
order to express the Repo protein without influence from miR-1. The sensitivity of this line 
for miR-1, called Repo#9 ((Matsuno et al. 2015), referred to as repo-myc in the mentioned 
paper) was first assessed by western blot. While miR-1 downregulates strongly the 
endogenous repo, it does not affect the expression of Repo#9 transgene, controlled by the 
myc tagged Repo level (Figure 5.2E, lower panel) and the level of expression is similar to 
that of wild-type (Figure 5.2E, upper panel). As already observed in the previous study, 
using this myc-tag Repo#9 line, a doublet can be seen by western blot. This could come 
from potential post translational modifications such as phosphorylation. However, since 
this line has been proven to rescue repo mutants, the formation of this doublet does not 
seem to affect Repo-myc function (Matsuno et al. 2015). 
 
The next question was then whether the miR-1 phenotypes were caused by the 
downregulation of repo. In order to determine whether the effects of miR-1 on lifespan and 
on larval brain development were due to repo downregulation, these experiments were 
repeated with the co-expression of Repo#9 beside miR-1. In the larval stage experiment, the 
overexpression of this miR-1-independent Repo#9 line did not rescue the L3 lethality or 
brain size (100% died at L3 larval stage, data not shown). However, in adult, even though 
the median survival is 13 days for miR-1 and 11 days for miR-1 + Repo#9 conditions, a tail 
in the miR-1 + Repo#9 genotype lifespan shows a rescue for 20% of the population. When 
such a tail is present, the maximum lifespan can be calculated using the median survival of 
the last 10 to 20% of the population (Slack et al. 2011). By taking the last 20% of the 
population (respectively 74 and 66 flies for miR-1 and miR-1 + Repo#9) Repo#9 expression 
rescues the lifespan by 33%, going from a median survival of 15 days for miR-1 to 20 days 
for miR-1 + Repo#9 (p<0.0001). This type of lifespan with such a tail could indicate an 
age-related effect on the Drosophila organism. It is also possible that there is a delicate 
balance between the survival and the death of the organism in this condition and only a low 
percentage of the population survives to it. This may suggest a minor rescue in the 
individuals that for additional reasons are more resistant to the expression of miR-1. In 
order to decipher further the implication of repo in the mechanism leading to the fly death 
via glial miR-1, a UAS-Repo line lacking not only the repo 3’UTR but also a large part of 
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the transcriptional activation domain, called Repo#14, was used ((Matsuno et al. 2015) 
referred to as repo-mycΔAD302, potentially acting as dominant negative). This line 
provides a sensitized background for repo, challenging glial cells on the repo “pathway” 
beside the miR-1 effect. The lifespan of flies expressing Repo#14 only have a mild, 
although significant, decrease compared to control, showing a mild toxic effect of this line 
(Figure 5.2A). However, when expressed beside miR-1, a much greater reduction of the 
lifespan is observed with a chi square of 371, compared to repo#14 alone compared to 
control with a chi square of 33 (note that the Chi square values are very high since the 
number of flies assessed were greater than 240 per genotype). This result suggests that the 
function of repo as transcriptional activator is important when miR-1 is overexpressed in 
glia, in order to maintain a certain viability of the organism. 
 
Both results of the attempted rescue in adult and developing glia, suggest that other factors, 
in addition to repo, are responsible for most of the effects provided by the ectopic 
expression of miR-1 in glial cells. It is well established that miRNAs can downregulate 
many genes at the same time, thus it is possible that another gene, or even more likely a 
combination of several genes, are responsible of the different phenotypes. It is also possible 










5.2.1.2 miR-1 is involved in the regulation of glia-specific repo expression during 
embryogenesis 
 
So far, the relationship between miR-1 and repo was in the context of an ectopic expression 
of miR-1 in glial cells using the pan-glial driver Repo-Gal4, where it is not supposed to be 
expressed, at least during embryogenesis where its expression pattern has been 
characterized. miR-1 is normally expressed in the mesoderm, which will later on generate 
hemocytes (future “blood” cells) and muscle cells. The question is why miR-1 would be 
able to downregulate repo, a gene not supposed to be expressed at the protein level in the 
mesoderm. Is it the result of an artefact of overexpression, which allows the miRNA to bind 
less specifically to some mRNAs, which in physiological conditions would not happen? Or 
is it an interaction that happens during development in order to maintain mesodermal fate in 
some cells susceptible to express repo by blocking the RNA translation? 
 
As mentioned in 5.1.1, miR-1 expression in early embryogenesis, when hemocytes are 
being formed, is regulated by both twist and gcm. However, gcm is also able to directly 
trigger repo transcription in the neuroectoderm. There are many ways to repress 
transcriptional activation, by the binding of transcriptional repressors for instance. But it is 
also possible to repress the protein expression at the post transcriptional level and the 
discovery of the role of some miRNAs on the control of cell fate determination goes in this 
direction (Tsuyama et al. 2015). 
 
It has been shown by our collaborators at IGBMC, that in a twist mutant (twi1 -/-, 
(Castanon et al. 2001)) background embryo, there is an overlap between repo and srp in 
around 10 cells per embryo in the mesoderm (Trebuchet et al, 2016, manuscript in 
preparation). srp is used as an early marker for hemocytes. To answer the above mentioned 
question, a miR-1 KO embryo line was used to see whether there would be such an overlap 
between these two different markers in the mesoderm. The co-staining with Repo and Srp 
antibodies of miR-1 KO embryos revealed a very similar phenotype to the twist mutant 
embryos (Figure 5.3A). In the heterozygous miR-1 embryos (-/+), there is an increase in 
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cells positive for both markers but it did not reach significance. However, in homozygous (-
/-) embryos, 8 to 12 cells on average were positive for Repo and Srp staining per embryo in 
the mesoderm, phenocopying the twist KO phenotype (Figure 5.3B). This result suggests 
that miR-1 is important for proper separation of the hemocyte and glial lineage and this 
might happen via downregulation of repo in physiological condition. It is likely that this 
interaction occurs in the early stages of embryogenesis, when gcm is transiently expressed 
in the mesoderm. The phenotypes of both twist KO and miR-1 KO are weak. This may 
suggest that there are other potential redundant repressors acting to prevent ectopic repo 





















5.2.2 Adult glial repo expression is constantly necessary for CNS homeostasis 
 
5.2.2.1 repo downregulation in adult glia reduces lifespan and motility 
 
miR-1 downregulates repo in adult glial cells, and although repo co-expression alone 
alongside miR-1 did not fully rescue the lifespan phenotype, the small effect shown by 
Repo#9 left me still wondering whether adult repo expression was still important and could 
participate to the lifespan phenotype observed with miR-1. This time, an RNAi strategy was 
used to specifically downregulate repo, only at the adult stage using temperature sensitive 
Gal80 to inhibit Gal4 during development and then shift the flies at 29°C (from 3 to 5 days 
post eclosure onwards). 
 
The lifespan of Repo Knock-Down (KD) flies was dramatically reduced using two different 
RNAi lines, coming from two different RNAi collections (VDRC for RNAi 1 (GD) and 
Bloomington for RNAi 2 (TRiP)). The flies from the RNAi 1 line die within 10 days while 
the ones from the RNAi 2 line die within 15-20 days (Figure 5.4A). In addition, the Repo-
RNAi 1 flies exhibit strong motor defects from 7 days and become paralyzed by day 8-9 
just prior death as assessed by climbing assay (Figure 5.4B). The Repo-RNAi 2 flies 
present a stronger difference between males and females compared to the Repo-RNAi 1 
flies, which die within 2 days after the first motor defects for both sexes. The Repo-RNAi 2 
males start to have motor defects by day 8 (Figure 5.4B, lower panel) and die by day 10-11 
(data not shown). The females start to have motor defects by day 11 and are almost 
paralyzed by day 12 (Figure 5.4B, top right graph) but take longer to die as seen in Figure 
5.4A. Thus, the onset of the motor defects correlates with the lifespan phenotypes.  
 
The specific adult knock-down of repo was then assessed by western blot. When the flies 
are kept at 18°C, Gal80 inhibits Gal4 activity, thus repo is not downregulated and the 
motility and the lifespan are not affected (Figure 5.4B and C and Figure 5.5A). However, 
after only 3 days spent at 29°C to allow the siRNA expression and the downregulation of 
repo, a very strong reduction of Repo protein level was already observed, confirming the 
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efficiency of the RNAi (Figure 5.4C). It also demonstrates that Repo protein has a very 
fast turn over since within 3 days of activation of the RNAi, almost all the already produced 
proteins are not detectable anymore by western blot. The efficiency of the Repo-RNAi 2, 
giving a slightly weaker lifespan and motor phenotypes, was also evaluated. After 7 days 
spent at 29°C, while the RNAi 1 was fully downregulating repo expression, the RNAi 2 
was less efficient, at least in females (Figure 5.4E). The Repo protein levels of males were 
not assessed. It is thus possible that knock-down is stronger in males than in females, which 
could explain the delay in the onset of the phenotypes. However, this weaker knock-down 
is still having a strong effect on both lifespan and climbing abilities (Figure 5.4A and B, 
right panel). These results show that a partial reduction of Repo protein level in adult glial 
cells has a very important impact on fly viability. Thus, the regulation of repo expression 
level in glial cells seems to be a critical issue for the CNS homeostasis. 
 
In order to rescue the phenotype, a UAS-Repo line was co-overexpressed beside the RNAi. 
This line is sensitive to RNAi strategy, being a wild-type version of repo.  However it is 
possible that it could counteract the effect by buffering the RNAi and allowing sufficient 
Repo protein level to get a rescue. The lifespan of these “rescue” flies was assessed in the 
first time. The rescue experiment by co-overexpressing repo beside the RNAi had a weak 
but significant effect, extending the lifespan by 5 days, starting from a lifespan of 10 days 
(Figure 5.4D). This “rescue” experiment displays actually a stronger phenotype in terms of 
short lifespan than using the Repo-RNAi 2 line. The levels of Repo protein were then 
assessed at different time point to understand the mild rescue of the co-overexpression of 
repo. After 3 days of expression at 29°C, the protein level in the “rescue” set-up is weak 
(Figure 5.4E). This result shows that the RNAi expression is strong enough to 
downregulate a very high level of repo expression. After 7 days at 29°C, there is still a 
residual level of Repo protein in the “rescue” condition, meaning that the UAS-Repo line is 
able to constantly counteract the RNAi 1 effect, even though it is to a very low extent 
(Figure 5.4E). The low levels of Repo protein in the rescue experiment, being even lower 
than the RNAi 2 knock-down alone can explain why the flies in this set-up live only 3-5 
days more than the Repo-RNAi 1 flies compared to the 5-10 days difference between Repo-
RNAi 1 and Repo-RNAi 2 and establish a good correlation between the levels of Repo 
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protein and the fly lifespan and the onset of the motor defects. In addition, the co-
overexpression of Repo#9 line beside the Repo-RNAi 1 did not rescue the lifespan 
phenotype (data not shown). This result might suggest that the Repo#9 line is not as strong 
as the UAS-Repo and gives even more relevance to the small rescue of miR-1. Altogether, 
these results point again toward the fact that a tight threshold of Repo protein expression in 
glial cells is needed to maintain a viable organism. Since Repo-RNAi 1 was stronger than 
the Repo-RNAi 2 line and was downregulating fully the protein level, the rest of the study 
will be carried on with the Repo-RNAi 1 (GD from VDRC collection). 
 
In order to investigate further the motor defects, I took advantage of Tsh-Gal80. This Gal4 
inhibitor is known to be expressed in the VNC but not in the head and is broadly used to 
study the effects of motor neurons or generally VNC specific function (Davis et al. 2014). 
The Gal4 inhibition in glial cells of the VNC was first assessed as it was only tested for the 
Gal4 inhibition in neurons in the past. While the expression of Repo-RNAi downregulates 
the expression of repo in the entire nervous system using Repo-Gal4 driver, the use of Tsh-
Gal80 inhibits the Gal4 activity in the VNC and rescues repo expression, at least partially 
since immunofluorescence cannot be used for accurate levels of expression (Figure 5.4F, 
arrows). Interestingly this also happens in the lamina glia of the optic lobe (Figure 5.4F, 
arrowhead). The motor defects observed previously were assessed again using Tsh-Gal80. 
The rescue of the repo expression only in the VNC is not enough to rescue the climbing 
defects since after 7 days at 29°C there is no significant difference between flies with or 
without Tsh-Gal80 (Figure 5.4F, right panel). According to the previous western blot 
results using different RNAi lines, the more repo is downregulated, the earlier and more 
dramatic is the phenotype. It means that even though the levels of Repo protein in the VNC 
with Tsh-Gal80 were not to wild-type levels, the motor defects would be at least delayed 
from the 7 days if the VNC was the only motor system responsible. Since it is not delayed, 
as the motor defects appear at the same time, it strongly suggests that the central brain is 
mostly responsible of the motor impairment. However, it is possible that the effect of the 
RNAi on the motor defects could come from the downregulation of repo in the PNS such 
as the sensory organs. 
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I next wondered whether some specific subpopulations of glial cells were responsible for 
the shortening of the lifespan, or at least would contribute to it. Similarly to the study done 
in the Chapter III, different Gal4 drivers were used. This time, they were combined with a 
ubiquitously expressed Gal80 temperature sensitive since the knock-down of repo during 
development leads to embryonic lethality or if expressed post embryogenesis, to the death 
at L1 larval stage, with the larvae being almost paralyzed before dying (data not shown). 
Once adult, the flies were transferred to 29°C to express the RNAi against repo. Contrary to 
what was observed when polyQ-Atro was expressed in different subsets of glial cells, only 
dEAAT1-Gal4 driver expressing Repo-RNAi 1 decreased significantly the lifespan with a 
Chi square of 77 compared to less than 10 for the others (Figure 5.4G). And it has been 
previously established that when lifespans were done using 60 flies per condition (since the 
Chi square value is linked to the number of flies assessed), a Chi square smaller than 10 is 
irrelevant as observed also often between genetically identical control populations. 
Compared to the effect of polyQ-Atro expression in those same subpopulations of glial 
cells, it is quite clear that the phenotypes are different. In the Chapter III, with the polyQ-
Atro expression, dEAAT1-Gal4 had a phenotype very close to the one of Repo-Gal4, having 
very similar median survival (15-17 days for Repo-Gal4>polyQ-Atro compared to 20 days 
for dEAAT1-Gal4>polyQ-Atro), indicating that the dEAAT1 positive cells were in majority 
responsible of the effects. However, using the same drivers to knock-down repo, Repo-
Gal4 driver has a much stronger phenotype than the one of dEAAT1-Gal4, having a median 
survival of 8-9 days compared to 25 days for dEAAT1-Gal4>Repo-RNAi 1 (Figure 5.4G). 
This difference indicates that in the case of repo downregulation, the dEAAT1 positive cells 
do not account for most of the effect on lifespan as it is the case for polyQ Atro. More 
specific drivers covering subtypes in dEAAT1-Gal4 positive cells, such as Alrm-Gal4 or 
NP2222-Gal4, were having significant effect when expressing polyQ-Atro with Chi squares 
between 30 and 60. The same drivers for Repo-RNAi 1 have respectively a Chi square of 7 
and 10 (Figure 5.4G). These results indicate that the downregulation of repo in these 
specific subtypes of glia has a much weaker impact on Drosophila viability than the 
expression of a toxic polyQ protein in the same cells. The strength of the phenotype using 
dEAAT1-Gal4 driver expressing Repo-RNAi 1 confirms this observation. When using 
Moody-Gal4 to express Repo-RNAi, which had a Chi square of 4 when expressing polyQ-
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Atro, the phenotype was not significant and having a Chi square of 2 for the expression of 
Repo-RNAi 1. Another driver, Gliotactin-Gal4, could be used for BBB glia. It has been 
shown in the Chapter III that it has stronger effect than Moody-Gal4 for polyQ-Atro 
expression. Unfortunately, a technical problem with the incubator arose while the lifespan 
using this driver was being done and lack of time did not allow me to repeat it. It would be 
interesting to see whether a stronger BBB driver could trigger lifespan defect by specific 



















5.2.2.2 Adult repo expression level is tightly regulated via a potential positive feedback 
loop 
 
The knock-down of repo is already dramatic after 3 days of RNAi expression. Using the 
possibility to turn on and off transgene expression by shifting temperatures from 18°C to 
29°C but also 29°C to 18°C, I asked whether a high level of Repo protein is constantly 
needed in glia in order to maintain Drosophila viability. The hypothesis is that the knock-
down of repo during a short period of time would be enough to trigger fly death. The flies 
are grown at 18°C. Once adult, they are shifted to 29°C for only 3 days and then put back at 
18°C in order to block the expression of any transgene. In these conditions, when the RNAi 
against repo is expressed only during 3 days, the lifespan is still dramatically reduced. 
Indeed, whereas the control flies have more than 80% alive flies after 50 days, the Repo-
RNAi ones have a median survival of 16 days and are all dead by 20 days (Figure 5.5A, 
lifespan labelled “3d”). The median survival is only delayed by a week compared to flies 
constantly exposed to 29°C. This difference could actually be explained by the fact that the 
entire organism is slowed down at 18°C, which would then slow down also the moment of 
the death. This result shows a completely different mechanism to polyQ-Atro build up 
process, for which a mere 3 days expression does not affect Drosophila lifespan (data not 
shown). In order to control that flies kept at 18°C are not affected by a leakage of Repo-
RNAi or the insertion of the transgene, a lifespan done entirely at 18°C was done. There 
was no difference between the control flies and the Repo-RNAi ones (Figure 5.5A, 
lifespan labelled by “18C”). The rescue experiment was then done in order to see if the 
small levels of Repo protein observed after 3 days at 29°C would be enough to maintain the 
organism alive longer. The flies co-expressing Repo-RNAi and UAS-Repo at the same time 
were partly rescued, with a median survival of 34 days compared to 16 days without the 
overexpression of repo. 15% of the flies were actually still alive after 50 days at 18°C. 
Moreover, motor capacity was also assessed after 7 days at 18°C, post 3 days at 29°C. As 
seen in Figure 5.5B, the co-expression of a repo copy is also enough to significantly rescue 
motor defects. This robust rescue of almost 20 days (compared to the 3 days observed at 
29°C) is unlikely to represent only a slowdown of the organism at 18°C. It is thus possible 
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that the residual amount of Repo protein, present after 3 days when UAS-Repo transgene is 
present, is enough to maintain some critical functions of the glial cells to keep the fly alive 
for longer. 
 
As mentioned in the Chapter I, it has been suggested that repo could act as a positive 
feedback loop on its own promoter during embryogenesis, but could be specific to certain 
conditions, like the presence of other activators or repressors. With the Repo-RNAi flies 
dying so quickly even after only 3 days spent at 29°C and then shifted at 18°C, I wondered 
what the protein levels were after few days spent at 18°C. The Repo protein levels at the 
same time point as the climbing assay were analysed by western blot. At this time point, the 
Repo-RNAi flies are about to start dying and have motor defects while the rescued flies 
(Repo-RNAi 1 + UAS-repo) perform better at climbing and are still 10 days ahead of the 
first flies dying (Figure 5.5A). In the case of the overexpression of repo only, the protein 
levels are not increased anymore compared to 3 days spent at 29°C (Figure 5.5C compared 
to Figure 5.4E, left panel). This result suggests that the Gal4 activity is abolished within 
few days after the shift of temperature and that the fast turnover of the Repo protein allows 
a tight regulation to maintain a specific level. However, in the Repo KD condition, the 
protein level was not back to normal and was still dramatically decreased, being not 
detectable by western blot analysis (Figure 5.5C). For the rescue experiment, the level of 
Repo protein was still strongly decreased, as it is the case already after 3 days and 7 days at 
29°C (Figure 5.5C). This result points partly toward a regulation by positive feedback loop 
as the Repo protein needs to be present, or expressed to a certain level, in order to get the 
endogenous protein expression back to its normal level. It is also possible that a previously 
accumulated pool of siRNA is still present, blocking the production of newly formed repo 
mRNA, which keeps Repo protein level down for 7 days since double strand siRNA can be 
rather stable in a cell for up to 3 days (Bosch et al. 2016) (Ameres et al. 2013) (Bartlett et 
al. 2006). However, after 7 days at 29°C in the rescue condition, there is also still a residual 
amount of Repo protein, indicating that the RNAi knock-down capacity has reached a 
maximum saturation. Furthermore, in the case of the 3 days at 29°C and then shift to 18°C, 
the small amount of protein present in the rescue is likely to come from mRNA produced 
by the endogenous repo gene, since the UAS-Repo transgene is not active at 18°C. It shows 
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that the small residual amount present after 3 days at 29°C is able to maintain at least a low 
level of protein production from new transcription of the endogenous repo gene. In order to 
confirm this hypothesis and to rule out the effect of potential RNAi during few days at 
18°C, Repo protein levels were assessed in both control and “rescue” flies that spent 3 days 
at 29°C and 20 days at 18°C. Since both RNAi and exogenous Repo protein are not 
produced anymore once at 18°C, the Repo protein present in the western blot will come 
from endogenous repo expression. Also, if after 7 days at 18°C the low levels of repo 
expression were due to the presence of a pool of siRNA accumulated at 29°C, this pool is 
likely to decrease over time, either by degradation or by its use to degrade newly produced 
repo mRNA. As a result, the protein level should increase as the siRNA pool would 
decrease. However, after 20 days at 18°C, the Repo protein level is still very low in the 
rescue condition, comparable to the one after 7 days at 18°C (Figure 5.5D). Thus, it is 
unlikely that the low level of Repo protein observed after 20 days at 18°C is due to a 
continuous knock-down of endogenous repo expression due to a pool of siRNA present 
after 3 days at 29°C. This result strengthen the hypothesis that a low level of repo 
expression is able to constantly maintain a low level of Repo protein but is not able to 
increase its expression level to go back to wild-type level. Surprisingly, the loading of all 
the conditions together on the same western blot showed that the Repo protein level after 3 
days at 29°C in both control and rescue conditions are reproducibly higher than the other 
ones (Figure 5.5D). It is possible that repo expression increases as a result of a heat shock 
response of glial cells before going back to normal levels after few days, as seen in the 
decrease of Repo protein level after 7 days at 29°C. It is also possible that there is an aging 
effect of repo expression. At 18°C, 7 days or 20 days are still early time points in 
Drosophila lifespan, which can survive more than 3 months at this temperature. Later time 
points would be needed to confirm this hypothesis. In the specific case of the repo rescue, 
there is further possibility that the decrease in Repo protein level observed between 3 days 
at 29°C and 3 days 29°C + 7 days 18°C could come from the effect of siRNA already 
produced before the shift of temperature, downregulating repo expression for few days 
before being all degraded or used. Then the low level of repo expression would remain. It 
would be required to establish whether the decrease between 3 days at 29°C and 3 days 
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29°C + 7 days 18°C in the rescue condition is the same than the one obtained in the control 
condition to clarify if an additional effect is present with the RNAi. 
 
In order to confirm a potential effect of repo on its own promoter, a repo reporter was used. 
This reporter is the coding sequence of a nuclear GFP (nGFP) downstream a 4.2kb portion 
of the repo promoter. A western blot analysis of the GFP signal after 7 days at 29°C was 
done, with or without Repo-RNAi. There is a clear and reproducible reduction of the GFP 
protein level compared to control (Figure 5.5E). The residual GFP protein in the Repo-
RNAi condition could be mere perdurance since it is known that GFP is relatively stable 
within a cell, especially when localised to the nucleus. This result strongly suggests that to 
be activated, this portion of repo promoter needs the presence of Repo protein and vice 
versa that Repo protein downregulation could also be partly mediated by a loss of 
transcription from the repo promoter. Altogether, these results provide strong evidence that 
repo expression could act as a positive feedback loop in the adult Drosophila glial cells. 
However, the results from the western blot of the rescue (Repo-RNAi + >Repo) (Figure 
5.5C and D) show that it might not only be a simple positive feedback loop and that some 
point of no-return is reached regarding the possibility of activating this promoter, behaving 
like a bistable switch. Indeed, the Repo protein level should be back up to normal if the 
presence of Repo protein was enough to activate its own expression. It is possible that a 
certain threshold is needed to bind to its own promoter, or other co-activating factors are 
present only when Repo protein is highly expressed or that in absence of Repo, its promoter 






5.2.3 repo downregulation does not increase the sensitivity to oxidative stress 
 
The expression of repo in adult glia is important at organism level, since the viability is 
dramatically reduced when it is knocked-down. Moreover, in addition to lethality, it 
impairs motor functions, surely coming from defects in neuronal activity since neurons 
control behaviour directly and glial cells interact strongly with neurons and regulate their 
activity, especially at the synaptic level. After investigating repo regulation at the molecular 
level, I wanted to understand what is happening at the organism level and try to 
characterize the possible causes of death. The glial cells providing a trophic support to the 
neurons and clearing neurotransmitters at the synapse, it is possible that if they fail in some 
of these functions, this can trigger neuronal damage, by oxidative stress for instance. 
Potential damage of the mitochondria can lead to a certain vulnerability to further stress, 
when the system is more challenged. And oxidative stress is known to reduce lifespan in 
flies (Fleming et al. 1992, Le Bourg 2001). A way to assess an increase in the sensitivity to 
oxidative stress is to feed the flies with paraquat. The paraquat generates free radicals and 
impairs mitochondrial functions (Hosamani et al. 2013). This molecule is generally used to 
assess resistance or increased sensitivity to oxidative stress. 
 
After spending 3 days at 29°C as adult to activate the RNAi expression, the flies are 
transferred to 18°C into vials with paraquat (see Material & Methods, Chapter II) and the 
death was recorded several times per day and the flies were maintained at this temperature. 
According to the results from the previous chapter, repo remains downregulated after the 3 
days at 29°C. However, no difference was observed between wild-type and Repo-RNAi 1 
flies (Figure 5.6). The flies in this set up start to have motor defects at 7-8 days, similarly 
to full 29°C set up. Only the start of death event is delayed by a week. The flies remained 4 
days in paraquat at 18°C, after spending 3 days at 29°C. This window for the experiment 
has been selected in order to monitor early phenotypic events possibly triggered by an 
exposure to strong oxidative stress. At later time point, it would be difficult to distinguish 
death events due to the paraquat or the fly death happening without it. This result indicates 
that there is no increased sensitivity to oxidative stress early on that could be responsible 
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for the neuronal dysfunction and death later on. However, it does not rule out increased 
sensitivity to oxidative stress later on, closer to time of death but cannot be assessed 














5.2.4 repo knock-down in adult glia does not trigger cell death or change of 
fate contrary to developmental stages 
 
It has been shown by our collaborators that in the embryonic VNC, the downregulation of 
repo could lead to the expression of neuronal marker such as Elav by presumptive glia, 
using the Repo-nGFP as glia reporter. (Trebuchet et al. 2016, manuscript in preparation). 
This confirms that repo is able to repress neuronal fate determination in glia. According to 
these results, and the fact that repo is a cell fate determinant, still expressed in adult 
differentiated cells, I asked whether it was possible that even in the adult fly, glial cells 
could have a certain flexibility in their identity that would allow them to adapt to some 
situations encountered throughout the life (CNS injury for instance). A switch to neuronal 
fate by glia would be surely a major disruption for the fly CNS and could lead to the motor 
defects and early lethality observed. Using the same set up as in the embryo, I co-stained 
brains and VNC of adult Drosophila with anti-GFP and anti-Elav antibodies, in the 
presence or not of Repo-RNAi. However, in Repo KD flies, no cells have been found 
positive for both GFP and Elav at the same time, either in the brain or in the VNC (Figure 
5.7). This negative result goes against a potential role of repo in repressing neuronal fate in 
adult glia. However, we cannot rule out this possibility as the time course in the observation 
was few hours in embryos and 7 days in the adult. It is possible that the GFP signal from 












To verify this hypothesis, the number of glial cells per specific areas of the brain was 
assessed, using the Repo-nGFP marker. Counting GFP positive nuclei both in the central 
brain or optic lobes, no significant difference was observed between wild type and Repo-
RNAi conditions (Figure 5.8A, the quantifications represent the counting of green cells in 
the full brain using ImageJ software. The images represent the optic lobes as an example of 
methodology). This result goes against the hypothesis that glial cells would have 
transformed into neurons and lost their GFP signal before the flies are sacrificed and 
stained. In this case we would have observed a drop in the number of glial cells present in 
the brain or an increase in elav+ cells. It is noteworthy that the immunostaining of nGFP 
seems contradictory with the western blot of the Figure 5.5E. However, in this case, the 
settings of the microscope were not calibrated on the control samples and thus no 
quantitative results can be assumed from the pictures on the level of GFP even though it 
seems strongly decreased from the western blot. In order to be more reliable and 
independent of the reporter (dependent on Repo protein presence), an irreversible labelling 
of the glial cells would allow a better counting to identify a drop in the cell number. 
 
In repo hypomorph mutants, it was shown that there were signs of neuronal apoptosis and 
degeneration. Glial cells being responsible of neuronal maintenance, by providing energy 
and trophic support, the potential cell death was evaluated by TUNEL assay, which stains 
for DNA breaks. No significant difference was observed between control and Repo-RNAi 
flies, both of them having no more than 10 cells positive (Figure 5.8B). A sample treated 
with DNAse was done to confirm that the enzymatic activity of the assay has worked. It 
suggests that the fly death is not due to any cell loss, even though a time course for the 
assay would be needed to evaluate previous cell loss. In the case of the hypomorph mutant 
used in the past, the mutation of repo had its effect from embryo through all developmental 
stages. As a result, the glial cells in the optic lobe were misplaced from early development 
to adult, which could have led to more severe phenotypes as the glia would have failed to 
provide their correct supports from developmental stages. In the case of specific adult 
knock-down, the glial cells are correctly located in the CNS and their functions during the 
developmental stages were not affected. This could explain the difference observed 




5.2.5 repo regulates the expression of glial-specific genes and functions in 
adult stage 
 
The previous results have shown that the different phenotypes observed (decrease of 
lifespan and motor defects) do not seem to come from a loss of cells in the CNS. However, 
it is possible that potential cell loss in the PNS could have caused these phenotypes, in 
particular the motor defects. Glial cells interact strongly with neurons at multiple levels 
such as synaptic level, axonal ensheathment or energy support. Dysfunction of neuronal 
activity or failure to maintain normal cell homeostasis in the CNS can lead to the death 
prior any sign of degeneration.  
 
5.2.5.1 repo controls the activation of specific genes in adult glia 
 
Since there were no signs of cell death or fate change, I set out to test whether there were 
any changes at the molecular level which might result in functional alterations in glia. 
Using a ChIP assay on S2 cells, repo has been shown to potentially bind to several gene 
promoters, including glia-specific genes. It is has been demonstrated for some of them, 
including the Glutamine synthetase 2 (Gs2), dEAAT1 and dEAAT2 genes, that repo null (-/-
) mutant embryos did not express any of the above mentioned genes mRNA (Soustelle et 
al. 2002, Kerr et al. 2014). Since repo is involved in the activation of specific sets of genes 
during the terminal glial differentiation, it is possible that, being still expressed, its presence 
in adult glia is still required to maintain the expression of such genes. A list of some genes 
obtained by the ChIP, known to be expressed in Drosophila glia or in the Wg signalling 
pathway, has been published by Kerr et al. I decided to focus on some of those genes, based 
on their functions or previous established direct interactions: Gs2 (expressed mostly in 
astrocyte and involved in glutamate recycling in glial cells), dEAAT1 (Glutamate 
transporter that shows motor defects in both larvae and adult when downregulated (Rival et 
al. 2004)), Gliotactin and loco (involved in the establishment and maintenance of the BBB 
(Auld et al. 1995, Schwabe et al. 2005)), wg (secreted by glia at the larvae neuromuscular 
junction (NMJ) under the control of repo (Kerr et al. 2014)) and Pointed (known to co-
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activate with repo some specific genes in glia such as loco (Yuasa 2003)). The only known 
Drosophila glial GABA transporter Gat was also added to this list of genes (Stork et al. 
2014), based on the fact that it was very specific to astrocyte-like glia and likely to be under 
the control of a glia specific transcription factor. In order to see whether repo was able to 
control the expression levels of such genes in adult Drosophila brain, a qPCR was done at 
different time point, either in wild type or RNAi conditions. The two time points chosen 
were after 5 hours spent at 29°C, before any possible effect of the expression of the RNAi 
on repo expression but the flies were still subjected to this temperature to control for a 
potential increase in gene transcription due to a higher temperature, and after 7 days, when 
the flies start to have motor defects, 3 days prior to death, in order to maximize the chances 
to see potential changes in other gene mRNA levels. Two reference genes were used, 
Gapdh and eIF4A, previously used in a microarray study in the lab (Napoletano et al. 
2011), being common control genes. 
 
While after 5 hours at 29°C there are no significant changes in all the analysed genes, after 
7 days at 29°C, several genes display a statistically significant decrease in their mRNA 
levels (Figure 5.9A). Indeed, dEAAT1, Gat, Gs2 and loco have a significant reduction of 
their mRNA level and both dEAAT1 and Gat are also significant post FDR corrections, 
with Gs2 and loco having a P-value post FDR of 0.06 and 0.07 respectively. However, the 
other genes did not reach significance. It is possible that for a gene like wg, not only 
expressed in glial cells, the level of mRNA could be diluted by its expression from other 
cells since the qPCR is done on whole head samples. These four genes are involved either 
in neurotransmitter clearance and recycling or in BBB maintenance. Each of these 
functions has been shown to be important in motor functions or generally longevity (Kim et 
al. 2010), which correlates with the Repo-RNAi phenotypes. Gat being the gene with the 
strongest mRNA level reduction, its protein level was analysed by western blot, again after 
7 days spent at 29°C. Gat is known to express three protein isoforms (Muthukumar et al. 
2014). In the Figure 5.9B, the western blot analysis of Gat protein level shows that all 
three isoforms seem to be downregulated, though to a different level. While the middle 
isoform is strongly downregulated, the top one is only mildly decreased. The signal of the 
lower band is a lot weaker so it is more difficult to assess it, however, the signal appears to 
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fade in Repo-RNAi condition. These results go in the same direction than the qPCR data 
for Gat, which indicate that repo could control, at least indirectly, the activation of Gat 
transcription in adult Drosophila astrocyte-like glia. However, the question of a direct or 
indirect control remains open. 
 
According to the qPCR data and the western blot for Gat, I asked whether the 
overexpression of each of these four genes would be able to at least partially rescue the 
lifespan phenotype of repo knock-down. However, none of them alone has been able to 
increase the lifespan, with the overexpression of loco decreasing it significantly even more 
(p<0.001) (Figure 5.9C). It is possible that, Repo-Gal4 driver being a knock-in and Repo 
protein possibly acting on its own promoter, the Gal4 expression becomes very low when 
Repo protein is absent. Thus the expression of other transgenes in parallel of Repo-RNAi 
could be blocked or not high enough to rescue such a strong phenotype. The only 
significant effect is an even further decrease of the lifespan by overexpressing loco. While 
rescuing a phenotype can be difficult if it is very strong or coming from different origins, 
an additive effect can be more easily seen. It has been shown that the overexpression of 
loco, similarly to its knock-down, could have detrimental effect on the BBB, indicating that 
a tight control of its expression level is required for its function in the BBB when 
interacting with different GPCR signalling molecules (Schwabe et al. 2005). Moreover, it 
was suggested that its overexpression could reduce the Drosophila lifespan (Lin et al. 
2011). This last study was overexpressing loco using a ubiquitous driver, hiding a potential 
specific role of glial cells in these phenotypes. However, when overexpressed specifically 








5.2.5.2 repo expression in adult glial cells maintain the BBB integrity 
 
According to the previous results, especially the fact that loco overexpression was 
worsening the phenotype, I wondered whether a potential BBB impairment could be linked 
to the fly death and associated to the motor defects. By injecting a fluorescent dye in the fly 
thorax, the dye reaches the hemolymph and diffuses throughout the body (Bainton et al. 
2005). If the Drosophila BBB is intact, the dye does not penetrate the brain and 
accumulates around it. However, if there is BBB impairment, the dye can leak into the 
brain. By confocal microscopy, the presence of the dye inside the brain can be assessed to 
identify potential BBB leakage. All the four conditions (wild-type, Repo-RNAi 1, Repo-
RNAi 1 + UAS-Repo and Repo-RNAi 2) were assessed first after 8 days at 29°C, the dye 
being injected the day before, when the Repo-RNAi 1 flies do not move. However, at this 
time point the flies from the other genotypes, wild-type, Repo-RNAi 2 and Repo-RNAi 1 + 
UAS-Repo, do not display motor defects yet, having their median survival delayed by few 
days. 
 
The analysis of the BBB leakage was done by evaluating the strength of the leakage. If the 
dye is kept outside, it is considered intact. If the dye is present in specific areas, close to the 
edge of the brain, it is considered mild penetration and if it is throughout the brain, it is a 
strong penetration. The wild-type flies have their BBB intact in most of the cases, only 3 
out of 18 brains had mild dye penetration (Figure 5.10). In the case of a very strong knock-
down of repo, using the Repo-RNAi 1, 14 out of 16 brains had dye penetration and in most 
of the cases it was throughout the entire brain, with a strong penetration (Figure 5.10). 
When repo is overexpressed beside Repo-RNAi 1 (RNAi 1 + >Repo), which delayed the 
death by only 3 days, 6 out of 8 brains were positive for the dye penetration (Figure 5.10). 
However, half of the positive ones were mild penetration of the dye, similarly to wild-type 
positive cases. When the Repo-RNAi 2 is used to knock-down repo, which delay the death 
by a week in females and has a weaker knock-down of Repo protein after 7 days at 29°C, 
only 3 out of 10 brains were positive for the Dextran dye (Figure 5.10). These 3 positive 
brains were having a mild penetration of the dye.  
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The Repo-RNAi 2 flies have a longer period of paralysis before death than the Repo-RNAi 
1 (Figure 5.4A and B). Moreover, the males start to have motor defects 4 days before the 
females. Indeed, males have locomotor defects from 8 days while the females show motor 
defects from 12 days (Figure 5.4B right and lower panels). I took advantage of this 
difference to assess the BBB integrity at 9 days. At this time point, the males just start to 
have motor defects while the female do not. Out of 11 females, 3 had mild penetration of 
the dye and the rest had none. Out of 8 males, 3 had strong penetration, 3 were mild and 2 
had none. In the control flies, 2 out of 6 for both males and females had mild penetration of 
the dye. These flies were assessed for climbing assay just prior dye injection on day 8. The 
females Repo-RNAi 2 showed no difference compared to control. However, 3 males were 
not climbing at all, 3 were variable between each replicate and 2 had no defects (Figure 
5.4B, lower graph). Thus, the ratios of impaired motor functions correlate with the ratios of 
the BBB defects. Another time point was done at 14 days when the female Repo-RNAi 2 
flies are paralyzed, just prior to death. In control flies, 3 out of 10 had mild dye penetration 
while the rest had none. In Repo-RNAi 2 female flies, out of 7, 1 had no penetration, 2 had 
mild and 4 had strong dye penetration, which is similar to the Repo-RNAi 1 flies at 8 days. 
Altogether, these data suggest a strong correlation between the strength of the Repo knock-
down, the onset of the motor defects and the BBB leakage. Indeed, an increase in BBB 
defects appears just prior motor impairment and strong leakage of the dye is visible when 
the flies are paralyzed, just before the death. However, even though there is a strong 
correlation between the phenotypes, it remains unclear whether the BBB defects are 









5.2.5.3 Adult repo expression acts non-autonomously on the photoreceptor neuron 
morphology 
 
Glial dysfunction, through probable defects in neurotransmitter recycling and BBB 
maintenance, will surely affect neurons given that the Repo-RNAi flies present strong 
motor defects. It is possible that there might be also morphological dysfunctions in the 
circuitry (beside functional dysfunctions). However, in most cases the really complex 
intermixing of neuronal network, including axons, dendrites, synapses and glia, makes 
difficult to visualize altered morphology. The visual system offers the unique opportunity 
of looking at neuronal morphology, which is organized stereotypically and has neuronal 
cell bodies physically separated from the glia. In this system, eventual morphological 
problems can be assessed more confidently and quantified. The photoreceptor neurons are 
present in the retina and send their axons either into the lamina or medulla of the optic lobe 
and form synapses with either corresponding lamina or medulla interneurons. However, 
glial cells are not present in the retina and sit only at the base of it and surround the lamina 
and medulla neuropils while ensheathing the respective neurons (Figure 5.11B, Optic lobe 
panels). Lamina and medulla astrocyte-like glia, also called epithelial glia, send their 
projections toward the synaptic contact between the photoreceptor neurons and the 
interneurons of the optic lobes (Morante et al. 2004). Glial cells are known to uptake 
histamine (neurotransmitter of these neurons) from the synapse and recycle it in 
cooperation with supportive cells of the retina back to the photoreceptor neurons (Borycz et 
al. 2002, Chaturvedi et al. 2014). Thus, Drosophila retina provides a good in vivo model 
for studying non-autonomous effect from glia to neurons. 
 
The retina is composed of roughly 800 ommatidia, each of these subunits containing 8 
photoreceptors surrounded by supportive cells such as pigment cells, cone cells or bristle. 
The photoreceptor neurons 7 and 8 are on top of each other and as a result, in each retina 
cross-section, only 7 are visible. Each photoreceptor possesses one rhabdomere, which is 
the folding of the plasma membrane at the apical part of the ommatidium. The pattern of 
retina sections is a series of perfectly aligned repetitive motifs (hexagon) composed of 7 
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black dots (rhabdomeres, membrane-rich structure). This repetitive structure can be easily 
observed by doing tangential sections of fly retina embedded in resin and stained with 
osmium. 
 
Even though it has been confirmed that the RNAi is not expressed during development and 
does not downregulate repo, the structure of the retina of Repo-RNAi flies kept at 18°C 
was still evaluated. As expected, no difference with wild-type retina could be observed. The 
7 photoreceptors visible were present in all ommatidia and the overall structure of the 
photoreceptors and retina was not affected. Then, the Repo-RNAi flies were aged 7 days at 
29°C alongside control flies, which have the same driver but not expressing the RNAi. 
Interestingly, no sign of cell degeneration was observed as all the photoreceptors were 
present in all ommatidia. However, at the top of the retina, where the cell bodies of the 
photoreceptor neurons and pigment cells sit, the pigment cells surrounding the 
photoreceptor neurons seem swallowed (black arrowheads in Figure 5.11A, localized on 
the schematic), potentially compressing the neuronal cell bodies. Surprisingly, in some 
cases, 13 to 15 rhabdomeres could be seen within one ommatidium, even though there were 
still 7 neuronal cell bodies (black arrows in Figure 5.11A and insets for the Repo-RNAi 
29°C condition, represented in the top schematic). This result shows that there are extra 
numbers of rhabdomeres, potentially split, in some photoreceptor neurons. This phenotype 
suggests a substantial reorganization of the actin cytoskeleton and the membrane in order to 
split or generate new rhabdomeres, which is a complex active folding of the membrane 
microvillae. This has only been observed in repo hypomorph mutants in which the 
mutation was present through developmental stages. In the rare cases shown of split/new 
rhabdomeres, there was one extra per ommatidia and often accompanied by degeneration of 
the neighbouring ommatidia (Xiong et al. 1995). In the case of adult specific knock-down, 
there is no neuronal degeneration and sometimes doubled the number of expected 
rhabdomeres. The interpretation of this phenotype is rather complicated as it has only been 
reported once, 20 years ago, without deeper understanding. 
 
In order to understand better the morphological defects observed in the tangential sections, 
the entire visual system morphology was investigated by doing horizontal sections of the 
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eye. The focus was on four different stereotypical regions, the retina, with long aligned 
tubular structures, the lamina and medulla neuropils and the fibrous optic chiasm between 
both neuropils, which has a typical wide angle made by the split of neuronal tracts reaching 
each side of the medulla. Also, it is noteworthy that there are only 2-3 sections per eye 
where the photoreceptor neurons are seen aligned in one section from apical to basal part. 
Thus, it increases the confidence of the specificity of the observed area between the 
samples. Confirming the previous results of the tangential sections, the pigment cells 
seemed either swallowed or compacted. In both type of controls, these supportive cells 
(SC) form spike-like structure on the apical side. However, after 7 days at 29°C, the Repo-
RNAi retina do not have clear spike-like structures (Figure 5.11B). Also, instead of long 
and aligned tubular structures present in both controls, the photoreceptor neurons in the 
RNAi condition were curved and appeared shorter. It is also possible that the increase in 
volume of the supportive cells exert a mechanical pressure onto the neurons resulting in the 
folding. However, the weakness of the tissue due to a potential lack of mechanical support 
resulting in the collapse of the structure during the embedding of the heads cannot be ruled 
out. Thus, it is difficult to conclude on an overall reduction of the size of either the retina or 
the photoreceptor neurons. 
 
Then, both lamina and medulla neuropil sizes were analysed since the photoreceptor 
neurons 1-6 and 7-8 send their axons in their corresponding targeted neuropils to make 
synaptic connections with lamina and medulla neurons respectively. The size of the 
medulla does not change in RNAi flies (data not shown) even though it appears more 
distant from the edge of the optic lobes, revealing more cell bodies in between. 
Furthermore, between the lamina and the medulla, the optic chiasm wide angle made by the 
fibres from photoreceptor neurons 7 and 8 and the lamina neurons seems less open, 
indicating a change in the organization of cells and fibres in the optic lobe (Figure 5.11B, 
Optic lobe panels). The size of the lamina was also evaluated. Contrary to the medulla, the 
lamina was significantly reduced by 26% in width (Figure 5.11B, graph) potentially due to 
loss of fibres. Another visible aligned structure in the controls was white fibres coming 
from the optic chiasm entering the medulla neuropil. In both controls about 30 to 32 of 
them were visible (Figure 5.11B, Optic lobe panel). However, these white fibrous 
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structures were absent in the Repo-RNAi flies and some black ones were visible instead. 
The length from the entrance of the medulla to the tip of these structures, white and black 
ones, was similar (data not shown), suggesting that these fibres target a similar layer in the 
medulla. These white structures in the medulla resemble closely the axons of the lamina 
neurons 1 to 3 (LN in the Figure 5.11B), which target the medulla layers M1, M2 and M5 
(Pantazis et al. 2008). However, this hypothesis would need to be confirmed by using a 
specific Gal4 driver for these neurons as the medulla is reached by membrane tracts from 
photoreceptor neurons, lamina and medulla neurons but also epithelial glial cells. 
Furthermore, there are only 15 to 20 black structures visible instead of the 30-32 white 
ones. It is thus not possible to confirm using these pictures whether the white and black 
structures are of the same origin and degenerate or if the black ones are different and 
become visible because of the loss of the white ones. Taken together, these data 
demonstrate that the downregulation of repo during only 7 days is enough to the trigger of 
substantial morphological changes in both the retina, where repo + cells are absent. The 
folding of the photoreceptor neurons and the morphological changes of the pigment cells 
and in the optic lobe suggest dramatic morphological changes of the neuronal tracts in the 
nervous system. 
 
Since there was an abnormal morphology of the photoreceptor neuron cell bodies, their 
connectivity has also been investigated. Using a specific reporter expressed specifically in 
the entire photoreceptor 7 including the axon, the morphology and the synaptic region of 
the axons in the medulla was assessed. The synaptic region of the photoreceptor 7 in the 
medulla is well characterized and its aligned structure can be easily evaluated. The 
alignment of the synaptic regions of the photoreceptor neurons 7 is conserved in the Repo-
RNAi flies as it is seen by confocal imaging using the Rh4-LacZ reporter with or without 
Repo-RNAi 1 expressed (Figure 5.11B, lower panels). While the alignment of the synapses 
between the control and Repo-RNAi conditions were similar, reaching the M6 layer of the 
medulla, the number of axons in the Repo-RNAi condition was difficult to assess because 
of the variability between the samples. Indeed, as observed in Figure 5.11B, there are often 
dark areas hiding potential tracts. However, out of 12 brains imaged for each genotype, the 
intensity of the signal and the number of axons were reduced in most cases (Figure 5.12). 
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A better staining using for instance the antibody 24B10 (staining the photoreceptor 7 and 8) 
































The glial cells being present only in the optic lobe and not in the retina itself, the changes of 
the cellular morphology for both pigment cells and photoreceptor neurons happen in an 
indirect way, potentially through dysfunctions in the downstream interactions between glia 
and neurons or glia and supportive cells. The two main interactions between glia and 
photoreceptor neurons are at the synaptic level and for the insulation of their axons once 
entering into the optic lobe. Also, as mentioned in the study by Chaturvedi et al. 
(Chaturvedi et al. 2014), the glial cells highly communicate with support cells of the retina. 
It is thus possible that the disrupted morphology of the pigment cells comes from an 
abnormal communication between these two cell types. 
 
Following the observations that there is a loss of membrane tracts in the medulla or at least 
a dramatic disorganization of the medulla at the synaptic layer, the integrity of the axonal 
bundles in the brain was assessed. Indeed, it has been shown that killing most of the glial 
cells specifically at the adult stage was resulting in some specific bundles degeneration 
called secondary axonal tracts (SATs), depending on their interactions with glial cells 
(Spindler et al. 2009). However, even though most of the glial cells were dead, very few of 
these SATs were affected by a degenerative process. In order to see if similar axonal tracts 
degeneration was happening when repo was downregulated, brains of 7 days old flies at 
29°C were immunostained with Neuroglian, the same marker used in the above mentioned 
study for these SATs. However, no degenerated SATs could be observed and there were no 
obvious differences between the wild-type and Repo-RNAi flies (Figure 5.12). It is 
actually not surprising since the phenotype when most of the glial cells were dead was very 
mild. It means that the fasciculation of these tracts is rather stable even when the glial cells 
are dramatically disturbed. Moreover, the optic chiasm between the lamina and medulla 




 5.3 Discussion 
 
5.3.1 miR-1 is involved in mesoderm-neuroectoderm fate determination during 
embryogenesis 
 
So far, miR-1 has been only studied in mesodermal fate commitment and muscle cell 
differentiation. In mammalian cells, Izarra et al. (Izarra et al. 2014) show that the 
expression of miR-1 triggers mesodermal fate in embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs), partly through the downregulation of neural fate factors. 
However, in vivo, in Drosophila, miR-1 KO (-/-) larvae appear normal in starved conditions 
that keep them into early larval stage (L1) but die when fed, which normally triggers 
muscle cell to enter endocycle in order to grow fast without division. However, the miR-1 
KO phenotype does not phenocopy entirely the phenotypes of genes involved in the 
endocycle. Thus, its function in muscle integrity and growth remains unclear. The main 
hypothesis is that miR-1 would maintain muscle cells identity by downregulating 
promiscuously transcribed non-muscle genes. These “ectopic” transcriptions could be the 
result of exceedingly active nuclei in muscle undergoing rapid growth. Also, before being 
expressed in myogenic cells, likely through the activation by the transcription factor Mef2, 
miR-1 is expressed in the entire mesoderm, including presumptive immune cells, through 
its activation by twist. Similarly to what was observed in mammalian stem cells, this early 
expression could indicate a role in cell fate commitment, to ensure that the cells will 
differentiate toward the desired fate. The results provided in this thesis, combined to the 
twist KO (-/-) from our collaborators support this theory. The redundancy of transcription 
factor expressions in different tissue would explain the need for safeguards to prevent 
ectopic expression of unspecific genes. The expression of gcm, first transiently in the 
mesoderm and then in the neuroectoderm, supposedly activating different sets of 
transcription factors, is the perfect example. Moreover, gcm has been more recently found 
to be involved in post-embryonic haematopoiesis by interacting with dPIAS and acting 
upstream the JAK/STAT pathway (Jacques et al. 2009). In this case, it is possible that the 
expression of gcm in non-neuroectodermal cells could potentially activate the ectopic 
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transcription of repo. Being a transcription factor activating multiple glia specific functions, 
a way to inhibit such potential ectopic expression would be to express specific miRNAs, 
which have a broad spectrum that allows them to downregulate several genes at the same 
time in a tissue specific manner. 
 
Also, the fact that twist KO and miR-1 KO embryos only display a weak phenotype, with 
around 10 cells in each case positive for Repo and Srp, shows that there are other 
mechanisms partly redundant to protect against such change of fate. However, whether 
those cells would become glial cells is still not clear as it would require the activation of 
other genes, which might be downregulated by other miRNAs or inactivated by other 
factors, such as Srp itself. 
 
The ectopic expression of twist in the neuroectoderm decreased dramatically its 
organisation and the number of glial cells (data not shown). Even though I could not 
reproduce a similar result by the overexpression of miR-1 at this stage of embryogenesis, it 
would be interesting to know whether the twist phenotype is at least partly due to the 
activation of miR-1 by repeating the twist overexpression in a miR-1 KO background. The 
larval brain phenotype obtained by the ectopic expression of miR-1 indicates a role of 
targeted genes in glia division and/or migration. The impairment of the glia localization in 
the presumptive optic lobe in L3 larval stage is actually very similar to the one of repo 
mutant, where it was demonstrated that repo was involved in glial migration (Xiong et al. 
1994). repo is a direct target of miR-1, being upregulated in the mesoderm in miR-1 KO 
embryos and downregulated by the ectopic expression of miR-1 in adult glia and in S2 
cells. However, the failure to rescue the phenotypes in L3 larval brain and partially in the 
adult with the overexpression of a miRNAs insensitive repo transgene (lacking its 3’UTR) 
indicates that miR-1 might downregulate other important genes in the glia. Pros could be 
such a candidate gene as it has been predicted to be downregulated by miR-1. Indeed, Pros 
is involved in glial cell division during development and its downregulation in larvae could 
lead to brain growth defects, by affecting the insulin pathway for instance. However, it is 
highly possible that the defects observed are the results of a combination of several genes 
downregulated whereby the overexpression of only one would not be enough to counteract 
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the effects of a miRNA. Indeed, the downregulation of inx1 and especially inx2 in surface 
glia led to a smaller brain in L3 larvae and thinner and elongated VNC in the case of inx2, 
very similar to what is observed with miR-1 overexpression in larvae (Spéder et al. 2014). 
Interestingly, inx2 is predicted by one miRNA targets website (microRNA.org) to be 
targeted by miR-1. This reduction in larval brain size is due to the blockage of NSCs into 
quiescence. The re-activation of quiescent NSCs is nutrient dependent and requires 
subperineurial glial gap junction, formed by the innexins family. Thus, if such gap 
junctions or related proteins in similar pathways are downregulated by miR-1, it would lead 
to a very similar phenotype. 
 
In summary, miR-1 seems to be an active player in cell fate commitment during 
development, both in invertebrates and vertebrates. Its role has been extensively studied in 
muscle and cardiac cells in different organisms, but it has also been reported as being a 
candidate tumour-suppressor (Hudson et al. 2012). In this thesis, I add to miR-1 another 
potential regulatory role, which would happen earlier in development, during early 
embryogenesis, where it would participate to the correct differentiation of hemocytes in the 
mesoderm, by inhibiting the glial gene repo. 
 
5.3.2 repo expression in adult glia is essential for Drosophila CNS 
homeostasis 
 
repo expression starts during the embryogenesis, triggered by gcm, but remains constantly 
expressed until adulthood. However, depending on the developmental stage, its function 
might be different. Indeed, its role in glial migration and terminal differentiation is not 
needed in adult differentiated cells. From embryogenesis, repo activates glia specific genes 
such as dEAAT1/2 and Gs2, or glial wg in the larvae. This function of transcriptional 
activator seems to remain in adult Drosophila, suggested by the fact that repo is needed to 
maintain the transcription of several glial-specific genes. It is actually one of the few cases 
in which an important developmental transcription factor keeps controlling the transcription 
of some of the same developmental target genes in the adult. It is possible that its specific 
developmental functions require other factors that are not present in adult glial cells, such 
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as ttk69 or gcm. It has been demonstrated that during embryogenesis, depending on the type 
of glial cells, repo cooperates with different factors to activate specific subsets of genes, 
which is the case for loco for instance in the BBB glia. Glial cells have different specific 
functions in the adult as well, even though repo is expressed in all of them. It suggests that 
this specificity might still be needed in order to maintain specific gene transcription. Gat is 
expressed only in astrocyte-like glia while loco is supposed to be subperineurial glia 
specific. Thus, a complex regulatory pathway, implicating repo, may regulate the 
expression of specific glial genes in specific subsets glial cells as it is the case during 
development with ttk69 or ptnp1. 
 
To add another layer of complexity to the study of repo function in the adult fly, the 
regulation of nGFP expression downstream the repo promoter suggests that it participates 
to the regulation of its own transcriptional activity, by a complex feedback loop. However, 
the repo promoter used to generate the Repo-nGFP reporter is only the sequence directly 
upstream the coding region, which might lack some other regulatory sequences. A potential 
feedback loop is however further supported by the fact that a high Repo protein level seems 
to be needed in order to maintain its own transcription and suggest a potential regulation as 
a transcriptional bistable switch. Even though the RNAi presence/absence after 7 and 20 
days at 18°C has to be checked, it is very unlikely that a pool of small RNA is stable and 
active that long within a cell, downregulating newly produced mRNA for 20 days. It is thus 
likely that a small amount of Repo protein is able to maintain a low level of transcription, 
enough to delay the death by more than 20 days. It would be interesting to investigate the 
molecular mechanisms behind this regulation. One possibility for the presence of this 
residual amount when repo is overexpressed beside its RNAi is that the inactivation of the 
gene is mosaic, meaning that some cells are more affected than others. A staining of the 
brains in this condition would allow us to see whether all the cells have low levels or if 
some have higher levels than others. This hypothesis comes from the staining of the full 
repo KD brains (using RNAi 1), where it is sometimes possible to see very small group of 
sparse glial cells, or single isolated cells, positive for Repo, though to a low level (data not 
shown), again suggesting the possibility of a transcription bistable switch regulation of 
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repo. These very few cells expressing low levels of repo do not allow detection by western 
blot as seen previously in the Result section (5.2). 
 
These results bring on one important question. How can the promoter be switched off 
irreversibly? It is possible that the repo promoter is also regulated by some epigenetic 
factors. The presence of Repo protein could be necessary to maintain the chromatin open 
and allow the transcription of the gene. However, when the protein is lost or down to a very 
low level, the chromatin could be modified and prevent the access to the promoter region to 
new transcription factors. In this case, newly formed Repo protein would not be able to 
reactivate its own promoter. To verify this hypothesis, we would need to be able to 
downregulate fully repo first, and then activate a transient exogenous expression of repo to 
see if endogenous Repo protein is formed. However, with the tools available, it is currently 
not possible to answer this question. Moreover, the Repo-nGFP reporter seems to be also 
affected by this auto-regulation. It suggests that this potential epigenetic mechanism is 
chromosome position independent and might be encoded in the 4.2kb promoter region, 
upstream the coding sequence. It would be interesting to see whether the nGFP level 
remains high in the rescue setting, when the RNAi 1 is co-expressed with the UAS-Repo 
line. It could help understand whether this residual amount of Repo protein is able to 
maintain the transcription of nGFP through the activation of the 4.2kb repo promoter. 
 
This complex regulation brings the question of the efficiency of the Repo-Gal4 driver in 
order to carry out rescue experiments as done here. Indeed, Repo-Gal4 driver is a knock-in, 
meaning that the Gal4 expression is dependent on the activation of the endogenous repo 
promoter. This could explain the failure to rescue the lifespan phenotypes because the Gal4 
protein levels may be too low to activate a high expression of the desired transgenes. In 
order to overcome this problem, it would help to generate a line that would activate an 
Actin-Gal4 driver specifically in glial cells using the FLP/FRT method. This line would 
allow the transgene expression independently from the presence of Repo protein, unlike 
potentially the Repo-Gal4 driver. 
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It has also been demonstrated that repo is necessary to maintain certain transcription levels 
of specific glial genes. In the group of genes evaluated for a potential repo-dependence, at 
least four of them seem to have their transcription affected. Three are involved in 
neurotransmitter clearance (dEAAT1 and Gat) and recycling (Gs2) and one in blood brain 
barrier maintenance (loco). However, only Gat protein levels have been confirmed to be 
also downregulated as we do not have antibodies for the others. Neurotransmitter clearance 
and recycling is a very important process to maintain a good synaptic activity and avoid 
neurotransmitter excess in the cleft, which triggers toxicity. Also, if the neurotransmitters 
are recycled back to the neurons, the pool available for the neurons to fire will decrease and 
thus affect the capacity for the neurons to activate properly the post-synaptic neurons. Glial 
cells are known to not only clear up the synaptic cleft but also regulate the synaptic activity 
through different receptors that allow them to compete with receptors from the post-
synaptic neurons. It has already been demonstrated that the downregulation of some of the 
neurotransmitter receptors, such as dEAAT1 and Gat, affects motility, a phenotype observed 
when repo is downregulated. However, the downregulation of Gs2 does not alter the 
motility and is not necessary to support the basic functional properties of the Dorso-
Longitudinal-Muscle (DLM) neuromuscular synapses (McCabe et al. 2015). However, it is 
possible that its activity becomes necessary to sustain glutamate release during prolonged 
periods of synaptic activity. The alteration of the transcription of such genes, may be 
among others that have not been assessed in the qPCR, will certainly affect this major 
function of glial cells, mostly astrocyte-like glia. Indeed, this cell type sits at the border of 
the neuropils where all the synapses are, and send their projections toward them. Even 
though it has not been shown yet that the projections are in very close vicinity with the 
synapse itself, contrary to what has already been observed in mammals, the fact that these 
cells send membrane projections in synaptic rich regions, and that they are specifically 
expressing neurotransmitter transporters, highly suggest a similar role to the mammalian 
astrocytes. 
 
loco on its side is known to be involved in the Drosophila “BBB” maintenance through a 
GPCR signalling pathway. This regulation would be important for the maintenance of a 
dynamic actin structures to keep the membranes gap sealed by septate junctions (Hatan et 
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al. 2011). The deregulation of this signalling pathway could disrupt the proper sealing 
between the subperineurial glial cells, forming the tight BBB layer. Acting in a complex 
with different G proteins, an overexpression or downregulation of loco would have both 
detrimental effects on its function. Thus, the decrease in the transcriptional activity of the 
loco promoter, leading to lower loco mRNA levels, could affect this signalling pathway and 
disrupt, at least partially, the tightness of the septate junctions formed between the 
subperineurial glia. It has been shown that a Dextran dye injected in the thorax of the fly 
could penetrate the brain when repo was knocked-down. It suggests that the “BBB” 
function of certain glial cell types is disrupted and possibly does not maintain the brain in a 
tightly regulated ion environment due to the BBB leakage. This specific extra-cellular ion 
environment is necessary to maintain healthy neuronal activity, by keeping a good ratio of 
extracellular ions to allow efficient axon potentials. Indeed, the hemolymph, present all 
around the CNS, has a very high potassium concentration (~26mM) (Limmer et al. 2014). 
While the CNS extracellular K+ concentration is known to be at least around 10 times 
lower than that, a leakage of such ion from the hemolymph would dramatically affect 
neuronal function (Limmer et al. 2014). As suggested by the co-overexpression of loco 
beside the RNAi 1, which decreased even further the lifespan, it is possible that 
subperineurial glia dysfunction can participate to the phenotype by disrupting septate 
junctions at the BBB and thus modifying the ion environment leading to neuronal defects. 
 
As I have shown in the results and explained above, the repo-activated genes seem to be 
involved in many different functions. Indeed, its downregulation triggers a lot of different 
defects such as BBB impairment, motor defects and changes in neuronal morphology and 
possibly connectivity. We yet have to investigate the neuronal activity in Repo KD 
condition, but with the strong decrease of glial GABA transporter, expressed at the synaptic 
level and the BBB leakage that will likely trigger massive changes in the extracellular 
environment, it is highly possible that the neuronal activity is impaired. Also, according to 
my results, this impairment may be rather general to all neurons as rescuing repo 
expression in the VNC (and potentially in the PNS depending to the Tsh-Gal80 expression 
pattern outside the CNS) did not improve the locomotor phenotype. However, the repo 
expression level in the VNC would need to be assessed in order to know whether Tsh-
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Gal80 fully rescues the expression or only partially. Indeed, I have demonstrated that a 
tight regulation of Repo protein level is necessary to maintain glial functions. Furthermore, 
the photoreceptor neurons, which are in close contact with glia at their synapse, are also 
dramatically affected. This may cause blindness, however, it is unlikely that this potential 
blindness triggers motor defects as “blind” flies have only very mild motor behaviour 
defects and live perfectly well, the eyes being not necessary for the fly to live in laboratory 
conditions. However, if Tsh-Gal80 is not expressed in sensory organs such as the 
chordotonal organs, it is possible that defects in the sensory organs could result in 
locomotor deficit similar to what observed in this study. To verify this hypothesis, repo 
would need to be downregulated specifically in the glial cells in those sensory organs to 
assess the locomotor activity and also potentially the lifespan. 
 
repo is expressed in all the glial cells in the entire CNS and PNS so it is unlikely that only a 
specific neuronal population is affected by general glial impairment. Surprisingly, the use 
of more specific drivers to target repo downregulation to subtypes of glial cells did not 
have any effects, apart from the use of dEAAT1-Gal4 (mild lifespan decrease, which is a 
combination of several glial subtypes, mostly astrocytes, cortex glia and ensheathing glia). 
This strengthens the hypothesis that such a strong lethality comes from an addition of 
defects from different subtypes of glia and not one dominant population involved, such as 
the astrocyte-like glia in the case of polyQ Atro toxicity. Also, the strength of the Gal4 
drivers used can be an issue as it is possible that Alrm-Gal4 is weaker than dEAAT1-Gal4 
in astrocyte-like glia. Moreover, when Moody-Gal4 driver was used to downregulate repo 
in subperineurial glia (BBB glia), no BBB defect could be observed, questioning the 
strength of this driver (data not shown). This could explain why the lifespan was not 
affected in this condition. The use of Gliotactin-Gal4, stronger than Moody-Gal4 for 
polyQ-Atro, could help to understand the importance of BBB breakage if it would reduce 
the lifespan or trigger dye penetration inside the brain. So far, the reason of the fly death 
and motor behaviour defects is yet to be fully understood. Indeed, the overexpression of the 
potential repo-downregulated genes did not rescue the phenotypes. However, it is possible 
that several of these genes have to be co-overexpressed in order to get a rescue in the 
lifespan since the strong phenotype in such a complex functional assay might come from a 
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combination of events. A solution may be to look at the rescue of more specific defects at 
cellular level. For instance, the BBB defects have to be investigated further in order to 
understand whether it actively participates to the lifespan and locomotion phenotypes since 
so far we can only correlate the strength of repo downregulation to the strength of the BBB 
leakage. The generation of a Gliotactin-Gal80 line to block the expression of the UAS-
Repo-RNAi specifically in BBB glial cells would provide a better understanding on the 
direct role BBB defects could have in motor defects and/or lethality of repo 
downregulation. However, these results show clearly that the active transcription of repo-
dependent genes is important to maintain a functional BBB. 
 
The dramatic morphological changes observed in the visual system are also very interesting 
as a paradigm for non-autonomous effects of glia, especially since they are not in direct 
contact with the photoreceptor neuron cell bodies. We know that some of the glial 
neurotransmitter transporters are downregulated but the histamine transporter(s) expressed 
by the epithelial glial cells surrounding the lamina and medulla has not been investigated. 
However, the identity of such glial transporters is unclear. Indeed, the staining for the glial 
specific histamine transporter was present only in the lamina but not in the medulla 
(Pantazis et al. 2008) and another study has shown its expression in clock neurons (Hong et 
al. 2006). It highlights the lack of knowledge and characterization of adult glial function in 
Drosophila. The split of rhabdomeres has been reported in a repo mutant, which was 
defective from developmental stages. It is then the first time that such a phenotype is 
observed specifically in adult. The flies are born with normal photoreceptor neurons and a 
normal glia organisation in the optic lobes, contrary to the former study, but within 7 days 
they develop extra rhabdomeres. The fact that the supportive cells are also affected could 
suggest that there are also defects in the interaction between the glia and those cells. 
Indeed, a tight cooperation is needed between these two cell types in order to recycle 
correctly the histamine back to the neuronal cell body. A defect specifically at this level 
would trigger photoreceptor neuron dysfunction, without the need of impairment at the 
synaptic level, especially in a system that requires such a high demand in histamine, being 
constantly secreting the neurotransmitter. However, the different studies investigating the 
recycling of histamine have not mentioned any abnormalities about extra rhabdomeres. 
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Either it has not been looked at or there were no such phenotypes. It is also possible that the 
extra number of rhabdomeres observed in the ommatidia come from the complex folding of 
the neuronal membrane observed in the horizontal sections of the retina. However, even 
though the entire structure looks curved, the extra numbers of rhabdomeres observed per 
tangential section would require a much more disorganized membrane. To confirm this 
hypothesis, a 3D reconstruction of the horizontal and tangential sections would be needed, 
which is technically very complicated. The dissection of the retina followed by phalloidin 
staining did not allow reasonable observations. Indeed, the phalloidin signal, usually 
concentrated at the rhabdomeres, was also intense in the supportive cells in the apical side 
of the retina, hiding potential signal deeper in the tissue (data not shown). Overall, the 
photoreceptor neuron membranes are completely disorganized and the fibre tracts-rich 
regions in the optic lobe seem dramatically affected by the loss of specific structures and 
the shrinkage of the lamina. The observations of a smaller lamina neuropil and changes in 
tracts morphology in the medulla suggest that repo expression in adult controls neuronal 
integrity and morphology. Since other neurotransmitter transporters are dependent on repo 
expression, it is also possible that the histamine recycling process is repo-dependent, at 
least at certain levels and could trigger neurotoxicity in the lamina and/or medulla. It is thus 
possible that the activity of all these neurons conveying the information of the visual input 
is impaired. Being a neuronal system particularly demanding in energy, it is possible that 
the visual system is more sensitive to glial impairment than others and it remains to be 
investigated whether other neurons and neuropils in the central brain are affected as well. 
Moreover, it would be interesting to see whether the astrocytic ramifications in the lamina 
and medulla are affected or not. A glial membrane staining has been done in Repo-KD 
condition using Repo-Gal4>UAS-CD8-GFP to assess potential glial membrane defects but 
the staining of astrocyte-like glia membranes was weak in this condition while the other 
glia populations did not seem to be affected (data not shown). 
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Conclusion and future perspectives 
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 The aim of this thesis was to investigate the different roles that Drosophila adult glial cells 
have in the maintenance of a functional nervous system. In order to tackle different aspects 
of their interactions with neurons, I used different genetic models. The first one uses the 
glial expression of a gene, Atro, responsible for a rare neurodegenerative disease called 
DRPLA. This approach allowed the investigation of the potential active role glial cells can 
have in triggering or in the progression of this disorder. It has been already shown that the 
expression of this polyQ protein in both glia and neurons was leading to autophagic defects. 
However, it is still unknown how the impairment of the glial cells only, via autophagic 
defects and surely other dysfunctions, would trigger neuronal impairment that lead to motor 
defects and early death. 
 
The second genetic model has been used to understand better the role of adult glial cells in 
the homeostasis of the brain. Indeed, glial cells interact extensively with neurons but are 
also the barrier with the outside world, regulating what goes in and what goes out. 
Drosophila has been used to model many neurological disorders but the focus was mostly 
on the molecular mechanisms happening in neurons that would lead to their own 
degeneration. The importance of glial cells was mostly disregarded. However, recent 
studies have highlighted the major direct or indirect contributions of glial cells in 
neurodegenerative diseases. The genetic tools available for studying Drosophila have made 
this invertebrate organism a first choice in the understanding of basic cellular and 
molecular mechanisms conserved across species. The nervous system development of the 
fly has been extensively characterized, sometimes to a single-cell resolution. Indeed, in the 
embryonic VNC, the equivalent of the spinal cord, the origin, location and migration of 
neurons and glial cells are well documented. However, when it comes to adult functions, 
very little is known about glial cells functions. During larval development and pupa 
metamorphosis, many different glial cells are able to engulf specifically neuronal debris, 
but what about in the adult? While in mammals, astrocytes have been heavily studied in 
providing energy metabolites to neurons mostly via the lactate shuttle, very little is known 
about a similar function in adult Drosophila. One study has identified the outermost 
peripheral glia of the BBB as the cells importing trehalose into the brain. And another 
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study, though again in larvae, has identified some cortex glia that store lipids and thus 
could be the one bringing the energy the neurons require to function (Kis et al. 2015). If we 
want to use Drosophila as a more complete genetic model for studying nervous system and 
its dysfunctions, it requires the understanding of the role of each of the players. Thus, I 
decided to focus on the role of a transcription factor expressed specifically in all the adult 
glial cells. Its function has been characterized during embryogenesis but very little is 
known about its role in adult glia. It is a major terminal differentiation factor, triggering the 
expression of many different glial genes in different subsets of glial cells. Thus, it makes it 
an ideal candidate to study the adult function of glia in Drosophila. 
 
 
6.1 Different glial cell populations are involved in 
Drosophila DRPLA neuronal impairment 
 
In order to characterize the role of glial cells in the impairment of the nervous system, I first 
wanted to understand if there were any glial subpopulations more vulnerable to the polyQ 
toxicity than others. Using different specific glial drivers, I highlighted the importance of a 
specific subset, the astrocyte-like glia. Indeed, the different drivers used, either overlapping 
or complementary in expression pattern, having the strongest effect, were expressed in this 
subpopulation. These results demonstrate that the impairment of specific glial cells is 
enough to deregulate the nervous system homeostasis, leading to the shortening of the 
lifespan. The astrocytic population in Drosophila has not been well characterized so far. It 
is known that they express the glutamate transporter dEAAT1 and the GABA transporter 
Gat, both of them overlapping in their neuropil expressions. The GABA transporter 
expression completely overlaps with the expression pattern of the specific astrocyte-like 
Gal4 driver Alrm-Gal4. However, the glutamate transporter seems to have a broader 
expression pattern, suggesting the presence of another astrocyte-like glia population in the 
Drosophila brain, possibly the so called “cortex glia”. Indeed, I have shown that the 
specific cortex glia Gal4 driver, NP2222-Gal4, also partially colocalizes with the dEAAT1 
Gal4/LexA driver. The hypothesis of a new definition of the cortex glia nomenclature 
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comes from their positioning, in direct contact with both BBB glia and neurons, similarly to 
mammalian astrocytes. The only function suggested so far about the cortex glia is its 
potential role in providing energy to neurons, assumed by its location, storage of lipid 
droplets in larvae and their membrane surrounding the neuronal cell bodies. Thus, 
potentially expressing some neurotransmitter transporters and providing energy to the 
neurons via their contact with BBB glia, this glial subtype could be redefined as a 
subpopulation of astrocyte-like glia. Also, the cortex glia driver leads to a reduction of the 
lifespan in the same range of Alrm-Gal4 when expressing the mutated polyQ Atro. The 
generation of a dEAAT1-LexA line in this thesis has helped to emphasize the lack of 
characterization of the glial populations and functions in the adult brain. Although the 
expression pattern and level of Gal4 lines have to be taken into account, not always fully 
representative of the real expression pattern of the endogenous promoter, the different 
stainings of the dEAAT1 protein seem to show a broader spectrum than the GABA 
transporter Gat, expressed only in the neuropil (Rival et al. 2004, Stork et al. 2014). In 
addition, the staining of the optic lobe neuropils with a glial histamine transporter has 
shown that it was present in the lamina but not in the medulla, suggesting a diversity in 
astrocyte-like glia population in both neuropil, especially since both photoreceptor neurons 
7 and 8 projecting in the medulla secrete histamine (Pantazis et al. 2008). In any case, the 
expression of polyQ Atro in neurotransmitter-expressing glial cells leads to a reduced 
lifespan. Thus, it is to be anticipated that the neurostransmitter clearance and/or recycling 
functions of these cells are possibly affected in this disease model. 
 
The diversity of the glial populations affecting the lifespan when they are impaired shows 
the broad detrimental effects on cellular functions in different cells provided by the 
expression of a mutated protein. It is possible that each of these cell types is affected by a 
similar dysfunction such as autophagy defects, which would lead to a general impairment 
of the basic cellular functions. Each cell population having a different function in the CNS, 
a similar impairment in each of them could have a different impact on the homeostasis of 
the nervous system. However, the large alterations in transcription seen when polyQ Atro is 
expressed could suggest that more specific functions are affected in different 
subpopulations and may explain why some glial cells are more sensitive than others, as it is 
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the case for neurons in DRPLA. To investigate this hypothesis, Gal4 drivers with similar 
levels of expression for each population of glial cells would be required. 
 
Furthermore, we have now demonstrated in the lab that the autophagic defects observed in 
our Drosophila DRPLA model were also present in a DRPLA mouse model. Thus, it is 
possible that other defects are also conserved between the models. It would be very 
interesting to know whether the expression of polyQ Atro specifically in mammalian 
astrocytes, using Gfap promoter for instance, would trigger similar effects to the ones seen 
using Alrm-Gal4 or dEAAT1-Gal4 drivers. This would allow a better understanding of the 
role of glial cells in the progression of the disease in a mammalian model. Indeed, the 
mouse models generated are not specific to one cell type. It is thus complicated to 
understand which population of neurons and/or glia is first affected and whether there is a 
propagation of the impairment overtime directly linked to the connectivity of the neurons or 
due to the sensitivity of each cell type to the toxicity of the mutated protein. The ability to 
tell the “chicken from the egg” would allow the development of targeted therapeutic 
strategies toward the starting point of the development of the disease and thus, possibly 
delay the onset of the symptoms. 
 
 
6.2 Using Drosophila for screening glia-neuron 
interactions to uncover new mechanisms 
 
The idea behind the screen was to be able to identify the above-mentioned issues in an 
indirect way. Instead of being dependent and limited by driver strength to identify how 
specific glial cell impairment leads to neuronal dysfunction, I targeted the neuronal 
functions to understand what the pathways affected in neurons that modify glia-neuron 
interactions are. Indeed, the modulation of neuronal gene expressions that enhances or 
suppresses the lifespan phenotype due to glial toxicity could give indirect answers on what 
goes wrong in glial cells. However, I have not been able to pinpoint specific glial functions 
that could be responsible for the impairment of the glia-neuron interactions and further 
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work is needed to confirm the screen candidates. Then, these impaired interactions would 
lead us to a potential specific glial population responsible of this type of interactions. 
Similarly to the large transcriptional alterations observed with the expression of polyQ 
Atro, a broad range of functions seems to be affected by impaired functions in glial cells. I 
decided to focus on three membrane proteins, mfas, caps and trn, each of them having 
differential effects in either glia or neurons. 
 
Nothing is known about mfas function in Drosophila. It has been studied in embryogenesis 
and is currently being investigated during metamorphosis by the Salecker group. However, 
the human ortholog TGF-ß-induced protein has been linked mostly to tumour processes 
such as cell migration or angiogenesis (Skonier et al. 1994, Aitkenhead et al. 2002). By 
binding to the extracellular matrix components such as collagen, laminin or fibronectin, this 
transmembrane molecule would regulate many processes in a TGF-ß-dependent manner 
(Irigoyen et al. 2008). TGF-ß is known to be an important player in neuroinflammation by 
modulating astrocytic scar formation (Cekanaviciute et al. 2014) or attenuating microglia 
activation (Norden et al. 2014) but is also involved directly in neuronal remodelling 
(Awasaki et al. 2011). It is thus possible that a similar signalling pathway in Drosophila 
regulates glial migration or “activation” by the expression of mfas in glia. It is also possible 
that mfas could modulate neuronal and/or glial shape via its binding to the extracellular 
matrix in a TGF-ß-dependent manner. 
 
caps and trn have different orthologs. Both of them belong to the family of the leucine rich 
repeat motif family. caps is related to Lrrn2 and Lingo-2 while trn is related to Lrrn3 and 
Lingo3. Lingo-2 polymorphisms have been linked to Parkinson’s disease (Su et al. 2012) 
and Lrrn2 has been shown to be involved in selective targeting of motor neurons (Andreae 
et al. 2009), which is similar to caps function in Drosophila antennal lobes (Hong et al. 
2009). Also, the trn ortholog Lrrn3 has been linked to autism spectrum disorder (Sousa et 
al. 2010) and neuroblastoma (Akter et al. 2011). Less is known about Lingo-3 but another 
member of the family, Lingo-1, has been linked to neurodegeneration by acting on EGFR-
PI3K-Akt signalling leading to the reduction of Purkinje cell survival (Zhou et al. 2012). 
These studies clearly suggest that Leucine rich repeat molecules have distinct roles during 
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development and adult stage. Moreover, modulating the expression of these genes, 
orthologs to caps and trn, could be a potential therapeutic intervention in order to alleviate 
symptoms of a wide variety of neurological disorders such as Parkinson’s disease or autism 
spectrum disorders. Deciphering the molecular functions of caps and trn in the Drosophila 
adult nervous system could help to find new strategies to modulate their interactions in 
disease conditions such as neurodegenerative diseases. 
 
Indeed, membrane molecules are easier to target with drugs, especially when their knock-
down triggers a positive effect. It is believed that few days rescue in Drosophila would 
correspond by translation to few months in humans, which is the effect of most drugs on 
genetic diseases such as neurodegenerative diseases or cancer. A first challenge is to be 
able to cross the Blood-Brain-Barrier but the increasing understanding of molecular 
transport happening at the BBB is already helping the design of new approaches to improve 
the efficiencies of the drug trans-cellular transport. However, getting the drug into the cell 
to have its effect is another level of complexity, making extracellular targets more 
appealing for potential treatments. Glia and neurons interact via different pathways, such as 
cell adhesion or secretion of molecules binding to receptors, but also via exosomes 
(Frühbeis et al. 2012). Modulating these interactions in disease conditions could help 
maintaining for longer a functional or partly functional nervous system that would 
potentially alleviate symptoms of patients. 
 
 
6.3 Investigating adult glial functions using the glial 
transcription factor repo 
 
In the first part of the thesis, I aimed at understanding if there were some specific subsets of 
glial cells more important than others in the participation of the phenotypes of our glial 
DRPLA model. This led to a first conclusion that Drosophila astrocyte-like glia play a 
major role in the toxicity of polyQ Atro expression for the organism viability. Since their 
functions are not well characterized in adult, a first approach was by modifying neurons 
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while the glia are impaired to help us understand which glial functions are affected. 
However, this approach is indirect and the results of the screen have shown how difficult it 
is to reveal non-cell autonomous effects between glia and neurons. 
 
In the last part of the thesis, I changed the approach by directly investigating adult glial 
functions in Drosophila. For that, I targeted a common glial transcription factor, repo, 
known to control glial gene expression during development. It is known as a terminal 
differentiation factor but its function in adult remains elusive. repo also regulates gene 
expression in larvae, thus it was likely that as a transcription factor still expressed in adult 
stage, it could still regulate glial function in the adult. The manipulation of repo expression 
specifically in adult would help to uncover new functions of glial cells. By this mean, it 
could be possible to discover new interactions between glia and neurons happening in the 
adult brain. 
 
The downregulation of repo in adult glia led to a wide range of molecular and cellular 
defects in both glia and neurons. However, the cause of the death remains elusive. The 
short lifespan of the Repo-KD flies shows the importance of the network of repo-dependent 
genes in the viability of the entire organism. It is highly likely the death is the result of 
cumulative effects from different dysfunctions of the nervous system. The infiltration of the 
dye through the BBB correlates with both the onset of the motor defects and the early 
death. It is though possible that both events are the results of different defects. The adult 
knock-down of Gat in glia did not lead to obvious motor defects or reduction of the 
lifespan (at least until 25 days at 29°C, before the breakdown of the incubator, data not 
shown). The modulation of repo-dependent neurotransmitter transporter expression at the 
synaptic level might not be the cause of the death itself but might participate by synergy to 
motor defects or other physiological functions such as memory or vision. The recording of 
neuronal activity in different regions of the brain would help to differentiate the functions 
affected by the repo downregulation and could link some of them to vital functions 
necessary for the organism viability. The role of glial cells in energy supply in adult 
Drosophila has not been investigated here. This function has been largely under-
investigated in adult Drosophila and might be responsible for some of the defects, even 
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though the cortex glia driver did not give a significant lifespan phenotype. The use of 
specific Gal80 drivers would be complementary to the Gal4 studies and could highlight 
some effects not seen using specific Gal4 drivers, especially if a synergy between different 
defective mechanisms is responsible of the strong phenotypes observed. 
 
Another question arose from the importance of a single transcription factor for such a 
diversity of glial functions. What is the evolutionary advantage of having such an unstable 
mechanism so important for the nervous system maintenance? repo activates different set 
of genes in different subtypes of glial cells. Similarly to developmental stages, it is possible 
that it cooperates with different specific transcription factors in each glial subtype. Even 
though it does not seem that glial cells can transform into neurons in the adult, possibly due 
to the lack of specific embryonic factors, it is possible that adult glia could change fate 
depending on the needs, becoming other glial subtypes. The neuronal debris clearance in 
adult Drosophila has not been well investigated. Thus, the “activation” of glia to do so in 
Drosophila might require a change in transcriptional program, partly controlled by repo in 
order to answer local needs due to a trauma for instance. Thus, the repo expression level in 
different glia subtypes could change locally. It would be interesting to investigate whether 
the level of repo expression in all glial cells is similar and remains constant. Another 
completely different answer to that question would be that evolution has led to very 
different mode of reproduction in order for the species to survive (r/K selection theory). 
While higher organisms give birth to few progenies, the parents taking a greater care for 
them in order to survive, lower ones such as Drosophila can generate hundreds of eggs and 
the ones not viable will die while the rest will survive, betting on the numbers rather than 
the “quality”. The ones that will have repo mutations or variability in expression level will 
die while the viable ones will survive. Evolution is not perfect and has its drawbacks. A 
relevant example could be the expansion of the CAG triplets within certain genes. The 
molecular machinery responsible for DNA replication does not reproduce perfectly the 
length over generation and leads to toxic effects of the translated protein, which can give 




Overall, the adult glial functions remain largely understudied and more effort is needed to 
characterize them and understand their role in the maintenance of a functional nervous 
system. A deeper characterization and subdivision of glia subtypes would help to 
understand specificity of their functions and how to modulate them in order to investigate 
glia-neuron interactions happening in the adult either in healthy or disease conditions. To 
this end, more genetic tools are needed along with specific molecular characterization to 
subdivide glial cells further. 
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